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Abstract 
 
There is increasing evidence that consumption of plant bioactives such as polyphenols 
reduces cardiovascular disease risk and improves endothelial function. In the Black Sea 
area, a number of plants are consumed alone and as ingredients in traditional foods, and 
dill, nettle, kale, Sideritis, pomegranate and persimmon were identified as polyphenol-
rich traditional food plants. Bioactive-rich extracts of their edible parts were used to treat 
human umbilical vein endothelial cells (HUVECs), to assess effects on the abundance or 
activity of signalling molecules related to increased vasodilation, a hallmark of improved 
endothelial function. Specifically, Akt and eNOS phosphorylation, levels of total eNOS 
protein and cGMP, secretion of ET-1 and levels of nitrate/nitrite in cell culture media 
were assayed. Alongside these experiments, HUVECs were treated with quercetin, a 
flavonol found in a number of the plant extracts, alongside a mix of its human 
metabolites to assess their effect on a broad range of phosphorylated proteins using an 
antibody microarray.  
 Quercetin (50 µM) significantly decreased eNOS phosphorylation (p < 0.05), 
while extracts of pomegranate and persimmon significantly increased levels of 
phosphorylated (p-) Akt, p-eNOS and cell culture media nitrate/nitrite (p < 0.05), and 
significantly reduced secretion of the vasoconstrictor ET-1 (p < 0.001). With regards to 
pomegranate bioactivity, signalling events upstream of p-Akt were explored, including 
inhibition of PTEN activity and phosphorylation of receptor tyrosine kinases, though no 
evidence could be found that either mechanism was involved in this case. Fractionation 
of the pomegranate extract into its main polyphenol classes revealed that procyanidins 
were responsible for its bioactivity. These findings suggest that procyanidin-rich foods 
can improve markers of endothelial function in vitro. Further studies on procyanidin 
bioavailability are required to determine if these effects can also occur in vivo. 
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Chapter 1: Polyphenols, cardiovascular disease and 
traditional diets 
 
1.1. Cardiovascular disease and endothelial function 
Cardiovascular disease (CVD) encompasses a number of conditions that affect the health 
of the vascular system, including the blood vessels and heart muscle, and is the leading 
cause of worldwide human mortality (World Health Organisation 2013). Lifestyle factors 
that have been shown to increase the risk of cardiovascular disease include tobacco use, 
lack of exercise and poor dietary choices. Higher prevalence is also found amongst those 
of low income (World Health Organisation 2010). Additional chronic conditions such as 
type 2 diabetes, hypercholesterolaemia and hypertension can be underlying factors for 
CVD progression (Sowers et al. 2001). Though disease progress occurs over the course of 
decades, it often results in severe acute responses, including heart attacks (myocardial 
infarction) and strokes. The physiological changes that result in these events are often 
tied to the formation of atherosclerotic plaques (Ross 1999), which in turn are marked by 
a change in the phenotype of the endothelial cells that form the inner lining of veins and 
arteries. Such cells are not simply a physical barrier; as an interface to the circulatory 
system, they activate signalling in response to numerous physio- and pathological stimuli, 
and play an important role in the control of vascular health. High blood pressure, 
increased levels of free radicals and oxidised low-density lipoprotein (LDL), infection by 
Chlamydia pneumoniae or damage from shear stress can all contribute to endothelial 
dysfunction. The outcome of such changes includes elevated levels of oxidative stress 
and inflammation, high expression of cell adhesion molecules, reduced vasodilatory 
factors and promotion of vasoconstrictive factors (Mudau et al. 2012; Grassi et al. 2011).  
 17 
Increased stress at the endothelium increases its permeability which causes build up of 
lipid-rich molecules, including oxidised lipoproteins, at the vascular wall (Corrado et al. 
2010; Libby & Theroux 2005). The rise in numbers of cell adhesion molecules such as I-
CAM, V-CAM and P-selectin at the cell surface increases adhesion of white blood cells, 
including monocytes, to the endothelium. Aided by the adhesion molecules, monocytes 
migrate to the intima layer between the endothelium and the smooth muscle tissue. Here 
they differentiate to macrophages, probably through stimulation from interleukins and 
growth factors such as M-CSF, though current in vivo evidence for this is limited (Chang 
et al. 2012; Shibata & Glass 2009). Proteoglycans in the vascular extracellular matrix 
contribute to matrix destabilisation, as well as to other pro-atherosclerotic activities, 
including cell migration, proliferation and lipoprotein retention. Their presence, alongside 
macrophage scavenger receptors and macrophage-secreted proteoglycans, and proteases 
promotes the accumulation of lipids in macrophages that leads to the formation of foam 
cells, a key step in the initiation of atherosclerotic lesions (Ley et al. 2011). Local release 
of cytokines and growth factors stimulate proliferation and migration of vascular smooth 
muscle cells (VSMCs), resulting in a fibrous ‗cap‘ separating the lesion from blood flow. 
Fibrotic material continues to be laid down as the plaque develops, aided by platelet 
aggregation and thrombus formation, leading to areas of increased thickness and arterial 
stiffness (Corrado et al. 2010; Ross 1999). Though the plaque may remain stable for a 
lengthy period, inflammation can lead to thinning of the lesion edges. Episodes of 
myocardial infarction or stroke occur when the fat-laden lesions rupture and clot vessels 
with the released material. Assessment of patient CVD risk can be performed by a 
number of physiological or anatomical measurements, including intima-media thickness, 
flow-mediated dilation of blood vessels and levels of C-reactive protein or asymmetric 
dimethylarginine (Davids & Teerlink 2012; Ray et al. 2009). 
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Fig. 1.1: Three stages of atherosclerotic plague formation. Top left panel: Factors such 
as increased inflammation encourage expression of cell adhesion molecules, and binding 
of white blood cells, such as monocytes. Top right panel: Inflammation also increases 
permeability of the endothelium, allowing monocytes to enter the intima space between 
endothelial and smooth muscle cells. Oxidised LDL, amongst other lipids, results in the 
transformation of monocytes to macrophages. Continued lipid uptake produces fat-laden 
foam cells. Lower panel: The atherosclerotic plaque increases in size, while the fibrotic 
tissue that develops around it can weaken over time. Eventually the plaque may rupture, 
and the released material can cause clots resulting in myocardial infarction or stroke. 
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Flow-mediated dilation is particularly useful as it gives a direct measure of one of the key 
factors resulting in endothelial dysfunction, that of increased constriction of arteries and 
reduced vasodilatory response. The tone of the vascular smooth muscle tissue is 
controlled primarily by the balance of a number of vasomodulatory factors, most 
originating from the endothelium, from where they then diffuse or are transported to the 
underlying smooth muscle. Relaxation of arterial tissue is induced by increased 
production of nitric oxide (NO) by endothelial nitric oxide synthase (eNOS), prostacyclin 
(PGI2) by cyclooxygenase, or by a number of endothelium-derived hyperpolarising 
factors (EDHFs) which activate K
+
 channels in smooth muscle cell membranes. EDHFs 
include certain small molecules (H2O2, carbon monoxide and hydrogen sulphate), 
epoxyeicosatrienoic acids, K
+
 ions and C-natriuretic peptide (Giles et al. 2012; Jin et al. 
2011). The decrease in intracellular Ca
2+ 
ions in VSMCs that results from K
+
 channel 
activation, as well as NO and PGI2 signalling, is one of the key changes that reduces 
vascular tone. 
 Vasoconstriction factors include prostaglandins, thromboxanes, angiotensin, 
endothelin and reactive oxygen species (ROS). Similar to a number of EDHFs, 
prostaglandins and thromboxanes are produced from arachidonic acid by 
cyclooxygenase. They activate thromboxane receptors on VSMCs to produce direct 
vasoconstrictive effects, while increased levels of superoxide, produced in endothelial 
cells by NADPH oxidase, scavenges NO and reduces the efficacy of stimulated NO 
production (Barton et al. 2012; Toda 2012; Versari et al. 2009). ET-1, the main 
endothelin peptide expressed in endothelial cells, binds to ETA and ETB receptors in 
VSMCs to induce vasoconstriction. It is noteworthy that ETB receptors in endothelial 
cells stimulate NO production upon ET-1 binding. Evidence from eNOS-blocking studies 
suggests that there is a link between NO and ET-1 release in endothelial cells, where 
reduced eNOS activity allows increased ET-1 levels, and that improved NO production 
inhibits ET-1 production (Bourque et al. 2011). eNOS activity can be increased by the 
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kinases AMPK, CaMKII, PKA and PKB (Akt), and in turn, these are activated by certain 
growth factors (such as VEGF), hormones, statins or shear stress (Vanhoutte et al. 2009; 
Huang 2009; Förstermann & Sessa 2012). 
 In vitro, human umbilical vein endothelial cells are often used as a model for 
determining signalling responses to molecules which might be present in the circulatory 
system. Preparation of cells from the umbilical vein is often carried out with the use of 
collagenase, facilitating their removal so that they can be collected and cultured for study 
(Crampton et al. 2007). Vasodilation through NO release in the human umbilical vein is a 
key method through which, like the arteries of the cardiovascular system, oxygenated 
blood is carried from the placenta to the foetus, as there is a lack of nervous stimulation 
to carry out this task (Gude et al. 2004, San Martín and Sobrevia 2006). 
 
1.2. The nitric oxide signalling pathway 
As has been mentioned, vasomodulation - the control of arterial and venous blood flow - 
is likely to play an important role in the development or control of atherosclerosis and 
CVD, with the enzyme eNOS being key to enabling vascular tissue to relax. Impairment 
of eNOS function leads to increased vasoconstriction, high blood pressure and oxidative 
stress in endothelial and smooth muscle tissue. All of these outcomes are associated with 
endothelial dysfunction (Giles et al. 2012; Atochin & Huang 2010). Indeed, 
polymorphism of the eNOS gene has been linked to increased incidence of coronary heart 
disease (Zhang et al. 2012b). Conversely, improvements in vasodilatory response through 
this mechanism have been shown to attenuate lesion progression and reduce 
inflammatory responses such as platelet aggregation and expression of adhesion 
molecules and cytokines (Chatterjee and Catravas 2008, Vanhoutte et al. 2009). CVD risk 
factors, such as ageing and high cholesterol are also associated with reduced vasodilation 
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and eNOS expression, as well as increased expression of vasoconstriction factors such as 
endothelin-1 (Seals et al. 2011; Toda 2012).  
 Dilation of veins and arteries is controlled at a molecular level by the nitric oxide 
(NO) signalling pathway (Fig. 1.2). NO is a free radical that acts as a signalling molecule 
in a number of different human tissues (Gao 2010). Formation of NO, as pertains to 
vasodilation, takes place in endothelial cells, which form the inner lining of veins and 
arteries (Buerk et al. 2011; Triggle et al. 2012). After production by the enzyme eNOS, it 
passes to surrounding smooth muscle cells, triggering their relaxation.  
 
 
Fig. 1.2: Nitric oxide signalling in endothelial and smooth muscle cells: Increased levels 
of PIP3 due to PI3K activity and PTEN inactivity, leads to binding of Akt and the plasma 
membrane so that it may become active through phosphorylation by PDK. p-Akt then 
activates eNOS through phosphorylation, allowing production of NO to increase. 
Diffusion of NO to smooth muscle cells leads to its binding of sGC, which produces 
cGMP, leading to the activation of PKG and relaxation of the smooth muscle tissue. P - 
indicates phosphorylation; GTP - guanosine triphosphate; NO - nitric oxide 
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The regulation of eNOS has been well studied and operates through a number of 
mechanisms. Acylation (specifically myristoylation and palmitoylation) facilitates eNOS 
translocation from the cytosol to caveolae in the plasma membrane, where it binds 
caveolin-1, holding it in an inactive state (Kolluru et al. 2010). Translocation brings it 
into close proximity with other proteins and cofactors that enable enzyme activity, the 
first of these being heat shock protein 90 (hsp90) and calmodulin (CaM) which displace 
caveolin-1. Hsp90 may also act as a scaffolding protein in regulation of signalling events 
related to nitric oxide signalling, and has been shown to form a complex with eNOS and 
Akt, an eNOS-activating kinase (Takahashi & Mendelsohn 2003). eNOS protein consists 
of an N-terminal oxygenase domain and a C-terminal reductase, connected by a 
calmodulin (CaM)-binding region (Balligand 2002). These contain sequences for binding 
cofactors, including haem and tetrahydrobiopterin (BH4) in the oxygenase domain and 
flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) in the reductase 
domain (Feng 2012). Increased intracellular Ca
2+
 increases CaM's affinity for the CaM-
binding region, and enables interdomain electron transfer, facilitating eNOS enzyme 
activity. One further requirement for active eNOS is that it forms a homodimer, which 
occurs through to the presence of haem in the oxygenase domain and the linking of two 
cysteine residues (also in the oxygenase domain) from each monomer by a zinc ion 
(Förstermann & Sessa 2012). Once activated, eNOS produces nitric oxide according to 
the formula: 
L-Arginine (+ 1.5 NADPH + 1.5 H
+
 + 2 O2) → NO (+ L -Citrulline + 1.5 NADP
+
 + 1.5 H2O) 
Electron transfer from the reductase domain to the oxygenase domain, which binds the 
eNOS substrate L-arginine, facilitates the synthesis of NO from the catalysis of L-arginine 
to L-citrulline. eNOS is phosphorylated at a number of serine, threonine and tyrosine 
residues which are key to the increase and decrease of enzyme activity (Fleming 2010). 
Ser1177 is one of the most well-studied residues involved with increased eNOS enzyme 
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activity. Its phosphorylation increases the affinity of eNOS for binding CaM and helps 
facilitate the interdomain electron transfer (Rafikov et al. 2011). Post-translation 
modifications such as these are not all beneficial to NO production, however. S-
nitrosylation of eNOS cysteine residues leads to inhibition of enzyme activity (Dudzinski 
& Michel 2007) while S-glutathionylation can cause uncoupling of the homodimer 
subunits. Uncoupled eNOS remains active, but without a partner monomer it acts as an 
NADPH oxidase, producing superoxide radicals and increasing intracellular oxidative 
stress (Zweier et al. 2011). 
 Once NO diffuses to smooth muscle cells it binds to haem in soluble guanylyl 
cyclase (sGC), greatly increasing cGMP production (Rocha et al. 2009). Besides the 
vascular smooth muscle, sGC is also found in a number of other different tissues in the 
human body, including the endothelium, (Potter 2011; Takeuchi et al. 2004). It increases 
production of cyclic guanosine monophosphate (cGMP), produced from Mg
2+
-bound 
GTP (Russwurm & Koesling 2004; Derbyshire & Marletta 2009). cGMP is then targeted 
to cGMP-regulated ion channels, phosphodiesterases (PDEs) (which catalyse hydrolysis 
of cGMP to GMP (Bryan et al. 2009)) and cGMP-dependent protein kinases, such as 
protein kinase G (PKG) (Francis et al. 2010; Hofmann et al. 2000). Binding of cGMP to 
allosteric sites on PKG cause conformational changes resulting in the release of the 
enzyme's catalytic domain and interaction with a number of substrates, such as IP3 
receptor-associated cGMP kinase substrate (IRAG). IRAG protein inhibits inositol 1,4,5-
trisphosphate (IP3) receptor activity and the release of intracellular Ca
2+
 stores and 
increases Ca
2+
-activated maxi-K
+
 channel (BKCa) activity, inhibiting influx of Ca
2+
 
through Ca
2+
 channels. This reduces the intracellular Ca
2+
 concentration and the Ca
2+
 
sensitivity of the contractile machinery. IRAG also activates MYPT1, which 
dephosphorylates myosin light chain and reduces myosin ATPase activity, interfering 
with the interaction between myosin and actin that brings about muscle contraction 
(Koubassova & Tsaturyan 2011; Schlossmann & Desch 2011). Additionally, increases to 
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NO levels may be related to decreases in levels of vasoconstriction factors, such as 
endothelin-1 (ET-1), augmenting the vasodilatory effect (Bourque et al. 2011). ET-1 
facilitates increases to vascular tone through its ability to raise the intracellular Ca
2+
 
concentration in smooth muscle cells (Bourque et al. 2011; Mazzuca & Khalil 2012) 
 An important regulator of eNOS activation through phosphorylation of Ser1177 is 
the kinase Akt (protein kinase B). It has three human isoforms, Akt1, Akt2 and Akt3, 
with Akt1 being the key isoform in vascular nitric oxide signalling (Matheny & Adamo 
2009). Each isoform is composed of an N-terminal pleckstrin homology domain (PH), a 
kinase domain and a C-terminal hydrophobic domain. Phosphorylation of Thr308 in the 
kinase domain and Ser473 in the hydrophobic domain are required for full Akt activity. 
The PH domain is recognised by PIP3, which is formed from the phosphorylation of PIP2 
by PI3K. PIP3 holds Akt1 at the plasma membrane after its translocation from the 
cytoplasm. Phosphorylation is carried out by PDK1 for the Thr308 residue and mTORC2 
or DNA-PK (other kinases may also be involved) for Ser473. Dephosphorylation of PIP3 
by phosphatases such as SHIP and PTEN can reverse this process (Bozulic & Hemmings 
2009). Akt activity is completely dependent on the phosphorylation of PIP2 to PIP3 by 
PI3K (phosphoinositide 3-kinase) (Hers et al. 2011), as evidenced by inhibited Akt 
phosphorylation after incubation of cell cultures with the PI3K chemical inhibitor 
LY294002 (Eisenreich & Rauch 2011). PI3Ks are grouped in three distinct classes, based 
on catalytic subunit similarity and preference of phosphoinositide substrate, but it is only 
class 1 PI3Ks which are able to produce PIP3 (Vadas et al. 2011). Class 1 PI3Ks are 
divided further, based on their catalytic and regulatory domains. Class 1A PI3Ks have 
p110 (α, β or δ) as their catalytic domain and p85 (α or β), p55 (α or γ), or p50α as their 
regulatory subunit, while class 1B PI3Ks are comprised of p110γ and either p84 or p101 
(Fougerat et al. 2009). 
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1.3. Plant polyphenols and other bioactive compounds 
One of the key factors behind progression of CVD is poor diet. Conversely, increased 
consumption of fruit and vegetables is associated with decreased CVD risk (World 
Health Organisation 1990; He et al. 2007; Pomerleau et al. 2007). There is strong 
evidence that the polyphenol content, and in particular the flavonoid content, of fruits, 
vegetables and other plant-derived foods is a major factor behind these health effects. 
Meta-analyses have shown that flavonoids, particularly those associated with cocoa and 
soy products, can significantly lower blood pressure and improve the flow-mediated 
dilation response in patients, though greater consistency between studies, such as in the 
choice of biomarkers for study outcomes, is required for stronger evidence in the future 
(Kay et al. 2012; Hooper et al. 2008; Hooper et al. 2012; Ried et al. 2012).  
 Flavonoids and other polyphenols are plant secondary metabolites, present in 
various forms throughout the plant kingdom. Their functions in plants encompass 
numerous roles including pigmentation, bitter or astringent tastes for the dissuasion of 
herbivores (Landete 2012), antioxidants (Agati et al. 2012) and UV radiation absorption 
(Pollastri & Tattini 2011; Lattanzio et al. 2008). According to the principles set out by 
White, Bate-Smith, Swain and Haslam, polyphenols are water-soluble plant phenolics, 
with mass of 500 to 3000 Da, 5-7 aromatic rings, 12-16 hydroxyl groups, and the ability 
to precipitate certain proteins, alkaloids and gelatin (Quideau et al. 2011; Haslam 2007). 
This therefore includes most condensed tannins, hydrolysable tannins and algae-borne 
phlorotannins. However, much polyphenol research in the last few decades has 
increasingly focused on smaller phenolic compounds, such as flavonoids, to the extent 
that the above definition is no longer appropriate. A more contemporary definition is 
offered by Quideau et al. (2011), which describes polyphenols as:  
 
―plant secondary metabolites derived exclusively from the shikimate-derived 
phenylpropanoid and/or the polyketide pathway(s), featuring more than one 
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phenolic ring and being devoid of any nitrogen-based functional group in their 
most basic structural expression.” 
 
Polyphenols are vast in number, encompassing the chemical families mentioned above, 
with their respective subdivisions, as well as stilbenoids, lignans, phenolic acids and 
additional derivative compounds (Del Rio et al. 2013). One of the larger families, with 
over 500 compounds identified so far, hydrolysable tannins consist of esters of gallic acid 
and sugar molecules, and can be classed as either ellagitannins, where galloyl moieties 
have bonded through oxidative coupling, or as gallotannins. Degradation of gallotannins 
releases gallic acid, whereas ellagitannins breakdown can produce numerous derivative 
compounds, including sugar esters of ellagic acid and gallagic acid (Landete 2011; 
Larrosa et al. 2010; Quideau 2009). Condensed tannins (also known as proanthocyanidins 
or non-hydrolysable tannins) represent a large number of oligomeric and polymeric 
structures, soluble in water up to approximately 10 monomer units (He et al. 2008; Xu et 
al. 2012b). These monomer units are flavanols, such as epicatechin or catechin, which 
belong to the extensive flavonoid family of polyphenols. Most flavonoids possess the 
three-ring flavan backbone structure (Fig. 1.3), coupled with a variety of hydroxyl, 
methoxy and ketone groups, and are often conjugated with sugars or organic acids in 
plants. 
  
Figure 1.3: Flavan backbone structure, featuring two benzene rings (A and B), and a 
dihydropyran ring (C). 
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Other subclasses of flavonoids included flavonols, flavones, isoflavones and 
anthocyanins. Flavonoids are by far the most commonly expressed polyphenol in plants, 
with over 5000 plant-derived flavonoids currently described (Keller 2009; Veitch & 
Grayer 2011). 
 Stilbenoids are phytoalexins, and are often found in wine due to their presence in 
grape skins. Of note is resveratrol, which has been the subject of much fervoured study 
due to its strong effects on cellular mechanisms relating to disease and ageing (Cucciolla 
et al. 2007; Rivière et al. 2012). Lignans, which are also phytoestrogens, are often present 
in the seeds of plants and include pinoresinol, lariciresinol and sesamin (Cunha et al. 
2012; Peterson et al. 2010). Phenolic acids, while not polyphenols by definition, are often 
included in polyphenol research, and may also be found as part of the structure of larger 
polyphenols. Two major classes of phenolic acids, hydroxycinnamic acids (C6-C3 
structure) and hydroxybenzoic acids (C6-C1 structure), are commonly found in a variety 
of plant species (Rice-Evans et al. 1996). Of the numerous phenolics found in nature, 
over 500 have been identified so far as forming part of human diets, across 400 different 
foods (Neveu et al. 2010). 
 Synthesis of polyphenols in plants occurs via enzymes of the shikimate and 
phenylpropanoid secondary metabolite pathways (Vogt 2010; Knaggs 2003). 
Dehydrogenation of 3-dehydroshikimate, an intermediary compound of the shikimate 
pathway, is the primary means for gallic acid formation, a key step in the production of 
ellagitannins (Haslam & Cai 1994). A sugar, usually glucose, forms an ester with gallic 
acid to produce β-glucogallin, which accepts galloyl groups from additional β-glucogallin 
molecules to form 1,2,3,4,6-pentagalloyl glucose (PGG) (Crozier et al. 2009). Oxidative 
linkage of PGG galloyl groups produces 3,4,5,3',4',5'-hexahydroxydiphenoyl (HHDP) 
subunits, characteristic of all ellagitannin molecules (Landete 2011; Okuda & Ito 2011). 
The final structure of these molecules, though, can vary greatly due to a number of 
factors, including HHDP group position, formation of bonds with additional galloyl 
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moieties, oligomerisation, further structural changes due to oxidation, and condensation 
with other molecules (Quideau 2009; Ascacio-Valdés et al. 2011). Breakdown of 
ellagitannins through hydrolysation releases the HHDP units, which convert to ellagic 
acid through lactonisation. Ellagic acid, alongside conjugated derivatives, is a common 
product of ellagitannin degradation. Cleavage of the lactone ring results in the production 
of urolithins, metabolites found in human plasma after consumption of ellagitannin-rich 
foods (Larrosa et al. 2010; Landete 2011).  
 Anthocyanins, like all flavonoids, are derived from the final metabolite of the 
shikimate pathway, p-coumaroyl-CoA, via a number of enzymatically synthesised 
intermediary compounds. p-Coumaroyl-CoA undergoes a condensation reaction, with 
three malonyl-CoA molecules, to produce naringenin chalcone (Fig. 1.4). The C-ring of 
the flavanone structure is formed, leading to the production of dihydroflavonols, which 
are converted to leucoanthocyanidins and then anthocyanidins (He et al. 2010; Xie et al. 
2011). Anthocyanins are formed after the attachment of a sugar group, often at the 3-O or 
5-O position (Fig. 1.5). 
 Flavan-3-ols can be synthesised from either leucoanthocyanidins, in which case 
they have 2R,3S-stereochemistry (i.e. (+)-catechin), or from anthocyanidins, and so 
feature 2R,3R-stereochemistry (i.e. (-)-epicatechin) (He et al. 2008). The exact 
mechanism for the poly- and oligo-merisation of the flavan-3-ol monomer units into the 
proanthocyanidin structure is still under investigation. It has been proposed that a laccase-
like polyphenol oxidase (PPO) encoded by TT10 is involved, and that oxidation of 
flavan-3-ols by PPO assists their formation of proanthocyanidin structures. 
Leucoanthocyanidin molecules may also be used, after conversion to quinone methide 
intermediate structures, followed by transportation to plant cells vacuoles, the acidic 
environment of which aids condensation of proanthocyanidin subunits (Zhao et al. 2010). 
There does not appear to be a standard order in which flavan-3-ol subunits are arranged in 
proanthocyanidins, giving rise to a large number of proanthocyanidin structures.  
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Fig. 1.4: Biosynthesis of ellagitannins and flavonoid precursor compounds from 
metabolites of the shikimate and phenylpropanoid pathway, through a number of 
enzymatic reactions. Pathway is continued in Fig. 1.5. 
 
Treatment of proanthocyanidins with strong mineral acids results in the release of 
anthocyanidin molecules, hence their name. Thus, proanthocyanidins capable of releasing 
cyanidin (those which contain 3'4'-dihydroxyflavan-3-ol subunits, i.e. (+)-catechin) are 
termed procyanidins (Fig. 1.6), while those capable of releasing delphinidin 
(proanthocyanidins containing 3'4'5'-trihydroxyflavan-3-ol subunits, i.e. (+)-
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gallocatechin) are termed prodelphinidins (though it is not unusual for a proanthocyanidin 
to contain both procyanidin and prodelphinidin monomer units).  
 
 
Fig. 1.5: Biosynthesis of flavanols (quercetin), flavan-3-ols ((-)-epicatechin and (+)-
catechin), anthocyanins and proanthocyanidins, continued from Fig. 1.5. An example of 
proanthocyanidin structure is demonstrated in Fig. 1.6 (procyanidin trimer). 
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Figure 1.6: Procyanidin trimer with structure (-)-epicatechin-(4α→8)-(+)-catechin-
(4α→8)-(-)-epicatechin. Procyanidins can feature multiple (n) extension units. 
 
There are a number of additional bioactive plant secondary metabolites besides 
polyphenols. Terpenoids have isoprene-based structures, and incorporate a wide range of 
compounds found across the plant kingdom (Ro 2011). They include numerous classes of 
phytochemicals, such as phytosterols (triterpenes) and carotenoids (tetraterpenes), of 
which lycopene may be important for lowering CVD risk (Ried & Fakler 2011; Böhm 
2012). Alkaloids are a diverse group of nitrogenous phytochemicals, possessing 
heterocyclic structure, and have been the basis for numerous pharmaceuticals, such as 
morphine and codeine, and continue to aid drug-discovery, in areas such as anti-cancer or 
anti-microbial therapy (Glenn et al. 2013; Hibino & Choshi 2002). In terms of structure 
variation, glucosinolates are perhaps the most conserved of the phytochemicals 
mentioned here, though there has still been considerable research into their effects on 
biological systems. Their structure consists of single thioglucoside and N-
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hydroxysulphate groups bound by an organic side chain, and are common to plants of the 
order Brassicales, such as cabbage or mustard (Mithen et al. 2010; Verkerk et al. 2009). 
Mastication of plants containing glucosinolates releases the enzyme myrosinase from cell 
vacuoles, which degrades the glucosinolates contained in adjacent 'S-cells' to their 
bioavailable form, isothiocyanates (ITCs), which can then be absorbed for further 
metabolism by the human body (Dinkova-Kostova & Kostov 2012; Mithen et al. 2000). 
The ability to convert glucosinolates to ITCs is also possessed by the gut microflora. One 
ITC of note is sulforaphane, for which there is now a large body of evidence supporting 
its beneficial effects on various aspects of human health (Elbarbry & Elrody 2011), 
particularly in the context of prostate cancer risk (Traka et al. 2008). 
 
1.4. Developments in polyphenol research 
Reports of polyphenol use by human populations date back almost three millennia, due to 
their importance in the process of leather tanning (Quideau et al. 2011), but it is only in 
the last 200 years that research on individual polyphenols has been performed. Through 
the 1800s, work was performed to isolate and characterise a number of polyphenols, 
including catechin (Zwenger 1841) and stilbenoids (Likhtenshtein 2009; Perkin 1868). 
The preparation of orange bitters by Lebreton (1828) led to the discovery of needle-like 
crystals, which he called hesperidin (Laszlo 2008), and were revealed in 1876 to be a 
flavanone glycoside by Hilger and Hoffman (Hendrickson & Kesterson 1954).  
 The ardent work of Fischer, Freudenberg and Karrer at the turn of the 20
th
 century 
gave a hint as to the potential vastness of the library of vegetable tannins (Haslam & Cai 
1994; Quideau et al. 2011). One of the first investigations into the health benefits of 
individual polyphenols was performed in the mid-1930s, when Albert Szent-Györgyi 
recognised that an impure preparation of vitamin C could improve capillary resistance, 
while isolated vitamin C proved ineffective to his patient. Hesperidin was identified from 
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the preparation, but despite good results with animal studies, additional human trials were 
unable to mirror the original effect. The development of paper chromatography by Martin 
and Synge in 1943 paved the way for a high volume of plant extract analyses, many 
performed by Bate-Smith and Swain in the following decades (Consden et al. 1944; 
Haslam 2007). A number of polyphenol classes were first described at this time, 
including lignans by Haworth in 1948 (Cunha et al. 2012), proanthocyanidins by 
Masquelier in 1951 (Fine 2000), and ellagitannins by Mayer and Schmidtt in the 1950s 
and 60s (Lei 2002). In the last few decades, identification of new polyphenols has 
increased exponentially due to the advances in high and ultra pressure liquid 
chromatography, gas chromatography, nuclear magnetic resonance and mass 
spectrometry techniques (Cuyckens & Claeys 2004; Monagas et al. 2010; Stalikas 2010). 
 The report of the Zutphen Elderly Study by Hertog et al. (1993) was one of the 
first to show that health benefits associated with high fruit and vegetable intake were 
related to the presence of flavonoids in the consumed foods. There have been a number of 
epidemiological studies since which provide evidence that flavonoids confer beneficial 
effects on CVD mortality and risk factors such as hypertension (Cassidy et al. 2011; 
Oude Griep et al. 2011; Mink et al. 2007). These studies are also backed by randomised-
controlled trials that focus on polyphenol-rich extracts or the compounds themselves, 
such as cocoa, epicatechin or quercetin, and their effects on markers of endothelial 
function (Loke et al. 2008a; Monahan et al. 2011; Arranz et al. 2013; Schroeter et al. 
2006; Hollands et al. 2013a). 
 To explain the underlying molecular mechanisms for these effects, there have 
been a considerable number of in vitro and animal studies carried out in the last two 
decades. A key characteristic of polyphenols is their ability to act as antioxidants, due to 
their hydroxyl groups (Rice-Evans 1995), allowing them to scavenge radicals or chelate 
metal ions involved in oxidative reactions (Perron et al. 2008; Ali et al. 2013). As 
oxidants such as superoxide or hydroxyl radicals contribute to protein damage and 
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deterioration of cells, one of the initial hypotheses of the mechanism underlying the 
health benefits of dietary polyphenols was their potent antioxidant activity. However, 
there has been little evidence to suggest that the concentrations at which polyphenols are 
present in the human body (nM to low µM range) contribute substantially to the 
intracellular or extracellular redox environment, especially in comparison to levels of 
endogenous antioxidants produced by cells (Hollman & Cassidy 2011). Polyphenols may 
still provide an indirect antioxidant effect, however, by altering the activity of enzymes 
which reduce oxidants, such as catalase or superoxide dismutase, or by inhibiting pro-
oxidant enzymes such as NADPH oxidase or lipoxygenase (Sies 2010). There are a range 
of additional mechanisms that have been proposed and studied to explain the decrease in 
CVD risk from consumption of polyphenols. These include anti-inflammatory, anti-
thrombotic or anti-atherogenic action, inhibition or promotion of signalling pathways 
related to the maintenance of vascular health, and changes to the expression of genes 
related to those pathways (Virgili & Marino 2008; Quiñones et al. 2013; Tangney & 
Rasmussen 2013). However, linking the in vitro or animals experiments which 
investigate these mechanisms to the human studies that demonstrate the health benefits of 
polyphenols is generally quite difficult, as compounds are often absorbed in limited 
quantities, and undergo extensive metabolism. 
 
1.5. Absorption and metabolism of polyphenols 
Though the types of phenolic compounds found within species of fruits and vegetables 
are often consistent between samples, specific concentrations of compounds can still vary 
due to a number of factors. These include environmental stresses such as temperature and 
humidity, farming practices, ripeness, length of time between harvest and consumption, 
transport, storage and method of cooking (D‘Archivio et al. 2010). The types of phenolic 
compounds which are available for absorption in the body can also be affected by certain 
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nutrients that are consumed alongside or as part of polyphenol-rich foods. For example, 
association with dietary fibre has been reported to reduce the bioavailability of 
polyphenols in the small intestine (Palafox-Carlos et al. 2011). On the other hand, 
increased quantities of dietary fats have been shown to protect cocoa procyanidins during 
duodenal digestion (Ortega et al. 2009). This was reported as being likely due to 
increased formation of micellar vesicles, similar to the observed in quercetin 
micellerisation observed when fat levels in a simulated digestion system were increased 
(Guo et al. 2013). The same study also showed increases to quercetin plasma 
concentrations after consumption of a high dose of quercetin (1.1 g) as part of a high-fat 
meal, compared to a fat-free meal with the same dose. Polyphenols are known for their 
ability to form complexes with proteins, an interaction which produces the astringent 
taste of some polyphenol-rich foods and beverages (Ferruzzi et al. 2012; Liang et al. 
2013; Ginsburg et al. 2012; Ozdal et al. 2013). Milk has been suggested to inhibit the 
bioavailability of tea polyphenols, as evidenced by in vitro and in vivo studies, due to 
complexes formed between phenolics, milk protein and fat globules (Lorenz et al. 2007; 
Zhang et al. 2012a). Such complexes were shown to be degraded during simulated 
digestion, however (van der Burg-Koorevaar et al. 2011), and additional human studies 
have been unable to show significant effects of co-consumption of milk and tea 
polyphenols (Roura et al. 2007). There is also in vitro evidence that milk may enhance 
the bioavailability of flavanols (Xie et al. 2012). 
 There is little evidence that the acidic conditions of the stomach causes 
breakdown of phenolic compounds, though the digestion of food matrices may improve 
polyphenol bioavailability (Saura-Calixto et al. 2007; Manach et al. 2004; Scalbert et al. 
2002; Larrosa et al. 2010). Once polyphenols reach the small intestine, the increase in pH 
can aid the release of ellagic acid from ellagitannins, while lactase-phlorizin hydrolase 
and β-glucosidase activity can hydrolyse and deglycosylate numerous phenolics, and 
improve their rate of absorption through the intestinal epithelium. Low-molecular weight 
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phenolics may be absorbed at the small intestine without such modification, though much 
of the phenolics consumed in the diet will likely pass through to the large intestine, where 
they can be broken down by colonic microflora. The absorption of polyphenols has been 
reported so far as particularly low. Systematic review of human studies which account for 
recovery of phenolics in urine found that recovery of flavonoids varied from 0.2% for 
anthocyanins, 1-3% for flavonols and flavanols, and 5-7% for flavanones. Recovery of 
phenolic acids varied from 1-12%, isoflavones from 1-37%, lignans from 13-37%, while 
resveratrol showed 19% recovery (Pérez-Jiménez et al. 2010). Analytical advances, that 
allow for improved identification of microbial metabolites in such studies, may help to 
account for a greater proportion of ingested polyphenols, particularly for compounds 
which are not readily absorbed in the small intestine, such as anthocyanins (Czank et al. 
2013). 
 Over 160 species of bacteria have been recorded in the human gut, but the 
particular species and the extent to which they are present varies from person to person, 
and so the range of microbial metabolites that can be potentially produced varies also 
(Bolca et al. 2013). It is also likely that the viability of particular species will be affected 
by certain phenolics in different manners. While some may inhibit bacterial activity, 
others, such as quercetin-3-O-rutinoside (rutin) may improve microbial attachment and 
proliferation (Parkar et al. 2008). The particular microbial metabolites varies between 
polyphenol classes, and includes phenolic acids (proanthocyanidins, anthocyanins and 
other flavonoids), such as benzoic, phenylacetic, phenylpropionic and phenylvaleric 
acids, equol (isoflavones), urolithins (ellagic acid) and enterolactone (lignans) (Selma et 
al. 2009; Williamson & Clifford 2010). The particular compounds produced can also vary 
between bacterial species. Through β-glucosidase activity, microbes can deglycosylate 
flavonoid glycosides, for example, hydrolysing rutin to quercetin-3-O-glucoside, and 
quercetin-3-O-glucoside to quercetin aglycone (Yang et al. 2012; Schneider et al. 1999; 
Knaup et al. 2007). This activity was shown of the species Enterococcus casseliflavus but 
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it was unable degrade quercetin aglycone further, unlike Eubacterium ramulus, which 
was capable of producing 3,4-dihydroxyphenylacetic acid as a ring-fission metabolite of 
quercetin (Schneider et al. 1999). Additional microbial phenolic acid metabolites of 
quercetin glycosides include 3-hydroxyphenylacetic acid, 3-(3-hydroxyphenyl)-propionic 
acid and 3,4-dihydroxyphenylbenzoic acid (Yang et al. 2013; Rechner et al. 2004; 
Jaganath et al. 2009). Acetlyation, hydroxylation, dehydroxylation and 
hydroxymethylation have also been reported of quercetin glycosides by human 
microflora (Lu et al. 2013). These metabolites can then be absorbed through epithelial 
cells, in a trans- or para-cellular fashion, or actively via monocarboxylic acid transporter 
(MCT) (Konishi 2005). 
 Besides MCT, absorption of phenolics into the epithelial layer of the small 
intestine is aided by multidrug resistance-associated protein 2 (MRP2) and the sodium-
glucose transport protein SGLT1. Compounds which have not already been hydrolysed to 
remove sugar moieties by lactase-phlorizin hydrolase (LPH) at the surface of enterocytes 
will be reduced to their aglycone by either intracellular β-glucosidase or LPH, at which 
point they become substrates for phase II metabolism (Walle 2004; Wu et al. 2011). The 
enzymes catechol-O-methyltransferase, UDP-glucuronosyltransferase and 
sulfotransferase in the intestinal epithelium produce a selection of phenolic conjugates, 
which are then transported via the hepatic portal vein to the liver, where further 
conjugation/deconjugation occurs. This can lead to a wide range of metabolites present in 
the blood. For example, phase II metabolites of quercetin (Q) include: 
Q-3-glucuronide (Q-3-GlcA), Q-3'-GlcA, Q-diGlcA, isorhamnetin (IR)-3-GlcA, IR-4'-
GlcA, Q-3'-sulphate (Q-3'-S), Q-GlcA-S, methyl-Q-GlcA, methyl-Q-diGlcA and Q-
glutathione, where Q-GlcA and Q-S are the most common human metabolites (Lee et al. 
2012; Mullen et al. 2006).  
 After passing through the hepatic portal vein, it is likely that further phase II 
metabolism then occurs in the liver and kidney (Mullen et al. 2006), before plasma 
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circulation and excretion of conjugates in urine. Nearly all of a radio-labelled quercetin 
dose of 4 mg/kg (bodyweight) given to rats was found to be excreted after 72 hours, with 
69% recovered in the urine, although there was little accumulation of metabolites in 
plasma or tissues outside the gastrointestinal tract over the three days (Mullen et al. 
2008). In this study, much of the quercetin was converted to phenolic acids such as 
hippuric acid, 3-hydroxyphenylacetic acid and 3,4-dihydroxyphenylacetic acid. 
 Following phase II metabolism, conjugates can also be carried back from the liver 
to the small intestine in the bile, as demonstrated by reports of N-acetylcysteine 
conjugates of quercetin, likely formed from glutathione conjugates re-entering the gut 
and undergoing microbial metabolism (Hong & Mitchell 2006). A proportion of 
metabolites will also enter the circulatory system and be transported in plasma to tissues 
throughout the body. Quercetin has been observed to accumulate in relatively small 
quantities in a number of rat tissues, with the highest concentration found in the lungs 
(Paulke et al. 2012). Deconjugation of metabolites to the aglycone form, however, may 
take place at the interface with endothelial cells and other target tissues, through enzymes 
such as β-glucuronidase. It is also possible that polyphenols. including quercetin, may 
become deconjugated once inside cells (Terao et al. 2011; Perez-Vizcaino et al. 2012). 
Conjugation has the effect of reducing the hydrophobicity of quercetin, which facilitates 
transport through lipid bilayers of the plasma membrane. Inflammation of tissues may aid 
in transport of quercetin conjugates, however, as Q3GlcA was reported to pass through 
aortic endothelial cells and reach vascular smooth muscle cells under such conditions 
(Mochizuki et al. 2004). Once in these tissues, further conjugation/deconjugation may 
occur before efflux back to the circulatory system. Excretion of most phenolic 
metabolites then occurs 24-48 hours after initial ingestion. While there has been a 
growing effort in the past decade to include human metabolites of polyphenols in in vitro 
studies alongside the forms found in plants, their synthesis can prove difficult and may 
not provide the quantities necessary for such experiments.  
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1.6. Proposed mechanisms underlying polyphenol bioactivity 
The means by which polyphenols exert their beneficial effects on the cardiovascular 
system are still under investigation, though a number of mechanisms have been proposed 
and shown to be effective in vitro. As was previously mentioned, while the physiological 
concentrations of phenolic compounds are unlikely to provide a strong antioxidant effect, 
they may still act as antioxidants indirectly by inhibiting ROS-generating enzymes or 
activating cellular antioxidant responses. Increased expression of antioxidant response 
enzymes such as thioredoxin or peroxidases by activation of transcription factors such as 
Nrf-2 can also be trigged by exposure of cells to phenolic compounds such quercetin 
(López-Alarcón & Denicola 2013). Lipoxygenases, which catalyse the oxidation of fatty 
acids, can be inhibited by a number of flavonoids, likely through the chelation of iron 
from its catalytic domain. Production of superoxide by NADPH oxidase can also be 
inhibited by polyphenols, notably by epicatechin and its methylated/glucuronidated 
conjugates (Steffen et al. 2007; Steffen et al. 2008). Xanthine oxidase (XO) generates 
xanthine from hypoxanthine, and uric acid from xanthine, converting water to hydrogen 
peroxide in the process (Ozyürek et al. 2009). Polyphenols, including quercetin and 
luteolin (Pauff & Hille 2009), have been shown to inhibit xanthine oxidase activity, and 
dietary intake of phenolics alongside vitamins has also been shown to reduce uric acid 
levels in human plasma (Qureshi et al. 2012). A structure-activity study reported that an 
unsaturated 2,3-bond is important for inhibition of XO by flavonoids, alongside the 4-
keto group of flavonols and flavones (Mladenka et al. 2010). 
 Small changes to a phenolic compound's structure can have a significant effect on 
its bioactivity. The addition of a single hydroxyl group, i.e. the difference between 
catechin and gallocatechin, can produce significant differences in the spatial arrangement 
of the molecule (Du et al. 2012). Methylation of flavonoids can reduce their ability to 
inhibit ROS-generating enzymes (Loke et al. 2008b), as well as their induction of 
apoptosis in cancer cells (Landis-Piwowar et al. 2008). Glycosylation of polyphenols can 
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reduce their suppression of liver cancer cell proliferation (Loa et al. 2009), and a planar 
structure can improve antioxidant activity (Moalin et al. 2011). Structural changes can 
also affect the binding affinity of polyphenols for proteins. Increased hydroxylation of the 
A- and B-rings, the presence of an unsaturated 2,3-bond, a lack of sugar groups and the 
presence of galloyl groups are all factors which improve polyphenol-plasma protein 
binding affinity (Xiao & Kai 2012). The binding of plasma and cellular proteins to 
polyphenols is likely to be important in the context of in vivo bioactive effects. For 
example, flavonoids have been shown to bind to the anti-atherogenic protein PON1 and 
protect it from inhibition (Atrahimovich et al. 2013). Quercetin has been shown to inhibit 
a wide array of human kinases at 2 and 30 µM (Boly et al. 2011), and was reported to 
bind to and inhibit the microbial enzyme D-alanine ligase, with greater potency than 
apigenin, indicating the importance of quercetin's extra hydroxyl groups for this 
interaction (Wu et al. 2008). Flavone and flavanone structures were found to be more 
effective than other polyphenols at inhibiting the activity of the cytochrome P450 enzyme 
aromatase, in particular flavones and flavanones with hydroxylation at the 3', 4', 5 and 7 
positions (Neves et al. 2007).  As well as proteins, polyphenols can also interact with the 
lipid bilayer of the plasma membrane, where they are likely to bind and penetrate the 
layer and form interlayer bridges, causing the collapse of the interbilayer fluid space and 
hyperpolarisation of the membrane (Huh et al. 1996). 
 Additional potential mechanisms for the beneficial vascular effects of polyphenols 
include prevention of platelet aggregation through inhibition of the thromboxane receptor 
or synthesis of thromboxane itself (Hubbard et al. 2004; Vita 2005), as well as reducing 
the expression of cell adhesion molecules, such as ICAM-1 and VCAM-1 (Kim et al. 
2011; Song et al. 2011). Evidence from animal studies indicates that polyphenols are also 
able to cause dilation of vascular tissues, in both endothelium-dependent and 
endothelium-independent manners, likely involving decreases to intracellular Ca
2+
 
concentration and increases to nitric oxide production (Hotta et al. 2006; Villar et al. 
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2005; Romano & Lograno 2009; Schmitt & Dirsch 2009). It appears that the 4-keto 
group, as well as hydroxylation of the A-ring of flavonoids are important for this activity, 
alongside the removal of sugar moieties (Xu et al. 2007). Quercetin, epicatechin-gallate, 
isoflavones and resveratrol have all been shown to have potent vasodilator effects on 
vascular tissue. 
 Signal transduction plays an important role in mediating early responses to 
circulatory compounds that lead to functional outcomes with important implications for 
vascular health. While changes to RNA transcription and protein levels are important for 
mediating downstream functional changes, protein-protein interactions and changes to 
their structures are a critical part of early signalling events. Introduction of individual 
polyphenols to cells and tissues may initiate one key signalling event that varies 
depending on the type of cell, or may start a number of events that cause cascades of 
various signalling pathways. Crosstalk between signalling pathways downstream of 
initial signalling events can complicate analyses, especially if sensitivity to additional 
external factors was the case, and make it difficult to draw conclusions between 
functional outcomes and upstream signalling. Therefore focusing on early signalling 
events would theoretically provide a simpler view of the mechanistic effects induced by 
bioactive compounds. 
 One common method for proteins to transduce signals is through the attachment 
of phosphate groups (phosphorylation) to serine, threonine or tyrosine residues. This 
affects the structural conformation of the protein, changing them into a state where they 
have enzymatic activity. Often this activity can directly or indirectly lead to 
phosphorylation of additional proteins (kinase activity), causing a signal cascade 
(McCubrey et al. 2012). There are many biochemical methods routinely used for 
measuring levels of phosphorylated (phospho-) proteins, such as ELISA or western 
blotting, which generally allow assay of a small numbers of targets. 
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1.7. Consumption of polyphenols in traditional diets 
Though there are still limits to the methods by which dietary intake of polyphenols are 
accessed, mostly by databanks and food diaries (Spencer et al. 2008), consumption is 
estimated at 1 g/day (Touvier et al. 2011; Ovaskainen et al. 2008). This value can vary, 
however, as regions across the world have their own particular dietary habits. For 
example, a national survey of Spanish households found that intake was closer to 3 g/day 
(Saura-Calixto et al. 2007). This variation in levels of phenolics consumed is also 
reflected in studies which show that diets of particular regions can provide beneficial 
effects to cardiovascular health. The so-called 'French paradox' notes that there is a 
relatively low incidence of CVD amongst populations located along the north 
Mediterranean coast, in spite of diets that include high levels of saturated fats and red 
meats, indicative of higher CVD risk. It is suggested this may be in part due to increased 
consumption of polyphenol-rich foods in these regions, including red wine and olive oil 
(Shukla et al. 2010; Rasmussen et al. 2005). To date, the focus of many of the studies 
concerned with the connection between polyphenols and health have been food plants 
common to the modern diets of Western European and North American countries, 
including cocoa, coffee, tea, onions and apples (Crozier et al. 2009). Limited attention 
has been given to less well-known foods of other international regions. Such foods are 
likely to make use of plant ingredients that, while uncommon in western diets, may prove 
to be rich sources of polyphenols with potential benefits to human vascular health. 
 Traditional foods (defined by the European Food Information Resource (EuroFIR) 
as those that are produced by practices dating to before the Second World War (Costa 
2007)) by their nature have the advantage of being both affordable and easy to obtain, 
and are usually of high cultural importance. There is evidence, however, that such foods 
can also be perceived as being high value or inappropriate for daily consumption, often 
being reserved for festive occasions (Almli et al. 2011). Changes to dietary habits, such 
as inclusion of modern, convenience foods, may threaten the continued use of traditional 
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foods (Trichopoulou et al. 2006; Milošević et al. 2012). Providing evidence of health 
benefits, or developing means for improving nutritional value, would help reverse such a 
trend. Geographical areas where such traditional foods have received little attention with 
regards to health effects, provide the potential for uncovering new sources of beneficial 
polyphenols, as well as building evidence for future health claims and providing support 
for the continued production of traditional foods and sustained crop diversity 
(Trichopoulou et al. 2007). One such area is that of the Middle Eastern European 
countries surrounding the Black Sea. This is an area which has had little research into the 
health outcomes of their traditional and modern diets. It is likely that a number of the 
plant foods consumed in these countries to provide some health benefit, and by 
understanding which foods these are, better nutritional advice can be provided for those 
who suffer health problems such as cardiovascular disease, in these countries. 
 There is epidemiological evidence from recent studies that high CVD risk, 
measured using markers which include obesity, C-reactive protein and levels of lipids, is 
associated with a significant proportion (> 50% in some cases) of the populations of 
countries surrounding the Black Sea, including Turkey (Onat 2004; Onat et al. 2011), 
Bulgaria (Dyakova et al. 2008; Kurktschiev et al. 2009), Georgia (Davis et al. 2005; Grim 
et al. 1999), Romania (Daina et al. 2008; Dorobantu et al. 2010) and Ukraine (Khalangot 
et al. 2009). There are currently no reports as to whether easily accessible foods, such as 
those found in traditional diets, are able to counter levels of CVD risk when they are 
included in the diet. To assess potential health benefits that could be derived from 
traditional diets in this region, the EU FP7 project 'BaSeFood' was set up to study foods 
of Romania, Ukraine, Georgia, Turkey, Bulgaria and Russia (D‘Antuono et al. 2010). 
Part of the preliminary work for this project was to compile a list of traditional dishes 
indigenous to the mentioned countries. This list would act as a basis from which to select 
foods of plant origin for this project, with an aim to study their polyphenol contents and 
potential bioactive properties.  
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1.8. Aims of the project  
It was hypothesised that plant foods originating from traditional diets of countries 
surrounding the Black Sea would contain polyphenols which, in their native or phase-II 
metabolised form, would be able to influence endothelial cell signalling in a manner 
associated with improved endothelial function. To test this hypothesis, polyphenols and 
polyphenol-rich plant extracts would be prepared for incubation with endothelial cell 
cultures, followed by analysis of specific or broad ranges of signalling molecules. 
Specifically, this work would involve: 
 
 The systematic selection of plant foods traditionally eaten in countries 
surrounding the Black Sea, for the preparation of bioactive-rich extracts and 
representative individual compounds. 
 
 Treatment of endothelial cell cultures with the plant extracts or pure compounds, 
and preparation of cell lysates for the analysis of signalling molecules, including 
those related to endothelial function, for the identification of bioactive 
compounds. 
 
 Determining which compounds were responsible for any observed bioactivity 
after exposure of cells to plant extracts, and identification of the underlying 
molecular mechanisms for the polyphenol bioactivity. 
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Chapter 2: Selection of food plants, and general methods for 
their biochemical analysis 
 
2.1. Selection of traditional food plants 
2.1.1. Determining the main ingredients of selected traditional dishes 
This PhD project was funded by a Framework Programme 7 (FP7) grant (Sustainable 
exploitation of bioactive components from the Black Sea Area traditional foods 
(BaSeFood), grant number: 227118) from the European Union in which the Institute of 
Food Research was a full beneficiary. The FP7 project ‗BaSeFood‘ was concerned with 
evaluating the potential benefits of bioactive-rich plants that were used in traditional 
foods in the little studied Black Sea region countries. At the 2nd BaSeFood Consortium 
Meeting (October 2009), a shortlist of traditional foods was compiled by the BaSeFood 
consortium partners (Table 2.1), with each of the Black Sea area country representatives 
selecting a traditional dish in each of the following categories; (i) fruit, (ii) vegetables, 
(iii) herbs and spices, (iv) oilseeds, (v) cereals and (vi) fermented foods (Tables 2.2 and 
2.3).  
 
Table 2.1: BaSeFood project partners of countries surrounding the Black Sea 
Project Partner Country 
University of Food Technologies Bulgaria 
Elkana Biological Farming Association Georgia 
Academy of Economic Studies Romania 
Moscow State University of Food Production Russia 
Yeditepe University Turkey 
Uzhhorod National University/Odessa 
National Academy of Food Technologies 
Ukraine 
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Table 2.2: Representative country of project partners and their chosen foods. 
 
Table 2.3: Representative country of project partners and their chosen foods. 
 
Information provided by the BaSeFood project partners was used to determine the main 
ingredients in the dishes listed in Table 2.2 (work to determine the main ingredients of 
the dishes presented in Table 2.3 was carried out by Wendy Hollands, IFR, UK), and 
where recipe information was not available from the project partners, systematic web 
searches were performed using the search engine Google (www.google.com) to 
determine the main ingredients of the dishes. Web searches were performed using either: 
(i) the dish's name as given by the project partner, i.e. ―vegetable okroshka‖ 
(ii) the name translated into the project partner‘s native language, i.e. ―овощной 
окрошка‖, or  
(iii) single keywords from the whole name using either of the aforementioned 
methods. i.e. ―okroshka‖ or ―окрошка‖ 
Translation was performed using the Google Translate facility. Recipes (date of access, 
Nov. 2009) were deemed to be of use for determining the dish‘s main ingredients when: 
 the recipe‘s website featured within the top 20 results 
Country Vegetables Fermented Herbs & spices 
Bulgaria Tikvenik Boza Mursal tea 
Georgia Nettles and walnut sauce n/a Wild plum sauce 
Romania Sour nettle soup Socata Herbal dish 
Russia Vegetable okroshka Southern kvass n/a 
Turkey Kale Pickled green beans Black tea 
Ukraine Ukrainian borscht Sauerkraut Dill 
Country Fruits Cereals Oilseeds 
Bulgaria Fruits of the forest Wheat bread Sesame seeds 
Georgia Churchkela Doli wheat bread Flax oil 
Romania Plum jam/pomegranate Mamaliga n/a 
Russia Watermelon juice Buckwheat porridge Mustard oil 
Turkey Persimmon Corn bread n/a 
Ukraine Uzvar Sour rye bread Sunflower seeds 
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 a majority of the ingredients were shared with other recipes in the search results 
The main ingredients of each dish, alongside the proportion of the dish that they represent 
are given in Tables 2.4 and 2.5. The sources for the information given in these tables are 
presented in Table 2.7, numbered accordingly between tables. The main ingredients of 
the dishes listed in Table 2.3 are presented in Table 2.6. 
 
Table 2.4: Main ingredients of the traditional dishes from the 'Vegetables' category 
(Table 2.2), alongside the approximate percentage of each ingredient in the dish. n/a - 
ingredient forms the whole of the dish, i.e. close to 100%. nd - no data available. Sources 
for the presented information are listed in Table 2.7. 
Dish Main ingredients % of dish Sources 
Kale n/a n/a i 
Nettles and 
walnut sauce 
Nettles nd ii 
Walnuts nd 
Sour nettle 
soup  
Nettle 80 iii 
Onion 10 
Bors n/a 
Carrots 5 
Celery Root 5 
Rice n/a 
Tikvenik Pumpkin 92 iv 
Walnuts 7.7 
Cinnamon 0.3 
Flour, Sugar, Oil/Butter n/a 
Ukrainian 
borscht 
Beetroot 25 v 
Cabbage 20 
Potatoes 25 
Carrot 10 
Onion 10 
White beans 10 
Parsley root, celery, garlic, tomato paste, 
kvass, lemon, sugar, sour cream, dill 
n/a 
 
Vegetable 
okroshka 
Potatoes 35 vi 
Cucumber 30 
Spring Onions 15 
Carrots 10 
Turnips 10 
Radish 10 
Kvass, dill, parsley, eggs, sour cream n/a 
 
 49 
Table 2.5: Main ingredients of the traditional dishes from the 'Fermented' and 'Herbs 
and spices' categories (Table 2.2), alongside the approximate percentage of each 
ingredient in the dish. n/a - ingredient forms the whole of the dish, i.e. close to 100%. nd - 
no data available for the percentage of this ingredient in as part of the whole dish. 
Sources for the presented information are listed in Table 2.7. 
Dish Main Ingredients % of dish Sources 
Boza Millet nd vii 
 
Sugar nd 
Socata Elderflowers nd viii 
 Lemons nd 
Sugar, yeast nd 
Southern kvass  Rye bread nd ix 
Sugar, yeast - 
Pickled green 
beans 
Green beans nd i 
Onions nd 
Sauerkraut  Cabbage nd x 
Mursal tea Sideritis n/a iv 
Wild plum sauce Plum nd xi 
Dill nd 
Coriander nd 
Herbal dish Parsley 40 xii 
Dill 40 
Onion 19 
Mint, sweet basil, sage <1 
Dill n/a n/a n/a 
Black tea n/a n/a n/a 
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Table 2.6: Main ingredients of the traditional dishes from the 'Fruits', 'Cereals' and 
'Oilseeds' categories (Table 2.3), alongside the approximate percentage of each 
ingredient in the dish. n/a - ingredient forms the whole of the dish, i.e. close to 100%. nd - 
no data available for the percentage of this ingredient in as part of the whole dish. 
Dish Main Ingredients 
Sunflower hulva 
 
Sunflower seeds, liquorice, cocoa powder, raisins, vanilla, 
sugar, molasses 
Uzvar Dried apple, pears and prunes, syrup 
Sour rye bread Rye flour, yeast, sugar 
Mustard oil n/a 
Water melon juice n/a 
Buckwheat porridge Buckwheat 
Plum jam Plums 
Mamaliga Water, salt, cornmeal 
Flax oil n/a 
Churchkela 
 
Walnut, hazelnut, almonds (skins removed), dried fruits, 
grape juice and corn flour  
Bread baked from 
Akhaltsikhe Mesfhetion 
tsiteli doli  
Wheat flour, Makhobeli (wild plant) grains  
 
 
Sesame seeds n/a 
Fruits of the forest Fruits bearing resemblance to blueberries 
Wheat bread Wheat flour 
Persimmon fruit  n/a 
Pomegranate n/a 
Fruit of the evergreen 
cherry laurel 
n/a 
 
Corn bread  Corn  
Cracked corn soup Corn, pinto beans, yoghurt 
Bulgar pilaf Bulgar, Chicken broth, onion, tomato, green pepper 
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Table 2.7: Citations referred to in Tables 2.4 and 2.5. 
No. References 
i (Yeditepe University 2009) 
ii (Charlotte‘s VVeb 2009; World Health Circle of International Cooking 2009) 
iii (Bucharest Academy of Economic Studies 2009; Eculinar 2009; Gastropedia 
2009; Retete Mancare 2009) 
iv (University of Food Technologies 2009) 
v (Elena Filatova 2007; Gotovim 2009; Russland Journal 2009a; Say7 2006; The 
Worldwide Gourmet 2009; Ukraine Orphans 2009) 
vi (Moscow State University of Food Productions 2009; Gastronom 2009; Good-
Cook 2009; Gotovim 2009; Povarenok 2009; Russland Journal 2009b; Russian 
Foods 2009; Wikipedia (RU) 2009) 
vii (Gotvarstvo 2009; Sulekha 2008; Wikipedia (BG) 2009) 
viii (Bucharest Academy of Economic Studies 2009; Europe-Cities 2009; Global 
Oneness 2009) 
ix (Moscow State University of Food Productions 2009; The Kombucha Journal 
2009) 
x (Boyko et al. 2009) 
xi (Elkana - Biological Farming Association 2009) 
xii (Dr Alexandru Stroia, ASE (personal communication), 11/12/2009) 
 
2.1.2. Bioactive constituents of the main plant ingredients 
Literature reviews were conducted using the online databases Web of Knowledge and 
PubMed, to determine main bioactive compounds in the plant ingredients detailed in 
Section 2.1.1 (the bioactive content of the food plants listed in Table 2.6 was researched 
by Wendy Hollands, IFR, UK). The polyphenol database website Phenol Explorer was 
also used to determine the phenolic content of food plants (Neveu et al. 2010), along with 
their total phenolic content (TPC). Reviewed literature was used to estimate the TPC of 
any foods not present on Phenol Explorer. This information is presented in Table 2.8, 
with sources for the information listed in Table 2.9. The main bioactive compounds 
found in the plant foods listed in Table 2.6 are presented in Table 2.10. 
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Table 2.8: Plant ingredients from the categories 'Vegetables', 'Fermented' and 'Herbs 
and spices' (Table 2.2) and their main bioactive compounds/classes, with compounds of 
note given in brackets alongside. The total phenolic content (TPC) of each food plant is 
given as mg/100 g. Sources for the information presented here are listed in Table 2.9. 
Plant 
ingredient 
TPC  Phenolics and other main bioactives Sources 
Kale 177 Large number glycosides of kaempferol (foremost), 
quercetin and isorhamnetin 
Glucosinolates (brassicin)  
Carotenoids (lutein & β-carotene) 
i 
Nettles 110 Hydroxycinnamic acids 
Flavanol glycosides (quercetin)  
Anthocyanins 
ii 
Walnuts 1625 Ellagic acid, gallic acid  
Hydroxybenzoic acids (vanillic and ferulic acid) 
Hydroxycinnamic acids 
iii 
Onion 46 Flavanol glycosides (quercetin)  
Protocatechuic acid 
iv 
Carrot 58 Flavonoids (quercetin) 
Phenolics – hydroxybenzoic/cinnamic acids 
Carotenoids (β-carotene) 
v 
Celery 
root 
59 Flavonoids (apigenin) 
 
iv 
Rice 95 Phenolics – hydroxybenzoic/cinnamic acids iv 
Pumpkin 16 Carotenoids (lutein and β-carotene) 
Phenolics – hydroxybenzoic/cinnamic acids 
vi 
Cinnamon 9700 Catechin, epicatechin, procyanidins (B2 dimer) 
Cinnamaldehyde, caffeic acid 
vii 
Beetroot 164 Betalains (betanin), flavonoids (luteolin)  viii 
Cabbage 
 
 
 
15 Flavonoids (quercetin and kaempferol glycosides) 
Glucosinolates (sinigrin, glucoberin) 
Hydroxycinnamic acids (sinapic acid derivatives, 3-
p-coumaroylquinic acid) 
ix 
Potatoes 31 Phenolics – hydroxybenzoic/cinnamic acids x 
White 
beans 
 
138 Hydroxycinnamic acids (ferulic acid), small 
quantities of flavan-3-ols 
Glycosides of quercetin and kaempferol 
iv 
Cucumber 18 Flavones (luteolin), kaempferol, quercetin  
Lignans (secoisolariciresinol) 
iv 
Spring 
Onions 
107 Kaempferol and quercetin glycosides 
Hydroxycinnamic acids (ferulic acid) 
Flavones (baicalein) and flavanones (hesperidin) 
xi 
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Table 2.8: Plant ingredients from the categories 'Vegetables', 'Fermented' and 'Herbs 
and spices' (Table 2.2) and their main bioactive compounds/classes, with compounds of 
note given in brackets alongside. The total phenolic content (TPC) of each food plant is 
given as mg/100 g. Sources for the information presented here are listed in Table 2.9. 
Plant 
ingredient 
TPC  Phenolics and other main bioactives Sources 
Turnips 
 
 
55 Glucosinolates (gluconapin), 
Glycosides of kaempferol, quercetin and 
isorhamnetin 
xii 
Radish 44 Lignans (pinoresinol) 
Kaempferol  
Glucosinolates (glucoerucin and glucoraphenin) 
Anthocyanins acylated with phenolic acids 
xiii 
Elderflower 
 
 
- Caffeic acid derivatives,  
Glycosides of kaempferol, quercetin and 
isorhamnetin 
xiv 
Lemons 60 Flavanones (eriodictyol, hesperetin) iv 
Rye bread - Ferulic acid, lignans iv 
Green beans 304 Catechin, epicatechin, procyanidin dimers 
Kaempferol and quercetin glycosides 
xv 
Cabbage 
(fermented) 
15 ITCs (allyl isothiocyanate, sulforaphane) xvi 
Sideritis 480 Flavone glycosides (apigenin, hypolaetin, luteolin) 
Phenolics – hydroxybenzoic/cinnamic acids 
Lignans (sesamin) 
Di- and tri-terpenoids (siderol, squalene) 
xvii 
Plum 410 Quercetin glycosides (3-O-rutinoside) 
(Epi)catechin, procyanidin dimers & trimers 
Peonidin and cyanidin glycosides 
Caffeic acid 
iv 
Dill 
 
208 Glycosides of kaempferol, quercetin and 
isorhamnetin 
xviii 
Coriander 159 Ferulic, caffeic & gallic acid 
Quercetin and kaempferol 
xix 
Parsley 90 Gallic, protocatechuic and caffeic acid 
Quercetin, kaempferol,  
Luteolin, myricetin and apigenin 
xx 
Black tea  105 (Epi)catechin, procyanidins, theaflavins 
Kaempferol and quercetin glycosides  
Phenolics – hydroxybenzoic/cinnamic acids 
iv 
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Table 2.9: Citations referred to in Table 2.8. 
No. References 
i (Yeditepe University 2009; Neveu et al. 2010; Kopsell et al. 2003; Sarikamis et 
al. 2008; Schmidt et al. 2010) 
ii (Chrubasik et al. 2007; Pinelli et al. 2008) 
iii (Neveu et al. 2010; Jakopic et al. 2009; Shan et al. 2005; Stampar et al. 2006) 
iv (Neveu et al. 2010) 
v (Neveu et al. 2010; Bub et al. 2000) 
vi (Neveu et al. 2010; Kurz et al. 2008) 
vii (Neveu et al. 2010; Peng et al. 2008) 
viii (Neveu et al. 2010; Kujala et al. 2002; Kujala et al. 2001) 
ix (Neveu et al. 2010; Mattila & Hellström 2007; Sousa et al. 2008; Tolonen et al. 
2002) 
x (Neveu et al. 2010; Mattila & Hellström 2007) 
xi (Neveu et al. 2010; Marinova et al. 2005; M. Parvu et al. 2010; Thompson et al. 
2005; Aoyama & Yamamoto 2007) 
xii (Neveu et al. 2010; Francisco et al. 2009) 
xiii (Neveu et al. 2010; Malik et al. 2010; Matsufuji et al. 2007) 
xiv (L. Christensen et al. 2008; Kaack & Christensen 2010) 
xv (Neveu et al. 2010) 
xv (Neveu et al. 2010; Hertog et al. 2002; Sarkams et al. 2009) 
xvi (Neveu et al. 2010; Tolonen et al. 2002) 
xvii (Gabrieli et al. 2005; Janeska et al. 2007; Koleva 2007) 
xviii (Neveu et al. 2010; Justesen & Knuthsen 2001; Justesen 2000) 
xix (Neveu et al. 2010; Hadjmohammadi & Sharifi 2009) 
xx (Neveu et al. 2010; Mišan et al. 2011) 
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Table 2.10: List of plant ingredients from the categories 'Fruits', 'Cereals' and 'Oilseeds' 
(Table 2.3) and their main bioactive compounds/classes, with compounds of note given 
in brackets alongside. 
Plant 
ingredient 
Phenolics and other main bioactives 
Sunflower seeds  Phenolics – hydroxybenzoic/cinnamic acids 
Liquorice Flavanols (quercetin) 
Cocoa powder 
 
Flavanols - epicatechin, catechin, procyanidins 
Phenolics - hydroxybenzoic/cinnamic acids 
Raisins Phenolics –hydroxybenzoic/cinnamic acids 
Flavonols - quercetin-3-O-rutinoside 
Dried apple  Flavanols and phenolics (but a reduced quantity due to drying) 
Dried pear Flavanols and phenolics (but a reduced quantity due to drying) 
Rye flour Phenolics – hydroxybenzoic/cinnamic acids (ferulic, sinapic 
and p-coumaric acid) 
Lignans 
Buckwheat Flavonols (rutin and other quercetin glycosides) 
Flavanols (catechin, epicatechin, procyanidins) 
Flax oil Lignans, phenolic acids 
Almonds Flavanols – Epicatechin, catechin, epigallocatechin gallate 
Flavanones – Naringenin 
Flavonols – Isorhamnetin, Kaempferol, quercetin 
Phenolics – Hydroxybenzoic acid  
Hazelnut Flavanols – Epicatechin, catechin, epigallocatechin gallate 
Grape juice Flavanols,  
Flavones (apigenin, luteolin),  
Flavonols (kaempferol, quercetin, myricetin)  
Wheat flour 
mixed with 
Makhobeli (wild 
plant) grains  
Flavonoids and phenolic compounds 
 
 
Pomegranate Anthocyanins (cyanidin, delphinidin) 
Ellagitannins (punicalagin) 
Catechins, procyanidins 
Sesame seeds Lignans 
Fruit of the 
evergreen cherry 
laurel 
Anthocyanins 
 
Persimmon Flavanols - Catechin, epicatechin, epigallocatechin, 
Phenolics - chlorogenic acid, caffeic acid, gallic acid 
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2.1.3. Criteria for the selection of food plants 
The following criteria were used to grade and rank the plant ingredients, from which the 
top six would be chosen for further study. 
(i) In-house expertise for bioactives - Preference was given to plants which 
contained bioactives that members of our lab had expertise in. This criteria, which 
was further divided into the categories of main expertise (A) and additional 
expertise (B - D) is graded (high to low) as follows: 
A. Plant contains flavonoids 
B. Plant contains glucosinolates 
C. Plant contains non-flavonoid polyphenols 
D. Plant contains non-polyphenolic, non-glucosinolate bioactives 
 
(ii) Proportion in final dish - Preference was given to plant-ingredients which were 
present in larger quantities in the final dish. The criteria is graded (high to low) as 
follows: 
A. 50 - 100 % of the final dish 
B. 25 - 49 % of the final dish 
C. 5 - 24 % of the final dish 
D. 0 - 4 % of the final dish 
 
(iii) Concentration of bioactives in plant-ingredients - Preference was given to 
plant-ingredients which contain higher concentrations of bioactives, based on 
information presented in Table 2.8. The criteria is graded (high to low) as 
follows: 
A. > 400 mg bioactives/100 g fresh weight 
B. 100 - 400 mg bioactives/100 g fresh weight 
C. 40 - 100 mg bioactives/100 g fresh weight 
D. 0 - 40 mg bioactives/100 g fresh weight 
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(iv) Prevalence of ingredients in Western European diets - Plant-ingredients which 
featured less prominently in diets of western Europe were graded higher. This 
criteria is graded (high to low) as follows: 
A. Rare occurrence in Western European diet 
B. Occurs in Western European diet to a lesser extent 
C. Common in Western European diet 
 
(v) Prevalence of ingredients in traditional dishes - Plant-ingredients which 
appeared in more than one of the dishes listed in Tables 2.2 and 2.3 were higher 
preference. This criteria is graded (high to low) as follows: 
A. Appearance in more than 2 dishes 
B. Appearance in 2 dishes 
C. Appearance in 1 dish 
 
2.1.4. Ranking of food plants 
Plant ingredients were sorted by criteria grades, with the criteria ranked in the following 
order (headings for Table 2.11 given in brackets alongside): 
(i) In-house expertise for bioactives (Expertise) 
(ii) Proportion in final dish (Propor.) 
(iii) Concentration of bioactives in plant-ingredients (Conc.) 
(iv) Prevalence of ingredients in Western European diets (Diet) 
(v) Prevalence of ingredients in traditional dishes (Dishes) 
(vi) Additional lab expertise of bioactives (Add. expertise) 
 
The final selected foods are underlined in Table 2.11. While plum was initially selected, 
a sample of the fruit could not be obtained, so pomegranate was selected instead. 
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Table 2.11: Plant-ingredients graded by the criteria from Section 2.1.3. The highest 
grading foods which were selected for further study are underlined. 
Plant 
ingredient 
Selection criteria 
Expertise Propor. Conc. Diet Dishes Add. expertise 
Sideritis A A A A C C, D 
Plum A A A B B C 
Kale A A A B C B, C 
Nettle A A B A B C 
Persimmon A A B A C  
Dill A A B B A  
Pomegranate A A B B C C 
Cherry Laurel A A B B C C 
Tea A A B C C C 
Green Beans A A B C C  
Watermelon A A C B C  
Blueberries A B A C C  
Beetroot A B B B C D 
Parsley  A B B C B  
Cucumber A B D C C C 
Elderflowers A C A A C C 
Cocoa Powder A C A C C C 
Raisins A C A C C C 
Liquorice A C A C C  
White beans A C B A C C 
Dried Apple A C B A C C 
Dried Pear A C B A C C 
Almonds A C B C C C 
Spring Onions A C B C C C 
Grape A C B C C  
Hazelnut A C B C C  
Onion A C C C A  
Turnips A C C C C B 
Radish A C C C C B, C 
Celery Root A C C C C  
Lemons A C C C C  
Sage A D B C C C 
Mint  A D B C C  
Celery  A D D C C C 
Mustard Oil B A A C C  
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Table 2.11: Plant-ingredients graded by the criteria from Section 2.1.3. 
Plant-ingredient 
Selection Criteria 
Expertise Propor. Conc. Diet Dishes Add. Expertise 
Cabbage B A D C B A, C 
Buckwheat C A A A C A 
Sesame Seeds C A A A C  
Corn C A B A B D 
Sunflower Seeds C A B B C  
Flax Seed Oil C A C A C  
Rye Flour C A C A C  
Wheat flour C A C C B A 
Potatoes C B D C B  
Walnuts C C A A B  
Coriander C C B C C A 
Cinnamon C D A C C A 
Sweet Basil C D B C C  
Rice C D C C C  
Pumpkin D A D A C C 
Carrots D C C C B A, B 
Garlic D D C C C  
 
2.1.5. Detailed literature analysis of the bioactive content for selected food plants 
Through systematic grading by defined criteria, the food plants dill, nettle, sideritis, kale, 
pomegranate and persimmon were selected for study in this project. The literature was 
studied exhaustively to determine all the phenolic compounds that had been identified in 
each of plants. Only studies which focused on the parts of the plant which would be of 
focus in this project (i.e. the edible parts) would be used for determining their phenolic 
content, these being the aerial parts of dill, nettle, kale and sideritis, persimmon fruit and 
pomegranate arils. The phenolic composition of the six plant foods are given in Tables 
2.12 to 2.21. The food plants were also analysed by Shikha Saha (IFR, UK), using a high-
performance liquid chromatography–diode array detection–mass selective detection 
system. Compounds similar to those presented in the following tables were detected, and 
the data from these analyses has been published elsewhere, by Hollands et al. (2013b). 
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Table 2.12: Phenolic compounds identified in dill by previous studies. 
Dill phenolic compounds Refs. 
Quercetin -3-O-glucuronide (Justesen 2000) 
-3-O-rutinoside 
-3-O-galactoside (Teuber & 
Herrmann 1978) -3-O-glucoside 
Isorhamnetin  -3-O-glucuronide (Justesen 2000) 
-3-O-rutinoside 
-3-O-galactoside (Teuber & 
Herrmann 1978) -3-O-glucoside 
Kaempferol -3-O-glucuronide (Justesen 2000) 
 
Table 2.13: Range of concentrations of phenolic compounds found in dill, and the 
number of samples used to calculate values. 
Dill phenolic compounds mg/100 g fresh weight Refs. and no. of samples (n) 
Quercetin aglycone 48 - 110 (Justesen & Knuthsen 2001) 
(n=2) Kaempferol aglycone 16 - 24 
Isorhamnetin aglycone 15 - 72 
 
Table 2.14: Phenolic compounds identified in either nettle leaf (L), stem (S) or both, by 
previous studies, the their range of concentrations found in plant material. 
Nettle phenolic compounds Leaf or 
stem 
mg /100 g 
fresh weight 
Refs. 
Quercetin-3-O-glucoside L & S 8.5 - 60 (Grevsen et al. 2008; 
Pinelli et al. 2008) Quercetin-3-O-rutinoside L & S 34 - 271 
Isorhamnetin 3-O-rutinoside L & S 5 - 61 
Kaempferol 3-O-rutinoside L & S 1.7 - 12 
Caffeic acid derivative L & S 27 - 43 (Pinelli et al. 2008; 
Chrubasik et al. 2007) 
p-Coumaric acid L & S 3.8 - 11.8 (Pinelli et al. 2008) 
5-O-feruloylquinic acid - - (Grevsen et al. 2008) 
5-O-caffeoylquinic acid 
S 6.6 - 15 
(Grevsen et al. 2008; 
Pinelli et al. 2008; 
Chrubasik et al. 2007) 
3-O-caffeoylquinic acid 
2-O-caffeoylmalic acid L 139 - 334 (Pinelli et al. 2008; 
Grevsen et al. 2008) 
Chlorogenic acid L & S 66 - 216 (Pinelli et al. 2008; 
Chrubasik et al. 2007) 
Peonidin-3-O-rutinoside S 7 - 34 (Pinelli et al. 2008) 
Peonidin-3-O-(6′′-O-p-
coumaroyl-glucoside) 
S 0 - 3.4 
Rosinidin-3-O-rutinoside S 11 - 68 
Scopoletin - - (Chrubasik et al. 2007) 
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Table 2.15: Phenolic compounds identified in persimmon by previous studies, their 
range of concentrations and the number of cultivars/samples used to calculate values. 
Persimmon phenolics 
compounds 
mg/100 g fresh 
weight 
Refs. and no. of cultivars and 
samples (n) 
(-)-Epicatechin 0.5 - 1.49 (Gorinstein et al. 2001) (n=8) 
(+)-Catechin 0.4 - 3.3 (Veberic et al. 2010; 
cultivars=11, n=15) 
(+)-Gallocatechin 0.17 (Neveu et al. 2010; Akagi et al. 
2009; cultivars=5, n=3; 
Suzuki et al. 2005; cultivars=5, 
n=3) 
 
Procyanidin dimer B1 0.13 
Procyanidin dimer B3 0.01 
Procyanidin trimer E→E→C 0.04 
Prodelphinidin dimer B3 0.30 
Quercetin-3-O-rutinoside Trace (Veberic et al. 2010; 
cultivars=11, n=15) Quercetin-3-O-glucoside 
Quercetin-3-O-galactoside 
Caffeic acid Trace 
Gallic acid 1.8 - 221 (Veberic et al. 2010; 
cultivars=11, n=15; Gorinstein et 
al. 2001; n=8) 
Ferulic 9.3 - 11 (Gorinstein et al. 2001; n=8) 
Protocatechuic 5.7 - 6.9 
Vanillic acid 0.50 
p-Coumaric acid 56 - 67 
Number of other 
procyanidin/ prodelphinidin 
oligomers with E, ECG, EGC 
and EGCG extender units, 
and catechin, EGCG and 
myricetin terminal units. 
- (Li et al. 2010) 
Abbreviations: E - epicatechin, C - catechin, ECG - epicatechin-gallate, EGC - 
epigallocatechin, EGCG - epigallocatechin-gallate. 
 
Table 2.16: Range of concentrations of phenolic compounds found in kale, and the 
number of cultivars/samples used to calculate values. 
Kale phenolic compounds Cultivar mg/100 g fresh 
weight 
Refs. and no. of 
samples (n) 
Total phenolics Reflex 305-478 (GAE) (Olsen et al. 2009; 
n=5) Total flavonols Reflex 491 - 831 (RE) 
Total hydroxycinnamic acids Reflex 148 - 250 (RE) 
Kaempferol (as aglycone) Reflex 52 - 61 
Quercetin (as aglycone) Reflex 34 - 56 
Kaempferol (as aglycone) Vates 24 - 35 (Zhang et al. 2003; 
n=2) Quercetin (as aglycone) Vates 7.7 - 24 
Abbreviations: GAE - gallic acid equivalent, RE - rutin equivalent 
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Table 2.17: Phenolic compounds identified in kale by previous studies. 
Abbreviations: Glc - glucoside; Gnb - gentiobioside; Sph - sophoroside; Fer - feruloyl; 
Sin - sinapoyl; Caff - caffeoyl; hFer - hydroxyferuloyl; Coum - p-coumaroyl. There is 
some discrepancy between glycoside names in the literature (i.e. diglucoside instead of 
sophoroside or gentiobioside, and triglucoside instead of sophorotrioside (Olsen et al. 
2009), so while these glycosides are listed separately, they may in fact be the same 
compound. 
Kale phenolic compounds Refs. 
Q
u
er
ce
ti
n
 N
o
n
-
A
ce
ty
la
te
d
 -3-O-(Glc/Gnb/Sph/triGlc) 
-3-O-Sph,-7-O-(Glc/diGlc) 
-3-O-Glc,-7-O-Glc 
-3-O-Glc,-7-O-Glc,-4‘-Glc 
(Lin & Harnly 
2009; Velasco & 
Francisco 2011; 
Schmidt et al. 2010; 
Olsen et al. 2009) 
A
ce
ty
la
te
d
 -3-O-(Fer/Sin/Caff/hFer)-Sph 
-3-O-(Fer/Sin/Caff/hFer/Coum)-Sph,-7-O-Glc 
-3-O-Sph,-7-O-(Sin/Fer)-diGlc 
-3-O-(diSin/Sin-Fer)-triGlc,-7-O-Glc 
-3-O-Sin-Fer-triGlc,-7-O-diGlc 
-3-O-Sin-triGlc,-7-O-Sin-diGlc 
K
a
em
p
fe
ro
l N
o
n
-
A
ce
ty
la
te
d
 -3-O-(Glc/Gnb/Sph/triGlc)  
-3-O-Sph,-7-O-(Glc/diGlc) 
-3-O-(Glc/triGlc),-7-O-Glc 
-3-O-Glc,-7-O-Glc,-4‘-Glc 
A
ce
ty
la
te
d
 -3-O-(Fer/Sin/Caff/ hFer/Coum)-Soph 
-3-O-(Fer/Sin/Caff/ hFer/Coum)-Sph,-7-O-Glc 
-3-O-(Fer/Sin/Caff/ hFer)-Sph,-7-O-diGlc 
-3-O-Sin-triGlc,-7-O-diGlc 
-3-O-(diSin/Sin-Fer)-triGlc,-7-O-Glc 
-3-O-(diSin/Fer-Sin/diFer)-triGlc,7-O-diGlc 
Is
o
rh
a
m
n
et
in
 
N
o
n
-
A
ce
ty
la
te
d
 -3-O-(Glc/Gnb/Sph,triGlc) 
-3-O-Gnb,-7-O-diGlc 
-3-O-(Sph/Glc/Gnb),-7-O-Glc 
-3-O-Glc,-7-O-Glc,-4‘-Glc 
A
ce
t-
 
y
la
te
d
 -3-O-Sin-Sph,-7-O-Glc 
-3-O-Fer-Sph,-7-O-diGlc 
-3-O-diSin-triGlc,-7-O-diGlc 
H
y
d
ro
x
y
ci
n
n
a
m
ic
 
A
ci
d
s 
3-(Caff/Coum)/-quinic acid (Lin and Harnly 
2009;Velasco et al. 
2011; Olsen et al. 
2009) 
4-(Caff/Fer)-quinic acid 
Sinapic acid 
Sinapylglucoside 
1-Sin-,2-(Sin/Fer)-Gnb 
1-Sin-,2-(Sin/Fer)-,2‘-Sin-Gnb 
Fer-(diSin/Sin)-triGlc 
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Table 2.18: Phenolic compounds identified in Sideritis scardica by previous studies. 
Sideritis scardica phenolic compounds Refs. 
F
la
v
o
n
es
 
Isoscutellarein -7-O-Alo(1→2)Glc (Petreska 
et al. 
2011) 
 -7-O-[6'''-O-Ac]-Alo(1→2)Glc 
 -7-O-[2''',6'''-di-O-Ac]-Alo(1→2)Glc 
 -7-O-[6'''-O-Ac]-Alo (1→2)-[6''-O-Ac]-Glc 
4‘-O-
Methylisoscutellarein 
-7-O-Alo(1→2)Glc (Gabrieli 
et al. 
2005; 
Petreska et 
al. 2011) 
 -7-O-[6'''-O-Ac]-Alo(1→2)Glc 
 -7-O-[6'''-O-Ac]-Alo(1→2)-[6''-O-Ac]-Glc 
 -7-O-Alo(1→2)-[6‘‗-O-Ac]-Glc 
Hypolaetin -7-O-Alo(1→2)Glc (Petreska 
et al. 
2011) 
 -7-O-[6'''-O-Ac]-Alo(1→2)Glc 
 -7-O-[2''',6'''-di-O-Ac]-Alo(1→2)Glc 
3‘-O-
Methylhypolaetin 
-7-O-Alo(1→2)Glc 
 -7-O-[6'''-O-Ac]-Alo(1→2)Glc 
 -7-O-[2''',6'''-di-O-Ac]-Alo(1→2)Glc 
 -7-O-Alo(1→2)-[6''-O-Ac]-Glc (Koleva 
2007; 
Koleva et 
al. 2003) 
 -7-O-[6'''-O-Ac]-Alo(1→2)-[6''-O-Ac]-Glc 
Chryseriol  (Janeska et 
al. 2007) 
4‘-O-Methyl-luteolin -7-O-[6‘‗‗-O-Ac]-Alo(1→2)Glc (Koleva 
2007) Apigenin -7-O-Alo(1→2)-[6‘‗-O-Ac]-Glc 
Phenylethanoids 3‖-O-p-coumaroyl-6‖O-Ac-melittoside  
 
Melittoside  
Echinacoside (Petreska 
et al. 
2011) 
Forsythoside A 
Verbascoside 
Alyssonoside 
Leucoseptoside A 
Hydroxycinnamic 
acids 
3-Caffeoylquinic acid 
5-Caffeoylquinic acid 
(Koleva 
2007) 
Abbreviations: Alo - allosyl, Glc - glucoside, Ac - acetyl. 
 
Table 2.19: Range of concentrations of phenolic compounds found in Sideritis scardica, 
and the number of samples used to calculate values 
S. scardica phenolic compounds % dry weight Refs. and no. of samples (n) 
Isoscutellarein aglycone 0.08 - 0.19 (Janeska et al. 2007; n=3) 
3‘-O-methylhypolaetin aglycone 0.07 - 0.20 
Apigenin aglycone 0.05 - 0.12 
Chryseriol aglycone Trace 
 64 
Table 2.20: Phenolic compounds identified in pomegranate arils by previous studies. 
Pomegranate phenolic compounds Refs. 
A
n
th
o
cy
a
n
in
s Delphinidin -3-O-Glc  
-3,5-O-diGlc 
(Alighourchi et al. 
2008; Borges et 
al. 2010; Robert 
et al. 2010) 
Cyanidin -3-O-Glc  
-3,5-O-diGlc 
Pelargonidin -3-O-Glc  
-3,5-O-diGlc 
A
n
th
o
cy
a
n
in
- 
fl
a
v
a
n
-3
-o
l 
A
d
d
u
ct
s 
EGC -delphinidin -3-O-Hex 
-3,5-O-diHex 
(Sentandreu et al. 
2010) EC 
EA 
EGC -cyanidin -3-O-Hex 
-3,5-O-diHex EC 
EA 
EGC -pelargonidin -3-O-Hex 
-3,5-O-diHex EC 
EA 
F
la
v
a
n
-3
-o
ls
 Catechin (de Pascual-
Teresa et al. 
2000) 
Epicatechin 
B1 Dimer 
B3 Dimer 
Gallocatechin 
Epigallocatechin 
E
ll
a
g
it
a
n
n
in
s 
Punicalagin A (Gil et al. 2000; 
Borges et al. 
2010) 
Punicalagin B 
Punicalin A 
Punicalin B 
Granatin A 
Granatin B 
Ellagic acid 
2-O-galloylpunicalagin 
Ellagic acid-O-hexoside 
Abbreviations: Glc - glucoside, Hex - hexoside, EGC - Epigallocatechin, EC - 
Epicatechin, EA - Epi-afzelechin  
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Table 2.21: Range of concentrations of phenolic compounds found in pomegranate, and 
the number of cultivars/samples used to calculate values. 
Pomegranate phenolic 
compounds 
mg/100 ml Refs. and no. of cultivars and 
samples (n) 
Cyanidin -3-O-Glc  0.2 - 36 (Alighourchi et al. 2008; 
cultivars=15, n=3) 
(Mousavinejad et al. 2009; 
cultivars=8, n=3) 
-3,5-O-diGlc 4.4 - 236 
Delphinidin -3-O-Glc  0.2 - 10 
-3,5-O-diGlc 0.3 - 530 
Pelargonidin -3-O-Glc 0.1 - 24 
-3,5-O-diGlc 0.01 - 0.1 
Ellagic acid 0.7 - 16 (Mousavinejad et al. 2009; 
cultivars=8, n=3) 
Total Anthocyanins 30 - 252 (Alighourchi et al. 2008; 
cultivars=15, n=3) 
 81.5 - 776
b
 (Mousavinejad et al. 2009; 
cultivars=8, n=3) 
 16.8 - 133
b
 (Sepulveda et al. 2010; 
cultivars=8, n=10) 
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c
 (Robert et al. 2010) 
Total Phenolics 420 - 930
a
 (Mousavinejad et al. 2009; 
cultivars=8, n=3) 
 68 - 124
d
 (Sepulveda et al. 2010; 
cultivars=8, n=10) 
 172
d
 (Robert et al. 2010) 
a
 Measured by Folin-Ciocalteu assay; 
b
 Measured by HPLC as cyanidin-3-O-glucose 
equivalent; 
c
 Measured by HPLC as malvidin-3-O-glucose equivalent; 
d
 Measured by 
HPLC as gallic acid equivalent. Additional details of phenolic concentrations are given in 
(Borges et al. 2010), but were quantified based on the extract volume (μmol/L) rather 
than the quantity of plant material, and so were not included.  
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2.2. General biochemical techniques for analysis of plant bioactivity 
The following techniques were used throughout this work, for culture and analysis of 
endothelial cells. All chemicals were purchased from Sigma-Aldrich unless otherwise 
specified and water was of MilliQ-grade purity. DMSO was stored under nitrogen to 
prevent contamination from moisture in the air. All cells and growth media/supplements 
were purchased from Lonza. 
 
2.2.1. General cell culture techniques 
Human umbilical vein endothelial cells (HUVECs) were chosen as the model for in vitro 
experiments in this work. Such cells are commonly used in studies which focus on 
signalling mechanisms in the endothelium, and as a means for understanding the 
molecular interactions behind functional outcomes seen in tissue culture studies. While 
most veins carry deoxygenated blood through the body back to the heart, the umbilical 
vein differs in that it carries oxygenated blood from the placenta to the foetus' heart. 
Therefore, there is a similarity between the function of arteries and the umbilical vein. 
However, the layer of smooth muscle surrounding the umbilical vein endothelium is 
much thinner that would be normally found around the endothelium of arteries, and so it's 
ability to contract and dilate is likely to be weaker. Still, such cells are relatively easy to 
obtain, as well as to characterise through endothelial cell specific proteins, such as von 
Willebrand factor, PECAM-1 (CD31) and endoglin (CD105), and provide a good model 
for endothelial cells in a non-diseased state. They also represent a more affordable model 
for signalling in the endothelium, in comparison to other sources for endothelial cells, 
such as the aorta, pulmonary artery, or micro-vessels of lung or dermal tissue. 
 HUVECs were supplied as frozen primaries (Clonetics, Lonza) and cultured at 37 
°C to passage 4 (10-11 population doublings) in fully supplemented endothelial growth 
media (EGM-2) (basal media (EBM-2) plus EGM-2 BulletKit™ supplements) before use 
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in experiments, which were performed also at 37 °C. Prior to all treatments, cultures were 
washed twice with warm EBM-2, supplemented with BulletKit™ antibiotics. Post-
treatment, cells were washed twice with cold PBS (Gibco, Life Technologies), the 
remaining liquid was aspirated, and ice-cold cell lysis buffer (1X concentration, Cell 
Signalling Technologies (CST) #9803) was applied to cells. The lysis buffer contained (at 
1X concentration): 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3VO4 and 1 µg/ml leupeptin. It was supplemented with protease inhibitor (1X 
concentration, Complete Mini, Roche), and, if target analyte(s) included phosphorylated 
proteins, with phosphatase inhibitor (1X concentration, PhosStop, Roche). 1 mM 
phenylmethylsulfonyl fluoride was added to the lysis buffer shortly before use. Plates 
were held at 4 °C for 2 minutes before harvesting the cells by scraping. Lysates were 
aspirated to eppendorfs, vortexed briefly, and kept on ice. Eppendorfs were vortexed a 
further 3 times every 5 minutes, keeping on ice in between vortexes, and centrifuged (4 
°C, 10 minutes, 17000 g). Lysates were aliquoted as necessary and stored at -80 °C until 
further analysis. 
 
2.2.2. BCA assay of total protein 
The bicinchoninic acid (BCA) assay provides a fast means for determining protein 
concentration, in a generally non-specific fashion. Protein structure, the number of 
peptide bonds, and the proportion of cysteine, tyrosine and tryptophan in the sample can 
all affect the colorimetric reaction of the BCA assay, but it is generally assumed that the 
influence of these factors will be minor  
 A stock of 2 mg/ml bovine serum albumin (BSA) was used to prepare a standard 
curve from which to measure protein concentrations in the lysates of each cell culture 
dish/plate well. NaPi buffer (43.85 mM NaH2PO4, 6.15 mM Na2HPO4, 5 mM EDTA) 
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was used to dilute lysate samples and the BSA standard, and was used as the 0 mg/ml 
standard. Lysate aliquots were diluted 1:20 and 25 μl of each standard/sample was 
pipetted into a 96-well plate in duplicate. 200 μl of a 50:1 mix of bicinchoninic acid and 
copper (II) sulphate pentahydrate was then added to each well, and the plate was 
incubated at 37 °C for 30 minutes. The absorbance of each well was read using a Dynex 
MRX II spectrophotometer set at 550 nm, and the protein concentration of each lysate 
was calculated. 
 
2.2.3. Western blotting 
For semi-quantitative analysis of specific proteins in HUVEC lysate samples, western 
blotting was chosen as a cost-effective protein assay, were single samples could be 
sequentially assayed for multiple proteins, or for protein post-translation modification. 
 30 μg samples of total cell protein were separated on SDS-PAGE gels (Expedeon; 
12-well SDS-PAGE gels (8% or 4-12%), RunBlue Rapid SDS buffer, DTT and LDS 
sample buffer), according to the manufacturer's instructions. Separated proteins were 
transferred to nitrocellulose membranes (Bio-Rad) using X-Cell II gel tanks (Bio-Rad). 
Western blot transfer buffer (192 mM glycine, 25 mM Tris base, 0.1% (v/v) SDS) and 
TBST buffer (20 mM Tris base, 137 mM NaCl, 0.1% (v/v) Tween-20, pH adjusted to 7.6 
with HCl) were prepared in house. Blots were washed with TBST (5 mins) after transfer 
and after the blocking, primary antibody and secondary antibody incubation steps. HRP-
conjugated anti-rabbit IgG antibody (CST, #7074), diluted 1:1000 in 5% w/v skimmed 
milk powder/TBST, was used as the secondary antibody. Blots were incubated with 
blocking buffer (5% w/v milk powder/TBST) for 60 mins, then overnight at 4 °C with 
primary antibodies, and finally with secondary antibody at room temperature for 60 mins. 
Blots were incubated with reagents (2 ml each) from the SuperSignal West Pico 
chemiluminescence detection kit (Pierce) for 5 mins at room temperature, protected from 
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light. Blots were imaged using a Bio-Rad FluorS Imager. For staining with additional 
primary antibodies, blots were incubated with Restore Western Blot Stripping buffer 
(Pierce) for 40 mins at room temperature, washed for 5 mins with TBST, and then re-
blocked and probed as before. 
 Densitometry analysis of western blots was performed with the software ImageJ 
(Abràmoff et al. 2004), using the 'Analyze/Gels' menu to produce curves representative of 
blot bands, and taking the area under the curve as the value represented by each band. 
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Chapter 3: A broad-targeted approach to determine effects of 
quercetin on early endothelial signalling events 
 
3.1. Abstract 
There is a large body of evidence from studies including epidemiological and human 
intervention trials that quercetin, a flavonol found in the plant foods selected in Chapter 2 
and many others world wide, may be beneficial to human health, particularly in the 
context of the cardiovascular system. The early molecular signalling events that underly 
these changes to vascular health, however, are not well understood. It would be of interest 
to study changes to endothelial cell signalling induced by quercetin and its human 
metabolites, as well as to observe if conjugation of quercetin affects such bioactivity. 
 Confluent HUVECs were treated with quercetin aglycone (10 µM), a mixture of 
quercetin human metabolites (total concentration 10 µM) or vehicle for 60 min (n=3, 
biological replicates). Subsequently, cell lysates were analysed with microarray slides 
spotted with antibodies representive of 736 different protein phosphorylation sites.  
A small number of protein phosphorylation changes (17, quercetin metabolites vs 
control; 29, quercetin vs control) were significant (p < 0.05), but of these, only eNOS 
phosphorylation at Ser1177 could be confirmed by western blotting. There were no 
significant results after taking multiple testing into account (q < 0.05). It is unlikely, 
therefore, that the quercetin or a mix of its metabolites had a strong effect on early 
phosphorylation events in resting endothelial cells, despite the decrease to eNOS 
phosphorylation. This is the largest reported antibody microarray study to date, the first 
antibody microarray study to assess HUVEC proteins in phosphorylated and 
unphosphorylated states, and the first antibody microarray study to assess the intracellular 
response to an individual polyphenol and its human metabolites. 
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3.2. Introduction 
A number of food plants were selected, as detailed in the previous chapter, for study of 
their ability to improve markers related to vascular health, in cultured endothelial cells. 
Of these, dill, nettle and kale have been previously reported to contain relatively high 
levels of the flavonoid quercetin. Since quercetin is a major dietary plant polyphenol for 
which there is reasonable evidence of health benefits in humans, it was selected as a 
relevant bioactive flavonoid for further study. 
 
3.2.1. Quercetin in the diet and its relationship with health 
In 1785, Edward Bancroft patented the production of an extract of black oak bark which, 
being yellow in colour, he called quercitron (from the Latin quercus citrina) (Bancroft 
1813). In 1854, it was discovered that the extract's main constituent, quercitrin, could be 
split by treatment with mineral acid to release rhamnose. The aglycone produced from 
this reaction became known as quercetin (Ott 1873). As flavonols are widespread in the 
plant kingdom, from bryophytes to higher vascular plants (Iwashina 2000), it is not 
surprising that quercetin is present in a large number of the food plants consumed in 
human diets (Larson et al. 2012b). It is found as the aglycone (i.e. without sugar groups 
attached) (Fig. 3.1), as O-methylated derivatives (i.e. isorhamnetin (IR) and tamarixetin) 
and with glycosidic conjugation, often at the highly reactive 3-hydroxyl group of the 
flavonol structure (Rice-Evans et al. 1996). In nature, quercetin is almost exclusively 
found as glycosides. The aglycone quercetin is usually found in a limited number of 
processed foods such as red wine (Hollman & Arts 2000).  
 Quercetin has received much interest in diet and health research as not only is it 
consumed in foods worldwide, but there is mounting evidence for its beneficial health 
effects in roles such as chemoprevention (Gibellini et al. 2011), improvement to drug 
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resistance (Chen et al. 2010), improvement in exercise endurance (Kressler et al. 2011) 
and prevention of cardiovascular disease (Perez-Vizcaino et al. 2006; Russo et al. 2012). 
 
Figure 3.1: Quercetin aglycone. 
 
Concerning the latter, there are a number of reports showing that quercetin can reduce 
blood pressure, as evidenced by intervention studies where volunteers with hypertension 
or pre-hypertensive symptoms were given large doses of quercetin (Larson et al. 2012b; 
Larson et al. 2010). Intervention studies lasting > 8 weeks have found evidence that 
quercetin can reduce CVD risk factors in cigarette smokers (Lee et al. 2011), and, when 
coupled with vitamin C, can reduce markers of oxidative stress and inflammation in fit 
and healthy individuals (Askari et al. 2012). It has also been reported that a dose of 200 
mg of quercetin can cause acute increases in plasma S-nitrosothiols and nitrites and 
urinary nitrates in healthy volunteers, which is indicative of increased production of the 
vasodilator nitric oxide (NO). The same study also reported quercetin-induced decreases 
in urinary and plasma levels of the vasoconstrictor endothelin-1 (Loke et al. 2008a). 
Whether or not quercetin-mediated reductions in blood pressure are products of the 
improvements in NO bioavailability and endothelial function is not yet proven, although 
there is one report which describes quercetin-mediated decreases in blood pressure that 
are independent of increased vasodilatory function (Larson et al. 2012a). A study using 
healthy volunteers also showed decreased platelet aggregation after acute 
supplementation with quercetin (Hubbard et al. 2006; Hubbard et al. 2004). 
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In animal models of hypertension, several studies have shown reductions in blood 
pressure and other factors related to cardiovascular disease (Perez-Vizcaino et al. 2009; 
Larson et al. 2012b). For instance, hypertensive rats fed daily with a 10 mg/kg dose of 
quercetin saw a reduction in their blood pressure and augmented effects of vasodilator 
compounds improvement in isolated aortic rings in an endothelium-dependent manner 
(Garcia-Saura et al. 2005; Sanchez et al. 2006). Treatment with quercetin also attenuated 
effects of vasoconstrictor compounds in aortic rings, with a reduced effect if an inhibitor 
of endothelial nitric oxide synthase (eNOS) was included (Nishida & Satoh 2009; Duarte 
et al. 1993), or an increased effect if a cofactor of eNOS, such as tetrahydrobiopterin 
(BH4), was included (Romero et al. 2009). 
 Quercetin-induced improvement of hypertension and endothelial function is 
unlikely to be as a result of a direct antioxidant effect (i.e. radical scavenging in vivo) 
(Loke et al. 2008b; Godycki-Cwirko et al. 2010; Hollman & Cassidy 2011; Askari et al. 
2012), although it is possible that changes to antioxidant enzymes, such as glutathione S-
transferases (GST) and glutathione peroxidases (GPX), or pro-oxidant enzymes such as 
NADPH oxidase may be involved. Quercetin treatment was shown to reduce superoxide 
(O2
-
) produced by NADPH oxidase, as well as expression of its subunit p47phox, to basal 
levels in vivo (Sanchez et al. 2006) and ex vivo (Sanchez et al. 2007). Furthermore, 
quercetin was shown to compete successfully against NO in scavenging O2
-
, allowing 
levels of the vasodilator to be maintained (Lopez-Lopez et al. 2004). 
 Further evidence of quercetin's ability to modulate markers of inflammation and 
endothelial function has been shown through cell culture studies (Chirumbolo 2010; 
Russo et al. 2012). Additional anti-atherogenic effects observed after quercetin treatment 
include reduced endothelial cell proliferation and migration (Donnini et al. 2006, 
Kuhlmann et al. 2005), downregulated components of the apoptotic pathway activated by 
oxidised-LDL (p38 MAPK, STAT3 and JAK2) (Choi et al. 2007), and upregulation of 
the apoptosis of intimal-type vascular smooth muscle cell (Perez-Vizcaino et al. 2006). 
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Furthermore, expression and release of the vasoconstriction factor endothelin-1 has been 
found to decrease after quercetin treatment, from both HUVECs and activated 
(aggregating) platelets (Nicholson et al. 2008; Xue-Ying 1996). Quercetin has also been 
shown to increase levels of cGMP, in a manner involving hyperpolarisation of endothelial 
cell membrane potential (Kuhlmann et al. 2005). 
 A significant limitation to much of the in vitro work and tissue studies performed 
with quercetin to date is that studies have focused on the aglycone alone, and have not 
included any of the metabolites that are found after consumption of quercetin-rich meals, 
given noted that there is little evidence that quercetin circulates in plasma as the aglycone 
form. Three of the main phase II metabolites that can be found circulating in plasma are 
quercetin-3-glucuronide (Q3GlcA), 3'-methyl-quercetin-3-glucuronide (IR3GlcA) and 
quercetin-3'-sulphate (Q3'S) (Mullen et al. 2006) (Fig. 3.2). 
 
 
 
 
Figure 3.2: Phase II metabolites of quercetin - quercetin-3-glucuronide (A), 3'-methyl-
quercetin-3-glucuronide (B) and quercetin-3'-sulphate (C). 
A B 
C 
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Peak concentrations of quercetin metabolites (often measured as the quercetin aglycone, 
following deconjugation techniques) in plasma can vary widely, ranging from nanomolar 
quantities to as high as 9.7 μM (Heinz et al. 2010b; Hubbard et al. 2004; Lee et al. 2012).  
 The bioactivity of quercetin is likely to be affected by phase-2 conjugation. For 
example, glucuronidation of quercetin reduced its ability to protect dermal fibroblasts 
from peroxide-induced damage (Spencer et al. 2003) and attenuated pro-oxidant effects 
of quercetin aglycone, such as nitric oxide scavenging (Lodi et al. 2008). Still, quercetin 
glucuronides and sulphates (0.3 μM dose) have been shown to reverse apoptosis in 
hyperglycaemic HUVECs (Chao et al. 2009), inhibit VEGF-induced endothelial 
functions such as migration and proliferation (> 1 μM dose) (Donnini et al. 2006) and 
reduce expression of the cell adhesion molecule VCAM-1 (2 μM dose) (Tribolo et al. 
2008). Metabolite concentrations from 0.1 to 4 μM attenuated human lymphocyte 
synthesis of COX-2 mRNA (important for vascular tone) ex vivo (though not in vivo after 
consumption of a quercetin rich meal, despite concentrations of the metabolites reaching 
4 μM in plasma) (de Pascual-Teresa et al. 2004). 10 μM Q3GlcA was shown to affect the 
signalling controlling smooth muscle cell migration in rat aortic tissue (Ishizawa et al. 
2009), while Q3‘S caused increased cGMP levels in porcine coronary arteries, in an 
endothelium-independent manner, and reduced inflammatory effects of 
lipopolysaccharide in similar tissues (Suri et al. 2010; Al-Shalmani et al. 2011).  
 
3.2.2. Analysis of vascular cell signalling 
The past decade has seen the emergence of technologies that allow for simultaneous 
analysis of increasingly larger numbers of phosphorylated proteins, utilising mass 
spectrometry techniques or libraries of binder molecules such as antibodies (Schulze 
2010; Kosako & Nagano 2011). The rise in numbers of unique phospho-site specific 
antibodies has allowed the development of phospho-protein antibody microarrays able to 
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quantify specific proteins in terms of total levels and phosphorylated levels 
simultaneously. The ability to target functionally important sites, rather than assess the 
entire phospho-proteome by mass spectrometry, provides a more convenient means of 
analysis (Zhang & Pelech 2012; Yang et al. 2011; Borrebaeck & Wingren 2009). 
―Normal-phase‖ antibody microarrays involve fixed spots of particular antibodies at 
known locations on a solid material, such as a glass microscope slide, similar to the 
format of routine cDNA microarrays, while reverse-phase protein microarrays require the 
spotting of biological material, followed by antibody incubation (Silvestri et al. 2010). 
These methods give the potential for tracking large subsets of phospho-proteins 
equivalent to multiple signalling pathways over the course of one experiment.  
 The work detailed in this chapter will focus on elucidating changes to early 
signalling events in endothelial cells after introduction of quercetin, a flavonoid present in 
a number of the food plants prioritised for study in the previous chapter. Cells will be 
treated with quercetin aglycone, or a mix of quercetin metabolites alongside a vehicle 
control. By using antibody microarrays complementary for large a number of proteins 
(phosphorylated and unphosphorylated), lysates will be analysed to determine what the 
effects of the quercetin treatments on protein phosphorylation, using a broad-targeted 
approach to phospho-protein analysis. 
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3.3. Aims 
The overall aim of the research described in this chapter was to identify changes in early 
signalling events in endothelial cells incubated with quercetin, a flavonoid found in a 
number of food plants typical of traditional Black Sea area diets. Specifically, the 
scientific objectives were to: 
(i) Measure the effects of quercetin on protein phosphorylation profiles in human 
vascular endothelial cells. 
(ii) Measure the effects of quercetin conjugates on protein phosphorylation profiles in 
human vascular endothelial cells and determine the impact of human metabolism 
of quercetin on its bioactivity in this context. 
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3.4. Methods 
3.4.1. Materials 
All water used was of MilliQ-grade purity, unless it is stated that deionised water (dH2O) 
was used instead. All cells and growth media/supplements were purchased from Lonza. 
Human umbilical vein endothelial cells (HUVECs) were supplied as frozen primaries 
(Clonetics, Lonza) and cultured to passage 4 (10-11 population doublings) before use in 
experiments. Details of the general materials and methods used for the cell culture 
experiments with HUVECs, including analysis of cell lysates by BCA assay and western 
blotting, are described in Chapter 2. All purified compounds were stored in single use 
aliquots at -20 °C. Quercetin, sinigrin, allyl-isothiocyanate (allyl-ITC) (Sigma-Aldrich) 
and sulforaphane (LKT Laboratories) were stored in DMSO. Quercetin-3‘-sulphate 
(Q3‘S), quercetin-3-glucuronide (Q3GlcA) and isorhamnetin-3-glucuronide (IR3GlcA) 
were prepared by Dr Paul Needs (IFR, UK) according to a published protocol (Needs & 
Kroon 2006) and stored in water. Tris-buffered saline solution (TBS) was prepared with 
tris base (20 mM) and NaCl (137 mM), adjusted to pH 7.6 using HCl. Antibodies for 
eNOS, p-eNOS (Ser1177), VEGFR2, p-VEGFR2 (Tyr951) (Cell Signalling Technologies 
(CST) #9572, #9570, #2479 and #4991 respectively), caspase-6 and p-caspase-6 (Ser257) 
(FMB) were used as primary antibodies in western blotting. Antibody microarrays 
(Phospho Explorer Antibody Microarray, PEX-100) were purchased from Full Moon 
Biosystems (FMB), who also provided kits containing the following buffers and reagents 
for processing the microarrays: 
 Blocking buffer, produced from 1.8 g dry milk powder dissolved in 60 ml blocking 
reagent solution 
 Labelling reagent, produced from 1 mg biotin reagent dissolved in 100 μl 
dimethylformamide 
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 Coupling buffer, produced from 0.36 g dry milk powder dissolved in 12 ml coupling 
reagent solution 
 Wash buffer, produced from a stock solution diluted 1:10 in water 
 Coupling chambers, which were 4 x 5 ml rectangular-well plastic dishes, similar to 
Nunclon #167063 
 Detection buffer, containing 0.5 ng/ml Cy3-streptavidin conjugate (GE Healthcare) 
dissolved in detection reagent  
 Cell lysis buffer and eppendorfs containing metal lysis beads to facilitate break up of 
cell material 
 Stop reagent, for halting the reaction of protein biotin-labelling  
 
The antibody microarray slide featured two columns of 8 blocks consisting of 1326 spots 
in total, each spot printed using the manufacturer's microarray printing buffer. The spots 
were featured on each microarray in duplicate across two columns, so that the relative 
location of the spots featured in the left column matched the same relative location in the 
right column. The microarrays were spotted with 1318 unique antibodies complimentary 
to phosphorylated and non-phosphorylated versions of 582 phosphorylation sites 
covering 320 different proteins, plus 154 additional ―unpaired‖ sites (phosphorylated or 
unphosphorylated) covering 126 different proteins. In total, 386 unique proteins were 
covered by the microarray. The names, targeted phosphorylation residue(s) and Uniprot 
accession IDs of each protein covered in this microarray are listed in Appendix I. Each 
column also contained two positive control spots, four negative control spots, four blank 
―spots‖ (where no materials had been printed) and two spots complimentary for the 
house-keeping proteins β-actin and GAPDH. The positive controls contained antibodies 
labelled with cyanine 3 (Cy3) dye, and so demonstrated that fluorescence scanning was 
working properly, and highlighted the printing boundaries for the microarrays. The 
negative controls contained bovine serum albumin (BSA) (concentration n/a) in the 
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microarray printing buffer. While the signal produced by these spots would likely be a 
close representation of within-spot background signal, there was no evidence to suggest 
that the signal produced from unspecific binding to BSA would be the same as the signal 
produced from unspecific binding to the microarray printing buffer, and so they were not 
used (for calculating within-spot background signal) as such.  
 
3.4.2. Cell culture experiments, BCA assay and western blotting 
General materials and methods used for cell culture experiments with HUVECs, unless 
specified otherwise, are as described in Chapter 2. These include details for the analysis 
of their lysates by BCA assay and western blotting.  
 
3.4.3. Incubation of cell cultures with quercetin 
Confluent monolayers of HUVECs cultured in 10 cm
2
 dishes were incubated for 60 
minutes with either 10 µM quercetin, a mix of 6 µM Q3‘S, 3 µM Q3GlcA and 1 µM 
IR3GlcA (ratio based on the relative levels of these compounds reported in plasma by 
Mullen et al. (2006)), or a vehicle control treatment (n=3, biological replicates). Such 
doses represent concentrations slightly higher than what might be expected in vivo after a 
high-quercetin meal. They are, however, intended to assist in showing changes to protein 
phosphorylation, in cases where use of physiological doses of quercetin or its metabolites 
(low μM) would show small, but not measurably significant, changes. Final concentration 
of DMSO in cell culture media for each treatment was 0.1% v/v. Post-incubation, cells 
were washed twice with cold 1X PBS (Gibco, Life Technologies). Any remaining buffer 
was aspirated and 150 μl of FMB lysis buffer was added to each plate. Cells were 
detached using scrapers and aspirated into eppendorfs, to which metal lysis beads (FMB) 
were added, filling to approximately half the lysate volume. Eppendorfs were vortexed 
for 30-60 s and then held on ice for 10 minutes, repeating this for 40-60 minutes, 
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followed by centrifugation at 13000 x g. Lysates were divided into small aliquots and 
stored at -80 °C until analysis. 
 
3.4.4. Analysis of cell lysates with antibody microarrays 
Cell lysate aliquots containing 330 μg protein were removed from -80 °C storage and 
brought to room temperature at the bench top. Three aliquots of 100 μg of protein were 
taken from each and made up to 50 μl total volume with labelling buffer, before addition 
of 1.5 μl of labelling reagent to each. Eppendorfs were incubated at room temperature for 
120 minutes with shaking at 55 rpm. 25 μl of stop reagent was then added to each aliquot, 
and incubated for a further 30 minutes with shaking on a Luckham R100 Rotatest orbital 
shaker (used for all subsequent incubations requiring shaking) at 55 rpm. 
 Alongside this, antibody microarray slides (details of microarray targets given in 
Section 3.4.1) were removed from 4 °C storage and equilibrated to room temperature 
before removal from foil packaging. Throughout their use, microarray slides were kept 
antibody-side up. Slides were placed in 30 ml of blocking buffer in a 10 cm
2
 dish. Dishes 
were covered and incubated at room temperature for 45 minutes with shaking at 55 rpm. 
 After blocking, dishes were filled with TBS. Slides were then transferred to a new 
dish containing 30 ml TBS, while being kept as horizontal as possible to reduce draining 
of liquid, which would lead to drying of milk proteins in the blocking buffer to the slide 
(communication with Full Moon Biosystems). Dishes were covered and incubated at 
room temperature for 10 minutes with shaking at 55 rpm. Two more 10 minute washes 
were then performed with fresh TBS each time. Slides were placed in 50 ml 
polypropylene centrifuge tubes (Corning) containing 45 ml dH2O. The lid was screwed 
on, and the tube was shaken vigorously for 10 seconds. Slides were then transferred to 
fresh dH2O and shaken for another 10 seconds. This was repeated for a total of 10 
washes, and upon completion the slides were kept in fresh dH2O. The three aliquots of 
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biotin labelled cell lysate protein were combined and added to 6 ml of coupling buffer, 
turning gently end over end to mix. The cell protein/coupling buffer mixture was 
decanted into a coupling chamber well, and a blocked antibody microarray slide was 
submerged into it. The coupling chamber was then covered and incubated for 120 
minutes at room temperature with shaking at 35 rpm. 
 Coupling chamber wells containing microarray slides were filled with wash buffer 
before transferring slides, keeping them as horizontal as possible, to a 10 cm
2
 dish filled 
with 30 ml wash buffer. 3 x 10 minute washes with fresh 1X wash buffer were 
performed, with shaking at 55 rpm, followed by ten washes in polypropylene tubes with 
45 ml dH2O. Slides were then placed in a 10 cm
2
 dish containing 30 ml detection buffer. 
Dishes were covered and wrapped in foil to protect the detection agent from light, and 
then incubated at room temperature for 45 minutes with shaking at 55 rpm. Slides were 
washed with wash buffer followed by dH2O as described above. After the final wash, a 
flow of compressed nitrogen at 20 psi was used to remove water remaining on the slide. 
 
3.4.5. Analysis of microarray slides 
Antibody microarray slides were scanned using a GenePix 4000B microarray scanner 
(Molecular Devices), connected to a computer running the software GenePix Pro v6.1 
(Molecular Devices). The photo-multiplier tube (PMT) gain was adjusted to reduce the 
number of saturated pixels to < 1% of total image pixels, and this PMT gain setting was 
used for all the microarrays scanned. Slides were scanned at a resolution of 5 μm/pixel, 
using a 532 nm excitation laser coupled with a 557.5-592.5 nm emission filter. Images 
produced from the fluorescence scanning were saved as .tiff files, and microarray slides 
were then placed into storage at room temperature, protected from light. Slides were also 
scanned using a 635 nm excitation laser coupled with a 650-690 nm emission filter. 
Images produced from scanning at 635 nm scans assessed by eye to identify high levels 
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of signal generated by artifacts such as scratches, so that these could be taken into 
account when analysing images produced from scanning at 532 nm. 
 Analysis of the images produced from scanning at 532 nm was carried out with 
the assistance of Kate Kemsley (IFR, UK), who developed a program script for the 
Matlab software environment that identified the outlines of the microarray spots in the 
images produced from the fluorescence scans, and then calculated the median signal of 
the fluorescence inside these outlines (referred to here as the foreground signal). The 
median fluorescence intensity was calculated rather than the mean, as the median would 
be less affected by large outlier values, such as those produced by saturated pixels 
resulting from scratches or specks of dust. The script also generated a composite of the 
original image overlaid with the identified outlines, and a score from 0 to 1 of the 
accuracy of each spot outline (Fig. 3.3). The lowest circularity scores were found to 
represent spots with incorrectly identified outlines, and the median fluorescence of these 
spots were calculated manually using GenePix Pro. Any additional incorrectly outlined 
spots were identified by scanning the composite images by eye. The local background 
fluorescence surrounding each spot was also calculated, by either GenePix Pro (in the 
case of manually outlined spots) or the Matlab program script. 
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Figure 3.3: Example of fluorescently-scanned microarray, overlaid with circles 
representing the scored spot boundaries detected by the Matlab script. 
Prior to statistical analysis, Microsoft Excel 2007 spreadsheets were used to organise 
median spot fluorescence intensity (MSFI) values using the following labels: 
 unph - MFSIs representing an unphosphorylated protein residue. 
 phph - MSFIs representing a phosphorylated protein residue. 
 nopair - MSFIs representing a phosphorylated (or unphosphorylated) protein residue, 
but lacking a ‗partner‘ antibody corresponding to the alternate unphosphorylated (or 
phosphorylated) protein residue, spotted on the microarray. 
 
Statistical analyses of microarray slide data was carried out using the limma package for 
the R software environment (Smyth 2005; Smyth 2004; R Development Core Team 
2010), in accordance with documentation provided by the package developers. The phph 
to unph ratio for corresponding protein residues was calculated, log2 transformed (to give 
a Gaussian data distribution), and quantile normalised to adjust for variances due to 
unspecific binding (Bolstad et al. 2003). An empirical Bayes method, used to shrink 
standard errors towards a common value, was applied to the data, and p-values were 
calculated for comparisons of phph/unph ratios between each treatment (i.e. quercetin vs 
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control, quercetin metabolites vs control and quercetin metabolites vs quercetin). 
Subsequently, p-values were adjusted to account for multiple testing (MT) using the 
Benjamini-Hochberg method (Benjamini & Hochberg 2009) (p-values adjusted for MT 
are referred to in this chapter as q-values). To determine significant changes to nopair 
targets, MSFIs of all protein targets were first corrected for changes in total protein 
applied to each microarray, using the average MSFI of the house-keeping protein targets. 
As above, quantile normalisation and the empirical Bayes method were applied and p- 
and q-values were calculated for comparisons of nopair values between each treatment. 
 The distribution of foreground and background fluorescence values was also 
assessed, comparing the spread of values between the left and right hand sides of 
microarrays, and the spread of values between microarrays processed on the same day.  
3.4.6. Bioinformatic analysis of proteins highlighted by the microarray experiment 
Bioinformatic analysis of statistically significant changes (p < 0.05) to protein 
phosphorylation was performed using the website DAVID (v6.7) (Huang et al. 2009; 
Dennis et al. 2003), following instructions given on the website. A list of all the Uniprot 
accession IDs of the proteins included in the microarray was used as the analysis 
background list. A separate analysis was performed using this background list of Uniprot 
IDs as the background and experimental list, to highlight the signal transduction 
pathways represented by the microarray. 
 
3.4.7. Ontological analysis of phosphorylated proteins highlighted by the 
microarray experiment 
Protein ontologies were studied using the websites PhosphoSite (Hornbeck et al. 2004) 
and Uniprot (The Uniprot Consortium 2012) to determine: 
(i) The biological role of the protein ("Protein role") 
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(ii) The effect of phosphorylation of the particular residue on protein function 
("Effect/protein") 
(iii) The effect of phosphorylation of the particular residue on cell function 
("Effect/cell") 
(iv) Upstream proteins that may influence phosphorylation of the particular residue 
("Regulated by") 
This data was analysed to determine any links between the listed proteins, in the context 
of associated protein-protein interactions and associated effects on cell function. 
 
3.4.8. Confirmation of changes to selected phospho-proteins by western blotting 
Confluent monolayers of HUVECs cultured in 6-well plates were treated with either 
quercetin, the mix of quercetin metabolites or a vehicle control, in concentrations ranging 
from 5-50 μM for 60 minutes. Blots were then assayed for changes to the 
phosphorylation of caspase-6, VEGFR2 or eNOS. For the eNOS assay, cells were pre-
treated with epigallocatechin-gallate (EGCG) to stimulate eNOS phosphorylation prior to 
the above treatments. Etoposide was used as a positive control for the caspase-6 assay 
and VEGF was used to stimulate VEGFR2 phosphorylation prior to the above treatments. 
Densitometry values of western blot bands were tested for significance, comparing 
treatment against the vehicle control, using the Student's t-test. Details of the methods 
used for western blotting are given in Chapter 2. 
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3.5. Results 
3.5.1. Pilot antibody microarray experiment 
As a pilot experiment, three PEX-100 antibody microarrays were used to analyse lysates 
from cell cultures treated with quercetin (10 μM), EGCG (10 μM) or a vehicle control 
(0.1% DMSO), with the slides processed on the same day. All three microarrays suffered 
from high fluorescence across the slide, affecting both background and foreground 
values. It was advised to increase the vigour of the water washes after the blocking step, 
as milk proteins from this step may not have been properly removed in the images from 
scanned microarray slides (Shannon Zhang [Full Moon Biosystems], personal 
communication 11 May 2010). This was tested, using two Nuclear/Membrane Receptor 
antibody microarrays (FMB) to analyse lysates from cell cultures treated with quercetin 
(10 μM) or a vehicle control. This resulted in images with much lower local background 
and low variation for inter-microarray target replicates (n=6, no. of unique antibodies = 
56). The main study was then undertaken, and the initial problems with high fluorescence 
were again encountered for the first microarray used. This was resolved after the addition 
of a TBS wash step after blocking (Shannon Zhang [Full Moon Biosystems], personal 
communication 11 May 2010). A key factor for the resolution of this issue may be the 
manner in which the slide was kept horizontal during the transfer between 10 cm
2
 dishes 
(as opposed to the transfer from 10 cm
2
 dish to plastic centrifuge tube for the water wash 
step), though this hypothesis was not fully tested. 
 
3.5.2. Analysis of microarray images 
The analysis of the first sample of cell lysate using the antibody microarrays resulted in 
an image containing very high background signal, adversely affecting the ability to 
extract meaningful fluorescence values from the spot foreground. As this effect was more 
prominent on one side of the microarray than the other, the differences between 
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foreground and background signals of the left and right negative control spots were used 
to attempt to correct this, according to the following formula, which is explained in detail 
in Appendix II: 
CSf = Sf – ([(Sb – LNb)/(RNb – LNb)] x (RNf - LNf)) – LNf +300 
Abbreviations: Corrected Spot foreground (CSf); Spot foreground (Sf); Spot background (Sb); 
average left negative control spot background (LNb); average right negative control spot 
background (RNb); average left negative control spot foreground (LNf); average right 
negative control spot foreground (RNf). 
 
To determine if the data from first microarray was of use, statistical significance testing 
was performed on the data set by either: 
(i) using the data without any correction 
(ii) using the data but correcting it as described above, or 
(iii) not including the data from the first microarray 
Of these three, not including the data from the first microarray resulted in a greater 
number of significant results (p < 0.05) (data not shown) and so this was the method used 
to produce the final set of results. Significance tests were also performed with and 
without use of quantile normalisation, do determine if its inclusion increased the number 
of significant results found (p < 0.05), which it did (data not shown). The statistical 
analysis was also tested by intentionally exaggerating a number of target values to 
different degrees so that the p- and q-values associated with these targets would be 
lowered in accordance, which they were (data not shown). 
 Density histograms of the raw MSFI data revealed a distinct difference between 
the data distribution of MSFIs from microarrays processed on the same day (treatments 
were processed so that no two microarrays processed on the same day would represent 
the same cell culture treatment) (Fig. 3.4). This difference was no longer present after 
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ratios were calculated from the data, as described in Section 3.4.5 (data not shown). Data 
distribution of the foreground and background showed a tendency for higher values in the 
duplicates on left side of the microarrays in both the foreground and background values 
(Figs. 3.5, only foreground data is shown). 
 
 
Figure 3.4: Density histogram of MSFI values, from microarrays grouped by the day on 
which they were performed. n=3 for days 3 and 4, n=2 for day 2 and n=1 for day 1 (the 
first microarray that was processed). 
 
Figure 3.5: Density histogram of MSFI values, from microarrays grouped by the day on 
which they were performed, and their left or right duplicate values. n=3 for days 3 and 4, 
n=2 for day 2. 
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3.5.3. Changes to protein phosphorylation after incubation of HUVECs with 
quercetin aglycone or quercetin metabolites 
Before adjusting for multiple testing, analysis of lysates from HUVECs for significant (p 
< 0.05) changes to protein phosphorylation highlighted 17 protein residues for cells 
treated with quercetin metabolites ( 
Table 3.1) and 29 for cells treated with quercetin aglycone (Table 3.2) when comparing 
both treatments to a vehicle control. However, there were no significant changes (q < 
0.05) after adjusting for multiple testing. 
 
Table 3.1: Quercetin metabolites vs vehicle control. 
a
 - nopair target, represented on the 
microarray by an anti-phosphoprotein antibody. 
b
 - nopair target, represented on the 
microarray by an anti-protein (unphosphorylated) antibody. 
Phospho-Protein 
p-value (unadjusted 
for MT) 
Fold Change 
Filamin A (pSer2152) 0.013 0.64 
Stathmin 1(pSer37) 0.008 0.74 
p90RSK (pThr359/Ser363) 0.011 0.82 
Caspase-9 (pSer196) 0.029 0.86 
JAK2 (pTyr1007) 0.047 0.87 
IkB-α (pSer32/36) 0.044 1.22 
PI3K p85-α/γ (pTyr467/199) 0.026 1.28 
BLNK (pTyr96) 0.014 1.29 
CREB (pSer142) 0.022 1.32
 
a
MER/SKY (pTyr749/681) 0.047 1.22 
VEGFR2 (pTyr951) 0.031 0.68 
eNOS (pSer1177) 0.018 0.77 
LCK (pTyr192) 0.039 0.85 
CaMK4 (pThr196/200) 0.036 0.87 
p130Cas (pTyr165) 0.046 1.17 
JAK1 (pTyr1022) 0.019 1.27 
GRK1 (pSer21) 0.049 1.28 
Casp6 (pSer257) 0.023 1.31
 
a
Synuclein-α (pTyr136) 0.022 0.90 
b
Smad2 (pSer255) 0.047 0.81 
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Table 3.2: Quercetin aglycone vs vehicle control. 
a
 - nopair target, represented on the 
microarray by an anti-phosphoprotein antibody. 
b
 - nopair target, represented on the 
microarray by an anti-protein (unphosphorylated) antibody. 
Phospho-Protein 
p-value (unadjusted 
for MT) 
Fold Change 
Ezrin (pTyr353) 0.038 0.60 
GluR1 (pSer849) 0.031 0.67 
Elk1 (pThr417) 0.016 0.72 
Progesterone Receptor (pSer190) 0.028 0.76 
p53 (pSer9) 0.044 0.77 
ER-α (pSer104) 0.049 0.78 
NF-κB-p65 (pSer529) 0.049 0.80 
PPAR-r (pSer112) 0.022 0.83 
EGFR (pTyr1172) 0.038 0.85 
PDGFR-α (pTyr849) 0.047 1.18 
Met (pTyr1234) 0.017 1.21 
IkB-ε (pSer22) 0.035 1.24 
MKK6 (pSer207) 0.046 1.28 
BRCA1 (pSer1457) 0.043 1.37 
Casp3 (pSer150) 0.019 1.76
 
a
Gab2 (pTyr643) 0.010 1.24
 
b
Smad2 (Ser255) 0.030 0.76 
Synapsin (pSer9) 0.021 0.60 
eNOS (pSer1177) 0.005 0.68 
STAT1 (pSer727) 0.013 0.72 
Smad1 (pSer465) 0.035 0.77 
GluR2 (pSer880) 0.028 0.78 
Connexin 43 (pSer367) 0.026 0.80 
c-Jun (pSer243) 0.022 0.82 
eIF2A (pSer51) 0.045 0.84 
Chk1 (pSer345) 0.041 0.86 
BCL-2 (pThr69) 0.048 1.19 
AMPKA1 (pThr174) 0.017 1.22 
IKK-β (pTyr188) 0.040 1.28 
Casp6 (pSer257) 0.029 1.33 
HDAC5 (pSer259) 0.002 1.55
 
b
eNOS (Ser1179) 0.035 0.90
 
a
VE-Cadherin (pTyr731) 0.013 1.28 
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3.5.4. Bioinformatic and ontological analysis of phosphorylated proteins 
highlighted in microarray results 
Analysis of the data sets resulting from significance testing (unadjusted for multiple 
testing) of the microarray data, to determine statistically significant representation of 
signalling pathways using the website DAVID produced no significant results (q < 0.05). 
The information collected from the websites PhosphoSitePlus and Uniprot are listed in 
Tables 3.3 and 3.4. Associations between proteins as indicated by the ontological study 
for Q. metabolites vs control are given in Fig. 3.6. A number of the phospho-proteins 
from the quercetin vs vehicle control comparison were identified as being associated with 
an anti-apoptotic effect (Fig. 3.7). Analysis of all the unique Uniprot accession IDs in the 
list of antibodies featured on the microarray using the website DAVID showed the 
microarray represented a large number of signal transduction pathways (Table 3.5). 
 
Table 3.3: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (Q. 
metabolites vs vehicle control). 
Protein Description Information 
Filamin A 
(pS2152) 
p = 0.013 
F.C. = 0.64 
Protein role 
Cytoskeletal protein, promotes branching of actin 
filaments, links actin to membrane glycoprotein 
Effect/protein Protein stabilization 
Effect/cell Regulates cytoskeletal reorganization 
Regulated by p90RSK, PAK1, JAK2 
CREB 
(pS142) 
p = 0.0383 
F.C. = 0.85 
Protein role 
Induces transcription in response to hormonal 
stimulation of the cAMP pathway. 
Effect/protein 
Enzyme activity, autophosphorylation, protein 
degradation, regulates molecular associations 
Effect/cell Regulates cell growth 
Regulated by CSFR, EGFR 
p90RSK 
(pT359/S363) 
p = 0.011 
F.C. = 0.82 
Protein role 
Kinase of AGC family, activated in response to 
hormones, growth factors and neurotransmitters 
Regulated by MKP-7 
STMN1 
(pS37) 
P = 0.008 
F.C. = 0.74 
Protein role 
Destabilisation of the microtubule filament system by 
destabilizing microtubules 
Effect/protein Inhibition, degradation 
Effect/cell Cell cycle regulation and cytoskeletal reorganization 
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Table 3.3: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (Q. 
metabolites vs vehicle control). 
Protein Description Information 
PI3K p85-α/γ 
(pY467/199) 
p = 0.049 
F.C. - 0.80 
Protein role 
Regulatory subunit of PI3K. Mediates interactions 
with a subset of tyrosine-phosphorylated proteins  
Effect/cell Regulates transcription 
Regulated by CSFR, EGFR, HS1 
eNOS 
(pS1177) 
p = 0.017 
F.C. = 0.77 
Protein role Synthesises nitric oxide 
Effect/protein Enzyme activity 
Effect/cell Cytoskeletal reorganization 
Regulated by Akt1, AMPKA1, PKACa, PKG2 
Casp6 
(pS257) 
p = 0.0447 
F.C. = 0.84 
Protein role Activation of caspase cascade, leading to apoptosis 
Effect/protein Inhibition of enzyme activity (Suzuki et al. 2004) 
Effect/cell Inhibits apoptosis 
Regulated by AMPK-related kinase 5 
Casp9 
(pS196) 
p = 0.0288 
F.C. = 0.86 
Protein role Activation of caspase cascade, leading to apoptosis  
Effect/protein Inhibition of enzyme activity 
Regulated by Akt1 
VEGFR2 
(pY951) 
P = 0.031 
F.C. - 0.68 
Protein role Receptor tyrosine kinase, regulates angiogenesis 
Effect/protein Enzyme activity 
Effect/cell Regulates cell motility 
Regulated by VEGFR2 
LCK (pY192) 
p = 0.039 
F.C. = 0.85 
Protein role 
Tyrosine kinase of the Src family, crucial for antigen-
receptor signalling in lymphocytes  
Effect/protein Inhibition, regulates molecular associations 
CaMK4 
(pT196/200) 
p = 0.036 
F.C. = 0.87 
Protein role 
Transcriptional activation of CREB protein-mediated 
signalling pathways  
Effect/protein 
Enzyme activity, intracellular translocation, regulates 
molecular associations 
Effect/cell Regulates transcription 
Regulated by BMP2, TOB1, TRRAP, BMPR1B 
JAK2 
(pY1007)  
p = 0.047 
F.C. = 0.87 
Protein role 
Tyrosine-kinase involved with cytokine receptor 
signalling pathways, including IL-3, -5 and GM-CSF  
Effect/protein 
Regulates molecular association, induce interaction 
with SOCS1 
Regulated by APS, FGFR1, JAK2, LEPR, SH2-B-beta, SOCS3 
p130Cas 
(pY165) 
p = 0.028 
F.C. = 0.78 
Protein role 
Docking protein, coordinates tyrosine-kinase-based 
signalling related to cell adhesion.  
Regulated by PXN  
IkB-alpha 
(pS32/36) 
p = 0.049 
F.C. = 0.78 
Protein role Regulatory protein that inhibits NFκB  
Effect/protein 
Enzyme activity, intracellular translocation, 
autophosphorylation, protein degradation 
Effect/cell Regulates transcription and apoptosis 
Regulated by PKD2, PLK1, SHIP, IKK-β, IKK-ε, CK2-A1, IKK-α 
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Table 3.3: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (Q. 
metabolites vs vehicle control). 
 
 
Figure 3.6: Signalling and interactions between phospho-proteins from the microarray 
results (Q. metabolites vs vehicle control), according to ontological information. Dashed 
lines indicate interactions between phospho-proteins that are not necessarily supported by 
the change in phosphorylation recorded by the microarray analysis. Greyed out lines 
indicated an association between proteins, but not necessarily due to the phosphorylated 
residue in question. Greyed out proteins indicate that they are not part of the microarray 
results, but are required to show the signalling pathway. 
Protein Description Information 
JAK1 
(pY1022) 
P = 0.026 
F.C. = 0.80 
Protein role 
Tyrosine-kinase involved interferon signal 
transduction pathways  
Effect/protein Inhibition  
Effect/cell Regulates cell motility  
Regulated by Tyk2, JAK3, PTPN2 
GRK1 
(pS21) 
p = 0.022 
F.C. = 0.82 
Protein role Phosphorylates and inactivates rhodopsin  
Effect/protein Inhibition 
Effect/cell Regulates transcription  
Regulated by PKACα 
BLNK  
(pY96) 
p = 0.022 
F.C. = 0.83 
Protein role 
Adaptor protein, regulates B-cell function and 
development  
Effect/protein Regulates molecular association 
Effect/cell Regulates transcription  
Regulated by Syk 
VEGFR2↓ 
Casp9↓ eNOS↓ PI3K↑ MEK1/2 ERK1/2 
p90RSK↓ 
STMN1↓ 
FLM1↓ CREB↑ 
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Table 3.4: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (quercetin vs 
vehicle control). 
 
 
Protein Description Information 
Casp6 
(pS257) 
p = 0.029 
F.C. = 1.33 
Protein role Activation of caspase cascade, leading to apoptosis. 
Effect/protein Inhibition of enzyme activity (Suzuki et al. 2004) 
Effect/cell Inhibits apoptosis 
Regulated by ARK5 (AMPK-related kinase) 
Casp3 
(pS150) 
p = 0.019 
F.C. = 1.76 
Protein role Activation of caspase cascade, leading to apoptosis. 
Effect/protein Enzymatic inhibition 
Effect/cell Inhibits apoptosis 
Regulated by p38α 
HDAC5 
(pS259) 
p = 0.002 
F.C. = 1.55 
Protein role 
Transcriptional regulation, cell cycle progression and 
developmental events 
Effect/protein 
Intracellular translocation, regulates molecular 
association, induces interaction with 14-3-3β 
Effect/cell 
Regulates cell differentiation, cell motility, chromatin 
organization and transcription 
Regulated by AMPKA1, CaMK4 
AMPKA1 
(pT174) 
p = 0.017 
F.C. = 1.22 
Protein role 
Regulates cellular energy in response to the balance 
between AMP/ATP, and intracellular Ca
2+
 levels. 
Effect/protein Enzyme activity 
Regulated by ATM, LKB1, p27Kip1, PKCZ, PPP2CA 
MKK6 
(pS207) 
p = 0.046 
F.C. = 1.28 
Protein role Activates p38 MAPK enzyme activity.  
Effect/protein Enzymatic activation  
Effect/cell Regulates transcription 
Regulated by ASK1, Cot  
STAT1 
(pS727) 
p = 0.0126 
F.C. = 0.72 
Protein role 
Transcription regulation in response to peptide 
hormone stimulus; NFκB cascade. Regulation of 
smooth muscle cell proliferation; induction of 
apoptosis  
Effect/protein 
Activation, regulates molecular associations, 
sumoylation 
Effect/cell 
Regulates apoptosis, regulates cell growth, regulates 
transcription 
Regulated by MKK6, Raf1 
eNOS 
(pS1177) 
p = 0.0046 
F.C. = 0.68 
Protein role Synthesises nitric oxide 
Effect/protein Enzyme activity 
Effect/cell Cytoskeletal reorganization 
Regulated by Akt1, AMPKA1, PKACa, PKG2 
p53 (pS9) 
p = 0.0437 
F.C. = 0.77 
Protein role 
Transcription factor and tumour suppressor, regulates 
cellular responses to DNA damage 
Effect/protein 
Auto-acetylation, enzyme activity (Caporali et al. 
2004) 
Effect/cell Regulates apoptosis, cell cycle and transcription 
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Table 3.4: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (quercetin vs 
vehicle control). 
Protein Description Information 
BCL-2 (pT69) 
p = 0.0476 
F.C. = 1.19 
Protein role Anti-apoptotic protein, inhibits caspase activity 
Effect/protein 
Regulates molecular association, likely anti-apoptotic 
and inducible interaction with Bax (Deng et al. 2006) 
Effect/cell Regulates apoptosis 
Regulated by JNK1 
IKK-β 
(pY188) 
p = 0.0401 
F.C. = 1.28 
Protein role Degrades inhibitors of NFκB 
Effect/protein Activation 
Effect/cell Regulates transcription 
Regulated by Src 
IkB-ε (pS22)  
p = 0.035 
F.C. = 1.24 
Protein role 
Inhibits NFκB by complexing with and trapping it in 
the cytoplasm 
Effect/protein Ubiquitin-mediated degradation. 
Regulated by IKK 
NFkB-p65 
(pS529) 
p = 0.0489 
F.C. = 0.80 
Protein role 
Subunit of NFκB transcription complex, regulates 
inflammatory and immune responses. 
Effect/cell Regulates transcription 
Regulated by CDK5RAP3, CK2-A1  
Ezrin (pY353) 
(354) 
p = 0.0377 
F.C. = 0.60 
Protein role 
Regulates cell surface structure adhesion, migration, 
and organization 
Effect/protein Activation, regulates molecular association 
Effect/cell 
Regulates cell motility, cytoskeletal reorganization, 
induce interaction with PI3K 
Regulated by EGFR 
Met (pY1234) 
p = 0.0174 
F.C. = 1.21 
Protein role A proto-oncogenic receptor tyrosine kinase. 
Effect/protein 
Enzyme activity, autophosphorylation, induce 
interaction with Grb2 
Effect/cell Regulates cell growth and motility 
Regulated by EGFR, Ron 
Chk1 (pS345) 
p = 0.0407 
F.C. = 0.86 
Protein role 
Regulates cell cycle arrest in response to DNA 
damage 
Effect/protein 
Enzymatic activation, protein degradation, regulates 
molecular associations 
Effect/cell Apoptosis and cell cycle regulation 
Regulated by ATM, ATR, Cot, Akt1, EGFR, ER-α, MCM7 
EGFR 
(pY1172) 
p = 0.0383 
F.C. = 0.85 
Protein role 
Receptor tyrosine kinase, regulates cell growth and 
differentiation. 
Effect/protein 
Enzyme activity, autophosphorylation, protein 
degradation, regulates molecular association 
Effect/cell Regulates cell growth 
Regulated by CSFR 
Estrogen 
Receptor-α 
(pS104) 
p = 0.0492 
F.C. = 0.78 
Protein role 
Regulates gene expression and cell proliferation and 
differentiation 
Effect/protein Enzyme activity, regulates molecular associations 
Effect/cell Regulates transcription  
Regulated by CDK2, ERK2 , GSK3B  
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Table 3.4: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (quercetin vs 
vehicle control). 
 
 
 
Protein Description Information 
Progesterone 
receptor 
(pS190) 
p = 0.028 
F.C. = 0.76 
Protein role 
Regulates gene expression and cell proliferation and 
differentiation 
Effect/cell Regulates transcription 
Regulated by CDK2 
c-Jun (pS243) 
p = 0.022 
F.C. = 0.82 
Protein role Component of the transcription factor AP-1 
Effect/protein 
Inhibition of enzyme activity, autophosphorylation, 
regulates molecular associations 
Effect/cell Regulates transcription  
Regulated by PPP3CA, CK2-A1, GSK3B  
PPAR-γ 
(pS112) 
p = 0.022 
F.C. = 0.83 
Protein role 
Regulator of adipogenesis and lipid metabolism, 
insulin sensitivity, proliferation and inflammation. 
Effect/protein Protein degradation 
Effect/cell Regulates differentiation, growth and transcription  
Regulated by Fyn, PARVB, PPP1CA, ERK2, JNK1  
eIF2A (pS51) 
p = 0.045 
F.C. = 0.84 
Protein role 
Translation initiation factor, active in the early steps 
of protein synthesis 
Effect/protein Enzyme activity, regulates molecular associations 
Effect/cell Regulates apoptosis, cell growth and translation  
Regulated by GADD34, Nck1, Nck2, PKR, HRI, PERK, PPP1CA  
PDGFRα 
(pY849) 
p = 0.047 
F.C. = 1.18 
Protein role 
Receptor tyrosine kinase, regulates cell growth, actin 
reorganization, migration and differentiation 
Effect/protein Likely enzyme activity, no direct evidence though 
Connexin 43 
(pS367) 
p = 0.026 
F.C. = 0.80 
Protein role Forms gap junctions with neighbouring cells 
Effect/protein Regulates cell motility 
Effect/cell Inhibition of enzyme activity 
Regulated by PKCE 
GluR1 
(pS849) 
p = 0.031 
F.C. = 0.67 
Protein role Membrane protein, regulates synaptic transmission 
Effect/protein Enzyme activity 
GluR2 
(pS880) 
p = 0.028 
F.C. = 0.78 
Protein role Membrane protein, regulates synaptic transmission 
Effect/protein Enzyme activity 
BRCA1 
(pS1457) 
p = 0.043 
F.C. = 1.37 
Protein role Regulation of DNA damage repair, ubiquitination 
Effect/protein 
Regulates molecular associations induce interaction 
with ATM 
Regulated by ATM, ATR 
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Table 3.4: Information regarding the descriptors given in Section 3.4.7, detailing the 
effects of increased phosphorylation on proteins from the microarray results (quercetin vs 
vehicle control). 
 
 
Figure 3.7: Signalling and interactions between phospho-proteins from the microarray 
results (quercetin vs vehicle control), according to ontological information. Underlined 
proteins are associated with an anti-apoptotic effect. Dashed lines indicate interactions 
between phospho-proteins that are not necessarily supported by the change in 
phosphorylation recorded by the microarray analysis. Greyed out lines indicated an 
association between proteins, but not necessarily due to the phosphorylated residue in 
question. Greyed out proteins indicate that they are not part of the microarray results, but 
are required to show the signalling pathway. 
 
 
Protein Description Information 
Synapsin 
(pS9) 
p = 0.021 
F.C. = 0.60 
Protein role 
Neuronal protein, associates with synaptic vesicles 
and binds to the cytoskeleton 
Effect/protein 
Inhibits binding to phospholipids and dissociates 
synapsins from synaptic vesicles 
Regulated by CaMK1 and PKA 
Elk1 (pT417) 
p = 0.016 
F.C. = 0.72 
Protein role 
Regulates transcription in response to serum and 
growth factors 
Regulated by PRP4 
Smad1 
(pS465) 
p = 0.035 
F.C. = 0.77 
Protein role 
Regulation of morphogenesis, proliferation, 
differentiation and apoptosis 
Effect/protein 
Enzyme activity, intracellular translocation, regulates 
molecular associations 
Effect/cell Regulates transcription 
ATM 
Chk1↓ 
BRCA1↑ 
AMPKA1↑ 
eNOS↓ 
HDAC5↑ 
p53↓ 
EGFR↓ 
Ezrin↓ Met↑ 
MKK6↑ 
p38 STAT1↓ 
Casp3↑ Casp6↑ 
IKKβ↑ 
IκBε↑ 
NFκB↓ BCL-1↑ 
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Table 3.5: Signalling pathways represented on the antibody microarray, the number of 
targets representative of these pathways, and their percentage of the total targets 
Signalling pathway Count % Signalling pathway Count % 
Neurotrophin signalling 
pathway 
65 16.1 
Adipocytokine signalling 
pathway 
22 5.5 
ErbB signalling pathway 54 13.4 Acute myeloid leukaemia 28 6.9 
B cell receptor signalling 
pathway 
36 8.9 
Epithelial cell signalling 
in Helicobacter pylori 
infection 
22 5.5 
Prostate cancer 47 11.7 Bladder cancer 17 4.2 
MAPK signalling pathway 76 18.9 Wnt signalling pathway 32 7.9 
Chronic myeloid leukaemia 42 10.4 
Jak-STAT signalling 
pathway 
32 7.9 
Focal adhesion 64 15.9 Axon guidance 27 6.7 
T cell receptor signalling 
pathway 
47 11.7 
NOD-like receptor 
signalling pathway 
18 4.5 
Pancreatic cancer 37 9.2 Thyroid cancer 12 3.0 
Fc gamma R-mediated 
phagocytosis 
41 10.2 
Vascular smooth muscle 
contraction 
23 5.7 
Glioma 34 8.4 Melanogenesis 21 5.2 
Pathways in cancer 96 23.8 Type II diabetes mellitus 14 3.5 
Insulin signalling pathway 46 11.4 Long-term depression 17 4.2 
Colorectal cancer 36 8.9 Endocytosis 29 7.2 
Fc epsilon RI signalling 
pathway 
33 8.2 
Pathogenic Escherichia 
coli infection 
14 3.5 
Long-term potentiation 31 7.7 Tight junction 22 5.5 
Regulation of actin 
cytoskeleton 
41 10.2 
RIG-I-like receptor 
signalling pathway 
15 3.7 
Non-small cell lung cancer 27 6.7 Endometrial cancer 24 6.0 
Cell cycle 38 9.4 Gap junction 16 4.0 
Chemokine signalling 
pathway 
47 11.7 
Calcium signalling 
pathway 
24 6.0 
Aldosterone-regulated 
sodium re-absorption 
11 2.7 
TGF-beta signalling 
pathway 
15 3.7 
GnRH signalling pathway 32 7.9 
Primary 
immunodeficiency 
9 2.2 
Melanoma 26 6.5 Viral myocarditis 13 3.2 
VEGF signalling pathway 28 6.9 Prion diseases 8 2.0 
Natural killer cell mediated 
cytotoxicity 
37 9.2 
Hematopoietic cell 
lineage 
13 3.2 
mTOR signalling pathway 23 5.7 Alzheimer's disease 19 4.7 
Progesterone-mediated 
oocyte maturation 
30 7.4 
Phosphatidylinositol 
signalling system 
11 2.7 
Adherens junction 27 6.7 Oocyte meiosis 31 7.7 
p53 signalling pathway 25 6.2 Renal cell carcinoma 24 6.0 
Apoptosis 28 6.9 Small cell lung cancer 26 6.5 
Toll-like receptor 
signalling pathway 
30 7.4 
Amyotrophic lateral 
sclerosis (ALS) 
20 5.0 
Leukocyte transendothelial 
migration 
32 7.9    
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3.5.5. Western blotting of selected protein phosphorylation changes identified using 
microarray analysis 
Three of the proteins identified as being significantly altered by quercetin treatment in the 
microarray analysis were selected for further analysis using western blotting. The 
selected protein changes selected were: 
(i) increased phosphorylation of caspase-6 (Ser257) by quercetin metabolites and 
quercetin aglycone 
(ii) decreased phosphorylation of VEGFR2 (Tyr951) by quercetin metabolites 
(iii) decreased phosphorylation of eNOS (Ser1177) by quercetin metabolites and 
quercetin aglycone 
The increase in caspase-6 phosphorylation and decrease in VEGFR2 phosphorylation 
identified by the microarray analysis could not be confirmed by western blotting. Bands 
representing phosphorylated or unphosphorylated caspase-6 (34 kDa) could not be 
confidently identified in blots of lysates from cells treated with either quercetin, its 
metabolites or with etoposide (Fig. 3.8). Etoposide has been shown previously to increase 
caspase-6 phosphorylation at Ser257 (as per documentation for Abcam anti-p-caspase-6 
(Ser257) antibody [#63440]), though no reports could be found which show such activity 
in HUVECs or other endothelial cell lines, which may explain the lack of increased 
phosphorylation observed here. While bands representing phosphorylated VEGFR2 were 
identified in blots of lysates from cells treated with VEGF, no clear bands could be 
identified for other treatments, or in blots stained for total VEGFR2 (data not shown). 
 Blots of lysates from HUVECs treated with EGCG (to stimulate eNOS 
phosphorylation and allow for more obvious detection of p-eNOS decrease) followed by 
increasing doses of quercetin metabolites did not result in decreases in eNOS 
phosphorylation as was putatively identified by the microarray analysis (Fig. 3.9). 
Treatment of HUVECs with EGCG followed by incubation with quercetin aglycone, 
however, did result in a dose-dependent decrease in eNOS phosphorylation (Fig. 3.10), 
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which was significant at 50 μM (p < 0.05) following densitometry analysis (Fig. 3.11). 
Pearson's correlation coefficient was calculated for the dose-dependent decrease in eNOS 
phosphorylation. The corresponding t-statistic showed the decrease to be borderline 
significant (p = 0.056). 
 
 
Figure 3.8: Western blots for Casp6 and p-Casp6(Ser257) from lysates of HUVECs 
treated for 60 minutes with 25 µM etoposide (E), 50 µM quercetin (Q) and 50 µM 
quercetin metabolite mix (Qm), alongside a vehicle control (V). The bands shown on the 
anti-Casp6 blot could not be confirmed as representative of caspase 6. Molecular weight 
marker (M) bands: 20, 30, 40, 50, 60, 80, 100, 120 and 220 kDa (bottom to top). n=3 
(culture well replicates) for each treatment, except for the quercetin metabolites treatment 
(n=2). 
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Figure 3.9: Western blots of p-eNOS/eNOS from lysates of HUVECs treated with 50 
μM EGCG for 30 minutes prior to varying concentrations (μM) of a mix of quercetin 
metabolites (in fresh culture media) for 60 minutes alongside a vehicle control (Ctrl). 
Underlined treatments indicate that the assayed lysates were from cells used for the 
original microarray experiment (no EGCG pre-treatment). n=3 (culture well replicates) 
for each treatment. Ratio of blot densitometry (p-eNOS/eNOS)is shown in the lower 
panel. 
 
 
Figure 3.10: Western blots of lysates from HUVECs treated with 50 μM EGCG for 30 
minutes prior to varying concentrations (μM) of quercetin (in fresh culture media) for 60 
minutes alongside a vehicle control treatment (-ve). n=3 (culture well replicates) for each 
treatment, except for the 20 µM treatment (n=2). 
Ctrl Ctrl Ctrl 
Ctrl Ctrl Ctrl Ctrl 
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Figure 3.11: Ratio of blot densitometry from western blots shown in Fig. 3.10. * - p < 
0.05 vs vehicle control treatment (0 µM). 
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3.6. Discussion 
Analysis of lysates from endothelial cells treated with quercetin, a mix of quercetin 
metabolites, or a vehicle control, with an antibody microarray complimentary for a large 
subset of phospho-proteins, provided a small selection of changes that, while unable to 
stand up to robust statistical testing, provided targets for validation by western blotting. 
After stimulation of phosphorylation of the enzyme eNOS, treatment with quercetin dose-
dependently caused a decrease in phosphorylation (p = 0.056), similar to what was 
observed using the microarray analysis. 
 
3.6.1. Endothelial signalling events in response to quercetin 
While a large number of signalling proteins were measured in the endothelial cells, only a 
small subset of these were shown to be significantly altered by the microarray analysis. 
There was a consensus amongst a number of the phospho-proteins highlighted by the 
quercetin treatment towards an anti-apoptotic effect, although this could not be shown as 
significant by bioinformatic analysis, and so it is unlikely to be a real effect of the 
quercetin treatment (Fig. 3.7 and Table 3.4). Despite the fact that quercetin can have 
strong cytotoxic effects at high concentrations, there is evidence that the dose of 10 µM 
used in this study can improve cell survival in both endothelial and non-endothelial cells 
(Chao et al. 2009; Spencer et al. 2003). p53, BCL-2 and caspase-3 are three of the 
phospho-proteins highlighted by the microarray analysis of quercetin-treated cells that 
were indicative of an anti-apoptotic response. Changes to these proteins have been 
reported previously in cells treated with quercetin, in terms of changes to phosphorylation 
or protein expression that are in line with a decrease in apoptotic cells (Choi et al. 2009; 
Choi et al. 2005; Choi et al. 2003). Such effects would not necessarily be related to the 
decrease in eNOS phosphorylation (enzyme inactivation), observed as the main effect of 
quercetin-treated cells, as this decrease is associated with anti-proliferation activity rather 
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than anti-apoptosis (Mata-Greenwood et al. 2008). The dose of quercetin at which p-
eNOS decrease was significant (50μM) was particularly high, however. The involvement 
of quercetin's cytotoxicity with observed effects/lack of effects should be considered in 
future experiments, and cell viability assays can be used to take cytotoxic effects into 
account.  
 The observation that quercetin can decrease eNOS phosphorylation mirrors 
previous reports which show decreases to eNOS activity and expression due to quercetin 
treatment (Jackson & Venema 2006; Wallerath et al. 2005), and while this decrease in 
phosphorylation was not statistically significant in the microarray analysis for q < 0.05, 
the western blotting results support this as a real effect (Figs. 3.10 and 3.11). However, it 
is also in contradiction to a number of animal studies which show improvement to 
vasodilation, an effect which would be associated with increased eNOS phosphorylation 
(at Ser1177) (Sanchez et al. 2006; Nishida & Satoh 2009; Khoo et al. 2010). Indeed, a 
decrease in Ser1177 phosphorylation of eNOS protein would be associated with increased 
vascular tone and could be indicative of endothelial dysfunction if such a decrease in 
phosphorylation was to be maintained for irregular periods. While improvements to 
vasodilatory function have been seen in human studies which record significantly lower 
blood pressure after consumption of quercetin (Lee et al. 2011; Egert et al. 2009), this 
effect has also been reported as being independent of changes to ET-1 and nitrites, 
markers normally associated with changes to vascular tone (Larson et al. 2012a).   
 The research reported here details effects in HUVECs after stimulation with only 
a polyphenol treatment. Bioactive effects due to quercetin are often reported in cells that 
have been co-treated with additional factors, such as hydrogen peroxide, oxidised low-
density lipoproteins, TNF-α or high concentrations of glucose (Chao et al. 2009; Choi et 
al. 2009; Choi et al. 2003; Mochizuki et al. 2004). Resting HUVECs may be in a state 
where quercetin or its metabolites cannot influence signalling associated with protein 
phosphorylation to the extent that is reported in studies where cells are first challenged 
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with inflammatory factors. It may be that the molecules involved in mediating signals in 
endothelial cells after exposure to quercetin may first require translocation, or their 
intracellular levels may be too low, and it is these stresses which can alter location or 
expression of molecules and allow signalling in response to quercetin to take place.  
  
3.6.2. Study of protein phosphorylation with antibody microarrays  
Through the microarray analysis, the phosphorylation of a large subset of endothelial cell 
proteins was studied. Considering the size of the experiment, it is likely that a number of 
the proteins complimented by the antibodies present on the microarray have not been 
previously identified in endothelial cell cultures, specifically those that are of low 
abundance and are less likely to be identified by mass spectrometry analyses. Therefore, 
secondary to the main objectives of this work, evidence for the presence of previously 
unreported proteins in endothelial cells is likely to have been found by this study, which 
may be of use for future broad-targeted phospho-protein studies in endothelial cell 
cultures (such evidence would of course be more robust had a cell-free control treatment 
been analysed by the antibody microarrays alongside the experimental treatments, to 
measure levels of non-specific binding). 
 At the time of the microarray analysis described in this chapter, most reported 
studies using phospho-protein antibody microarrays were focused on a small subset of 
signalling proteins, usually confined to one specific signalling pathway (He et al. 2009; 
Zhong et al. 2008; Kang et al. 2010). This highlights the novelty of such a technique 
involving numbers of target analytes an order of magnitude greater than previous reports. 
Though not necessarily a symptom of this, there were a number of issues upon initial use 
of the antibody microarrays.  
 While there appeared to be an additive effect of background fluorescence on 
foreground signal in the microarray images which suffered from high background signal, 
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normal levels (as per manufacturer's examples) of local background did not appear to 
have significant influence on foreground signal. In a number of cases, the signal 
surrounding spots would be higher than the foreground spot signal (Fig. 3.3, e.g. bottom 
row, 4th from the left), suggesting that the blocking buffer proteins (if these are indeed 
the main source of background signal) have lower affinity to the antibodies/spotting 
buffer than to the glass slide. The manufacturer's recommendation for dealing with 
normal levels of background fluorescence was to not factor it in to any calculations. A 
similar case of lower foreground signal compared to background signal was reported in a 
number of spots of the antibody microarray experiments conducted by Hecker et al. 
(2012), however they did not ignore the local background signal in their experiments. 
Their strategy was to increase all negative values to a value of 1, after subtraction of the 
background signals. While this allows calculations to take into account any influence 
high background fluorescence might have on foreground signal, information is likely to 
be lost from spots representing low abundance proteins/phospho-proteins by truncating 
their values. A third method would be to add a flat value to all spots after background 
subtraction, to increase lowest value to > 1. While this would not necessarily affect 
significance testing, there may be a need to take into account the fact that fold-changes 
for these targets would be skewed.  
 Analysis of the microarrays was further complicated by an inability of the 
GenePix software to determine the boundaries of many of the spots in the .tiff image files 
that were produced from the fluorescence scan of the microarrays. The manufacturer-
supplied .gal (genepix array list) file, which stores relative locations of each microarray 
spot along with each spot's target protein, could not be used for this task due to slight 
discrepancies between the locations stored in the .gal file and actual locations of spots on 
the slides. The issue appeared to be with the concentric nature of a number of the spots, 
and the negative/small differences between spot foreground and local background signals. 
The Matlab software script used to analyse images made use of a package designed for 
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detecting objects of a particular shape, and was able to cope much better with both of 
these factors. 
3.6.3. Analysis of antibody microarray data 
At the time of analysis, no reports could be found which described statistical significance 
testing of normal-phase phospho-protein antibody microarray data. The analysis of 
reverse-phase phospho-protein antibody microarray data by Petricoin et al. (2007) details 
the use of the Wilcoxon rank test, though such a test is more appropriate for non-
parametric data. The use of p-values is mentioned in the report by He et al. (2009), 
though no description is given as to the method of significance testing used. The limma 
package for the R software environment was designed around the use of linear models for 
analysing microarray data. Its use for handling large datasets in experiments with small 
numbers of microarrays has been well documented (Smyth 2005). The method 
development involved in this study highlights the of lack of established procedures for 
performing antibody microarray analysis on a relatively large scale (in terms of analytes), 
an issue discussed in the report authored by Hecker et al. (2012), where differences 
between antibody/protein microarrays and cDNA microarrays, such as the distribution of 
signal and the consistency of total signal across microarrays, were also highlighted. 
 Similar to other reported studies, Bhola et al. (2011) made no use of significance 
testing and reported only fold changes, in a study that involved a relatively small set of 
analytes. Reported fold changes were high enough, however, that changes to 
phosphorylation are obvious, and do not necessarily warrant thorough significance 
testing. This is in contrast to the fold changes recorded here for significant (p < 0.05) 
changes to protein phosphorylation (0.60 to 1.76). Such fold changes are also relatively 
low compared to what might be expected for obvious changes in more-routine 
biochemical techniques, such as western blotting assays or ELISAs, despite their values 
for significance.  
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Regardless of the fact that DAVID was designed for the analysis of data from cDNA 
microarray, rather than anti-protein antibody microarrays, it is still capable of 
determining significant analyte relationships in the context of cell signalling, whether or 
not the analyte is a gene or a protein. Therefore, pathway analysis software that is 
designed with protein networks in mind, such as Ingenuity Pathway Analysis 
(http://www.ingenuity.com), or MetaCore (http://portal.genego.com) are likely to have 
produced similar results. The PhosphoSite and Uniprot websites proved a good source of 
information on the functions of the protein phosphorylation events highlighted by the 
microarray study. Though not exhaustive, both sites are under constant development and 
are likely to continue to be excellent data sources for these types of studies in, and for the 
development of bioinformatics software in the future. The conclusion from studying these 
databases, that an anti-apoptotic effect was being represented by the changes in phospho-
proteins, was not backed by the statistical significance testing used in this study. It is 
likely the majority of phospho-proteins highlighted were simply chance occurrences, and 
that there were no strong effects on protein phosphorylation due to the 60 minute 
incubations of either quercetin or a mix of its metabolites. 
 This is the largest reported antibody microarray study to date (1320 unique 
antibodies per slide), surpassing that of Bodet et al. (2007) (approx. 600 different 
antibodies). Antibody microarrays capable of assessing > 100 targets at once are 
produced by a handful of companies, with most taking protein phospho-sites into account 
(Zhang & Pelech 2012). While microarrays have a number of advantages over techniques 
such as mass spectrometry analysis, including selectivity, improved reproducibility and 
relative ease of performance, it is still a relatively new method, and only one out of many 
techniques that now exist for relative and absolute quantification of large numbers of 
proteins simultaneously (Taussig et al. 2007; Ray et al. 2010; Rodríguez-Suárez & 
Whetton 2013). Until such methods become economical enough for routine use, with 
their capabilities confirmed through published studies, their limitations should not be 
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underestimated, and compromises in study design will most likely have to be made. The 
large number of target analytes on the microarrays used meant that their design could 
only include two replicates per microarray slide, and this may have been costly in 
obtaining results able to stand up to robust significance testing. Despite this, the decrease 
in eNOS phosphorylation shows that quercetin may have some effect on early signalling 
events in resting endothelial cells. By focusing on a small number of markers related to 
eNOS activity, further details as to the bioactivity of quercetin, or other polyphenols 
found in the food plants, may be uncovered. 
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3.7. Conclusion 
Quercetin, as a mix of its human metabolites and in its aglycone form, was used to treat 
endothelial cells to determine early responses of cell signalling related protein 
phosphorylation. To accomplish this, an antibody microarray, designed to target a large 
subset of signalling proteins in both their phosphorylated and unphosphorylated forms, 
was used to analyse cell lysates. Significance testing provided a subset of proteins with 
altered phosphorylation levels (17 for quercetin metabolites vs control, 29 for quercetin 
aglycone vs control). Analysis of protein ontologies indicated an anti-apoptotic effect. 
Using western blotting for validation of the microarray analysis results, quercetin 
aglycone was shown to dose-dependently decrease eNOS phosphorylation, significant at 
50 µM. More detailed analyses of eNOS activity and related signalling molecules may 
provide further clues as to the bioactivity of quercetin or other bioactive compounds in 
the food plants selected in Chapter 2. 
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Chapter 4: Effect of polyphenols on vasodilatory signalling 
molecules in endothelial cells 
4.1. Abstract 
Quercetin, a polyphenol found in numerous foods consumed worldwide, including those 
selected in Chapter 2, was shown to significantly (p < 0.05) decrease eNOS 
phosphorylation in HUVECs, as determined by western blotting and antibody microarray 
analysis. eNOS is part of the nitric oxide signalling pathway and involved in the 
regulation of vascular tone, an important factor in the control of endothelial dysfunction. 
It would be interesting to see if extracts of these and other selected plants could affect 
eNOS or other molecules related to nitric oxide signalling in endothelial cells.  
 Food plant extracts were prepared using hot 70% methanol for treatment of 
HUVECs, alongside a number of pure compound treatments. Quercetin was tested in the 
aglycone form and as a mix of phase II human metabolites, alongside the kale 
glucosinolate sinigrin, allyl-ITC, phase II metabolites of sulforaphane, and sulforaphane 
itself. Phosphorylation (activation) of Akt and eNOS was assayed by western blotting. 
Changes to cGMP, total eNOS protein and secreted endothelin-1 (ET-1) protein were 
quantified using ELISA. Levels of nitrates released into cell media were measured using 
a nitric oxide analyser. Effects of the treatments on cell health were determined using the 
WST-1 assay, and by making visual observations with a light microscope. 
 As evidence for their potential to increase endothelial nitric oxide production, the 
persimmon and pomegranate extracts (and only these two treatments) were able to 
increase the phosphorylation of both Akt and eNOS in HUVECs, significantly reduce 
levels of ET-1 in the culture media over 24 hours (p < 0.001), and significantly increased 
levels of nitrates/nitrites (p < 0.05), compared to vehicle controls, reported here for the 
first time. 
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4.2. Introduction  
4.2.1. Potential for polyphenols to affect production of nitric oxide in the 
endothelium 
There is evidence that dietary consumption of polyphenol-rich foods can improve 
endothelial function and reduce hypertension in humans (Shukla et al. 2010; Manach et 
al. 2005; Halliwell 2007; Schini-Kerth et al. 2011) based on in vitro and in vivo evidence, 
as well as long-term intervention trials (Chong et al. 2010; Oude Griep et al. 2011). The 
ability of plant-derived polyphenols to regulate nitric oxide release would provide good 
rational for these effects. Studies with polyphenol-rich foods, such as cocoa and 
chocolate (Flammer et al. 2012; Ried et al. 2012), wine (Li & Förstermann 2012), tea 
(Hollman et al. 2010), apple (Jensen 2009), cranberry (Dohadwala et al. 2011) and 
pomegranate (Lynn et al. 2012), have all shown improvements to markers associated with 
CVD, such as hypertension. Meta-analyses of intervention trials with foods such as these 
provide stronger evidence for beneficial effects, as well as highlighting potential method 
improvements so as to obtain results more comparable to previous studies by others in the 
field (Kay et al. 2012; Hooper et al. 2008; Peterson et al. 2012). Intervention trials which 
focus on pure polyphenol compounds, such as epicatechin (Jiménez et al. 2012), 
quercetin (Perez-Vizcaino et al. 2009), epigallocatechin-gallate (Brown et al. 2009; 
Widlansky et al. 2007) and chlorogenic acid (Mubarak et al. 2012), as well as subclasses 
of polyphenols such as lignans (Peterson et al. 2010) or flavonols (Hollman et al. 2010), 
reinforce results from studies focused on whole foods.  
 In the context of nitric oxide signalling or endothelium-dependent vasodilation, 
there are numerous studies showing positive effects in cells or tissues treated with 
phenolic compounds (Schmitt & Dirsch 2009; Schini-Kerth et al. 2010). The anthocyanin 
cyanidin-3-O-glucoside (Sorrenti et al. 2007), epicatechin (Ramirez-Sanchez et al. 2011; 
Brossette et al. 2011), epigallocatechin-gallate (Yamakuchi et al. 2008) resveratrol, 
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quercetin (Appeldoorn et al. 2009) and thearubigins (Lorenz et al. 2009) have all been 
shown to increase NO production or phosphorylation of eNOS (Ser1177). 
Epigallocatechin-gallate has also been reported to decrease secretion of ET-1 (Unger 
2010). Many of these studies make use of antibodies complimentary for signalling 
molecules such as eNOS with and without phosphorylation of enzyme-activity related 
residues. Other studies measure nitric oxide by way of its oxidation products or using 
NO-sensitive fluorophores. Cell culture studies are matched by experiments working with 
whole tissue, measuring the relaxation of endothelium-intact and endothelium-denuded 
vascular rings. Rings are usually taken from rats, mice and pigs and used as a model for 
the human vascular system. In such studies, relaxant effects have been reported with, 
amongst others, epigallocatechin-gallate (Alvarez et al. 2006), procyanidins (Tokoudagba 
et al. 2010) and grape juice (Anselm et al. 2007). Additional examples of plant extracts 
reported to increase nitric oxide signalling include treatment of porcine vascular rings 
with cranberry and lingonberry juices (Auger et al. 2011) and treatment of endothelial 
cell cultures with black tea (Anter et al. 2005) or grape seed extracts (Liu et al. 2012). 
Tested compounds may be metabolised in vivo to form additional conjugated or 
deconjugated forms, possibly with altered bioactivity. Such changes in bioactivity after 
conjugation could provide clues as to which moieties of the original compound are 
important for influencing cell signalling. For example, it has been reported that 
polyphenol hydroxyl groups, and their positions, are important for mediating biological 
effects (Auger et al. 2010). 
 
4.2.2. Plant extract and representative pure compound treatments for endothelial 
cell culture experiments 
The six food plants selected in Chapter 2 (dill, nettle, kale, Sideritis, pomegranate and 
persimmon) may be able to produce similar bioactive effects. By testing polyphenol-rich 
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plant extracts and representative pure compounds in assays measuring changes to 
molecules related to nitric oxide signalling, plants can be identified for further study, to 
examine how and why they are able to affect vasodilatory factors. It is likely that the 
presence of compounds in the plant extracts at the endothelium in vivo will be limited by 
human absorption and metabolism. Preliminary work to understand the bioactivity of the 
parent compounds has the potential to provide clues to the bioactivity of the 
physiologically-relevant metabolites, the measurement of which can be difficult under in 
vivo conditions. Literature evidence for the phenolic content of the six food plants, given 
in Tables 2.12 - 2.21 in Chapter 2, demonstrated that quercetin was a common flavonol 
in a number of the extracts, and was shown to have effects on eNOS phosphorylation in 
Chapter 3. It was included, along with a mix of its human metabolites, for testing 
alongside the plant extracts as a representative pure compound. As the extracts were 
likely to contain other bioactives besides polyphenols that may also be bioactive, the 
glucosinolate sinigrin was tested, alongside its isothiocyanate (ITC) product, allyl-ITC 
(found in kale). Phase II metabolites of sulforaphane, and sulforaphane itself, were used 
in place of sinigrin metabolites, which were not available. Together, these treatments 
would be used to study the effects of plant bioactives on the phosphorylation (activation) 
of Akt and eNOS after short incubation periods with HUVEC cultures and, after longer 
incubations, changes to levels of intracellular cGMP and total eNOS protein, and ET-1 
and nitrates/nitrites released into culture media. 
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4.3. Aim(s) 
The aim of this study was to determine if polyphenol-rich extracts of selected plants 
representative of traditional diets of Black Sea area countries, or representative individual 
compounds identified from published literature, were able to affect signalling molecules 
involved with nitric oxide production and the regulation of vascular tone. 
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4.4. Methods 
4.4.1. Materials 
All water used was of MilliQ-grade purity, unless it is stated that deionised water (dH2O) 
was used instead. The antibodies for Akt (#9272), phosphorylated (p-)Akt (#4060), eNOS 
(#9572), and p-eNOS (#9570) were purchased from Cell Signalling Technology (CST) 
and used at their recommended dilutions. All other chemicals were purchased from 
Sigma-Aldrich and were of analytical-grade purity, unless otherwise specified. 
 
4.4.2. Formulation of quercetin and sulforaphane metabolite mixes 
A mix of quercetin metabolites (Q. met.) were prepared based on the relative 
concentrations of metabolites previously identified in human plasma after consumption of 
onions (Mullen et al. 2006). Aqueous solutions of quercetin-3'-sulphate, quercetin-3-
glucuronide (GlcA) and isorhamnetin-3-GlcA were mixed in a molar ratio of 6:3:1. 
Likewise, a mix of sulforaphane metabolites (S. met.) were prepared based on the relative 
concentrations of metabolites previously identified in human plasma after consumption of 
broccoli (Gasper et al. 2005). Aqueous solutions of sulforaphane-cysteine, sulforaphane-
cysteine-glycine, sulforaphane-N-acetylcysteine and sulforaphane-glutathione were 
mixed in a molar ratio of 55:27:9:9. DMSO was also added to formulations before 
treatment of cells cultures, so that the final concentration of DMSO in culture media was 
of 0.1% v/v. 
 
4.4.3. Sourcing of plant materials used to produce polyphenol-rich extracts 
Plant material for dill, kale, nettle, Sideritis, pomegranate and persimmon were sourced 
from countries surrounding the Black Sea between June and October 2010 and delivered 
to our lab in November 2010. Aerial parts of Sideritis scardica was collected by those 
 120 
working alongside Dr Maria Glibetic at the Institute of Medical Research (IMR) 
(Belgrade, Serbia), from five different locations along the Pirin Mountain range near the 
Macedonian/Bulgarian border. After collection, plants were hung under a wooden roof 
out of direct sunlight and air-dried for a period of two months. Aerial parts of nettle 
(Urtica urens) and dill (Anethum graveolens L) were collected from private gardens and 
street markets in Uzhhorod, Ukraine by those working alongside Dr Nadiya Boyko at 
Uzhhorod National University (Uzhhorod, Ukraine). These were then oven-dried at 50-70 
°C for a period of 2-3 hours. Persimmon fruit and aerial parts of kale were collected by 
those working alongside Bike Koçaoglu at Yeditepe University (Istanbul, Turkey). 
Persimmon was purchased from a supermarket in Istanbul and Kale was collected from a 
farm in Akcaabat, near Trabzon, Turkey. Both were freeze-dried by Wendy Hollands 
(IFR, UK). Pomegranate fruit was purchased from a farmers market in Tbilisi by those 
working alongside Dr Mariam Jorjadze at Elkana (Tbilisi, Georgia) and was not treated 
with any drying procedure prior to extraction, but was kept refrigerated during transport 
and storage.  
 
4.4.4. Extraction of polyphenols and glucosinolates from plant material 
All polyphenol-rich plant extracts were prepared using hot aqueous methanol, with some 
minor differences in the method used for each plant. Extracts of dill, nettle and Sideritis 
were prepared at the Institute of Medical Research, Belgrade, Serbia, in the same manner 
described below.  
 A kitchen blender was used to prepare a homogenous mix of freshly de-hulled 
pomegranate arils, or to reduce dried plant material to powder. Arils or the powdered dry 
plant material were then decanted into polythene bags for weighing prior to extraction. 
Powdered plant material was decanted into glass containers before addition of hot (65-70 
°C) 70% methanol (methanol:water, 70:30, v/v; plant material:70% methanol, 1:10, w/v). 
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Arils were decanted into measuring cylinders before adding hot methanol (arils:methanol; 
30:70, v/v). Methanol/plant material mixtures were maintained at 70 °C for 20 minutes, 
resuspending material halfway through by swirling. Supernatants were decanted through 
muslin cloth, held in a porcelain filter/funnel (1 mm pores), and collected in glass 
containers. Plant material that had accumulated in the muslin cloth was wrapped and 
pressed to collect remaining liquid, and then back extracted in the original container 
using fresh solvent under the same conditions used previously. Back extraction was 
repeated until an obvious difference in the supernatant colour was observed, compared to 
the colour of the first supernatant produced (kale: 3-5 back extractions, persimmon: 5-7, 
pomegranate: 2). 
  Methanolic supernatants of pomegranate, kale and persimmon were decanted into 
50 ml plastic tubes and centrifuged in a Heraeus Megafuge 1.0r at 4200 rpm (3000 g) for 
10 minutes. They were then filtered through muslin cloth into round-bottom flasks (of 
size 250 or 500 cm
3
) and dried at 40 °C using a rotary evaporator, with further drying of 
pomegranate and persimmon extracts by vacuum oven (40 °C, 6 x 10
-2
 torr). When flasks 
remained at a stable weight (measured in grams to 3 decimal places, after equilibration of 
stoppered flasks to room temperature) the dried extract was removed by scraping and 
decanted into a new glass container, while keeping the contents of the flask and the 
container under nitrogen as much as possible. A glass rod was then used to homogenise 
the extracts. 
  All extracts were stored at room temperature (or -20 °C in the case of 
pomegranate) under nitrogen and desiccate in parafilm-sealed containers, in sealed 
polythene bags. The pomegranate extract was kept at -20 °C, rather than at room 
temperature, as it was found to adhere to itself and its glass container unless stored 
frozen. 
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4.4.5. Measurement of phenolic content by Folin-Ciocalteu assay 
Gallic acid (Sigma-Aldrich) was dried in a vacuum oven (40 °C, 48 hours, 6 x 10
-2
 torr 
pressure) and 31.85 mg were dissolved in 1 ml of absolute ethanol, making up to volume 
with water in a 25 cm
3
 volumetric flask. Dilutions of 100 μg/ml were made with water (in 
triplicate) and the absorbance of each was measured using a Nanodrop ND-1000, to 
calculate the extinction coefficient of gallic acid. The extinction coefficient was 
calculated on two separate days and the average of these was used as the final value 
(9443.81 M
−1
 cm
−1
). Dilutions of 500, 400, 300, 250, 200 and 100 μg/ml gallic acid were 
then prepared to produce a standard curve for the Folin-Ciocalteu assay (Waterhouse 
2001). Water containing 0.2% ethanol (equivalent to the 250 μg/ml gallic acid standard) 
was used as a blank solution, and eppendorfs were prepared containing 0.79 ml water, 
into which 10 μl of each gallic acid standard, blank or extract (n=3) were added and 
vortexed. 50 μl of Folin-Ciocalteu reagent was added to each sample, mixing by vortex, 
and leaving to stand for 0.5-8 minutes. 150 μl of 20% sodium carbonate was added with 
mixing and samples were maintained at 37 °C for 30 minutes, before being decanted into 
plastic cuvettes for measurement of their absorbance at 795 nm. Alongside the 37 °C 
incubation step, the absorbance of the 100, 200, 250 and 300 μg/ml gallic acid standards 
were measured at 270 nm using a NanoDrop ND-1000. Values obtained were then used 
to confirm then concentration of the gallic acid solution used to prepare the dilutions, 
using the extinction coefficient calculated for gallic acid. Total phenolics in each of the 
extracts were then determined (measured as gallic acid equivalents (GAE)) using the 
gallic acid standard curve. 
 
4.4.6. Preparation of plant extracts and pure compounds for cell culture studies 
Solutions of plant extracts were prepared using DMSO and basal cell culture medium 
supplemented with BulletKit antibiotics (Lonza). Stocks of pure compounds were 
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prepared using DMSO, except in the case of the sulforaphane or quercetin metabolites, 
which were prepared in water. In all cases, treatments were stored in single use aliquots at 
-20 °C and once applied to cells, the final concentration of DMSO was 0.1% v/v. 
 
4.4.7. Cell culture experiments 
The general materials and methods for the culture of HUVECs used in this work, and the 
analysis of their lysates by BCA assay and western blotting, are described in Chapter 2. 
 
4.4.8. Analysis of cell viability by WST-1 assay and observations of cell morphology 
Confluent monolayers of HUVECs cultured in 96-well plates were treated with plant 
extracts, pure compounds or a vehicle control and then washed once with EBM-2 before 
incubation with EBM-2 containing 10% (v/v) WST-1 reagent (Roche). After 30 minutes, 
the absorbance of the cell culture media in each well was measured at 450 nm using a 
microplate reader. The absorbance was read again after a further 30 minutes, and then 
every 60 minutes after, for a total of 240 minutes. The absorbance values were plotted 
against time and statistics based on the slopes produced were used to compare treatment 
effects on WST-1 metabolism. In conjunction with the WST-1 assay, photographs of 
cells viewed down a light microscope at 40X magnification were recorded, as reduced 
cell viability is associated with increased detachment of cells from the culture plate 
surface, a common effect observed in unhealthy endothelial cells (Bombeli et al. 1996). 
 
4.4.9. Treatment of endothelial cells with plant extracts and pure compounds for 
the study of signalling molecules relevant to vasodilation  
Confluent monolayers of HUVECs cultured in 6-well plates were treated with plant 
extracts, pure compounds or a positive or vehicle control for up to 60 minutes, for 
analysis of p-Akt and p-eNOS. The flavanol epigallocatechin-gallate (EGCG) had been 
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previously shown to be a good inducer of Akt and eNOS phosphorylation (Yamakuchi et 
al. 2008) in HUVECs, and so was used as the positive control for these assays, after 
confirmation of its bioactivity in-house (data not shown). 24 hour plant extract, pure 
compound or vehicle control treatments were performed to analyse changes to levels of 
total eNOS protein, ET-1 secreted into culture media, and nitrate/nitrite found in culture 
media. To show that eNOS phosphorylation was p-Akt dependent, an inhibitor of PI3K 
(LY294002) (CST) was used to treat cells for 60 minutes (50 μM dose) prior to and 
during selected plant extract and pure compound treatments, alongside vehicle controls. 
For the analysis of levels of cGMP produced by HUVECs, confluent monolayers of cells 
cultured in 6 cm
2
 dishes were treated with 1 mM solutions of 3-isobutyl-1-
methylxanthine (IBMX) for 45-60 minutes prior to and during 90 minute plant extract or 
pure compound treatments, alongside vehicle controls. IBMX inhibits 
phosphodiesterases, which hydrolyse cGMP to GMP, and treatment of HUVECs with 
IBMX allows intracellular cGMP to increase to measurable levels. Sodium nitroprusside 
was used as a positive control, as it had been previously reported to increase cGMP in 
HUVECs (Kung et al. 2007). 
 Post-treatment, cell lysates were prepared and the total protein concentration of 
each sample measured by BCA assay. Analysis of Akt and eNOS phosphorylation was 
performed by western blotting. This technique provides both a practical and cost-
effective analysis, due to the reusability and long-shelf life of the reagents and materials 
involved. ELISA kits, which were available for both phospho-proteins, would have 
allowed for analysis of 48 samples (in duplicate) in a single assay, the equivalent to 
blotting four 12-well gels, and provide quantitative analysis, while western blotting is 
generally semi-quantitative and quantification of blot bands is often subjective. They are 
relatively expensive, however, and at the time there were no kits which allowed for assay 
of phospho-protein and total protein simultaneously within the same microplate wells. 
Enzyme-linked immunosorbent assays (ELISAs) were used, however, to determine levels 
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of total eNOS protein and cGMP (ELISA kits purchased from R&D), and ET-1 (Enzo 
Biosciences), performed according to the manufacturer‘s instructions, with the addition 
of extra wash steps (1.5-2 times the number stated in the manufacturer‘s instructions, 
based on work by Amy Casgrain (IFR, UK, unpublished)). 
4.4.10. Measurement of nitrate levels in spent cell culture media 
NO is unstable when left in cell culture media (t½ < 4 minutes (Isik 2005)) and oxidises to 
nitrites and nitrates in the presence of O2 and superoxide (Chen et al. 1998). Based on a 
previous report (Boo et al. 2011), cells were incubated for 24 hours before spent media 
samples were injected in triplicate into a reaction chamber containing a saturated solution 
of vanadium chloride in hydrochloric acid, heated to 95 °C. This reduced nitrates and 
nitrites to nitric oxide, the levels of which were then measured using a Sievers 280i Nitric 
Oxide Analyser that was connected to the reaction chamber. Dilutions (0.1 – 50 µM) of a 
stock of sodium nitrate were prepared for the production of a standard curve, from which 
the concentration of nitrates and nitrites in culture media samples could be quantified.  
 
 126 
4.5. Results  
4.5.1. Yields of extracted material 
The weights of material used and obtained for the drying and extraction processes are 
given in Table 4.1. Quantities used/obtained during the drying of the plant material of 
dill, nettle or Sideritis by IMR (Serbia) were not available. 
 
Table 4.1: Quantities of material obtained after drying and extraction of plant material 
Plant Fresh 
weight (g) 
Weight 
after 
drying (g) 
Yield 
(%) 
Weight of 
material for 
extraction (g) 
Weight of 
extract (g) 
Yield 
(%) 
Dill n/a n/a n/a 135.0 24.61 18.2 
Nettle n/a n/a n/a 132.4 12.96 9.8 
Sideritis n/a n/a n/a 93.1 11.5 12.4 
Kale 2999.7 312.4 10.4 239.6 69.65 29.1 
Pomegranate 1119.9 n/a n/a 1119.9 139.75 12.5 
Persimmon 4745.6 808.5 17.1 336.0 212.28 63.2 
n/a - weight of material at the specific stage of preparation not available, or (in the case of 
pomegranate, as arils were not dried before extraction) not applicable. 
 
4.5.2. Total phenolic content of extracts 
Results from the Folin-Ciocalteu assay performed on samples of the plant extracts are 
given in Table 4.2, which were used to determine the mass of extract required for cell 
culture treatments, based on equivalent doses of phenolics. The highest levels of 
phenolics were measured in the Sideritis extract, while the lowest levels were found in 
the pomegranate and persimmon extracts.  
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Table 4.2: Mean concentration of phenolics in each plant extract, ± standard deviation. 
Extract μg GAE/ mg methanolic extract 
Dill 58.07 ± 0.11 
Kale 42.60 ± 0.06 
Nettle 69.44 ± 0.03 
Sideritis 156.66 ± 0.01 
Pomegranate 9.85 ± 0.20 
Persimmon 5.62 ± 0.45 
 
4.5.3. Effects of plant extracts and pure compounds on p-Akt and p-eNOS  
Western blotting of lysates from cells treated for 60 minutes with 50 μM of each of the 
pure compounds, or 100 μg GAE/ml of the dill, nettle, kale or Sideritis extracts, showed 
phosphorylation of Akt (at Ser473) or eNOS (at Ser1177) was not increased by these 
treatments, in comparison to a vehicle control treatment. The assay was shown to be 
performing correctly by the increase in phosphorylation seen from cells treated with 
EGCG from the same experiment (Figs. 4.1 to 4.4). 
 Treatment of cells with 100 μg GAE/ml of the pomegranate and persimmon 
extracts for 8-60 minutes caused induction of Akt phosphorylation (Figs. 4.2 and 4.5), 
while treatment of cells with 10-100 μg GAE/ml of the pomegranate and persimmon 
extracts for 60 minutes caused induction of eNOS phosphorylation (Figs. 4.4 and 4.6). 
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Figure 4.1: Western blots of p-Akt/Akt from lysates of HUVECs treated for 60 minutes 
with 50 μM pure compounds alongside a vehicle control. 50 μM EGCG was used as the 
positive (+ve) control. n=3 (culture well replicates) for each treatment. Ratio of blot 
densitometry (p-Akt/Akt) is shown in the lower panel. * - p < 0.05 vs vehicle control 
treatment. 
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Figure 4.2: Western blots of p-Akt/Akt from lysates of HUVECs treated for 60 minutes 
with 100 μg GAE/ml of plant extracts alongside a vehicle control. 50 μM EGCG was 
used as the positive (+ve) control. n=3 (culture well replicates) for each treatment. Ratio 
of blot densitometry (p-Akt/Akt) is shown in the lower panel. * - p < 0.05 vs vehicle 
control treatment. 
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Figure 4.3: Western blots of p-eNOS/eNOS from lysates of HUVECs treated for 60 
minutes with 50 μM pure compounds alongside a vehicle control. 50 μM EGCG was 
used as the positive (+ve) control. n=3 (culture well replicates) for each treatment. Ratio 
of blot densitometry (p-eNOS/eNOS) is shown in the lower panel. * - p < 0.05 vs vehicle 
control treatment. 
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Figure 4.4: Western blots of p-eNOS/eNOS from lysates of HUVECs treated for 60 
minutes with 100 μg GAE/ml of plant extracts alongside a vehicle control. 50 μM EGCG 
was used as the positive (+ve) control. n=3 (culture well replicates) for each treatment. 
Ratio of blot densitometry (p-eNOS/eNOS) is shown in the lower panel. * - p < 0.05 vs 
vehicle control treatment. 
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Figure 4.5: Western blots of p-Akt/Akt from lysates of HUVECs treated with 100 μg 
GAE/ml pomegranate and persimmon extract for different incubation periods (minutes). 
Blots representative of n=3 (culture well replicates) for each treatment. Ratio of blot 
densitometry (p-Akt/Akt)is shown in the lower panel. * - p < 0.05 vs vehicle control 
treatment. 
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Figure 4.6: Western blots of of p-eNOS/eNOS from lysates of HUVECs treated for 60 
minutes with different concentrations (μg GAE/ml) of pomegranate and persimmon 
extract. Blots representative of n=3 (culture well replicates) for each treatment. Ratio of 
blot densitometry (p-eNOS/eNOS) is shown in the lower panel. * - p < 0.05 vs vehicle 
control treatment. 
 
4.5.4. Total eNOS protein and secreted ET-1 from endothelial cells treated with 
plant extracts and pure compounds 
Treatment of cell cultures with 5 μM of the pure compound treatments over 24 hours had 
no effect on levels of total intracellular eNOS protein (Fig. 4.7) compared to the vehicle 
control. Secretion of ET-1 into cell culture media, however, was significantly decreased 
by quercetin (p < 0.001) and by the quercetin metabolites mix, sulforaphane metabolite 
mix and sulforaphane treatments (p < 0.05), compared to the vehicle control treatment 
(Fig. 4.8). 
 Treatment of cell cultures with pomegranate and persimmon extract at 20 μg 
GAE/ml for 24 hours resulted in significantly lower levels of ET-1 in the cell culture 
media (p < 0.01) compared to the vehicle control treatment. The pomegranate extract 
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caused significantly lower levels of intracellular eNOS protein (p < 0.001), as did the 
nettle extract (p < 0.05). The other extract treatments were not effective in these assays 
(Figs. 4.9 and 4.10). 
 
 
Figure 4.7: Mean levels of total eNOS protein in lysates from HUVECs treated with 5 
μM pure compounds for 24 hours, ± standard deviation. n=6 (culture well replicates), 
over two independent experiments, for each treatment. 
 
 
Figure 4.8: Mean levels of ET-1 secreted into culture media by HUVECs treated with 5 
μM pure compounds for 24 hours, ± standard deviation. n=6 (culture well replicates), 
over two independent experiments, for each treatment. *** - p < 0.001 vs the vehicle 
control. * - p < 0.05 vs the vehicle control. 
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Figure 4.9: Mean levels of total eNOS protein in lysates from HUVECs treated with 20 
μg GAE/ml plant extracts for 24 hours, ± standard deviation. n=6 (culture well 
replicates), over two independent experiments, for each treatment. *** - p < 0.001 vs the 
vehicle control. * - p < 0.05 vs the vehicle control. 
 
 
Figure 4.10: Mean levels of ET-1 secreted into culture media by HUVECs treated with 
20 μg GAE/ml of plant extracts for 24 hours, ± standard deviation. n=6 (culture well 
replicates), over two independent experiments, for each treatment. *** - p < 0.001 vs the 
vehicle control. 
 
4.5.5. cGMP production in cells treated with plant extracts and pure compounds 
Analysis of the effects of pure compound or plant extract treatment on cGMP production 
in HUVECs proved inconclusive. A number of data points for the experimental 
treatments were below the limit of detection and could not be used. Furthermore, a 
positive control treatment using sodium nitroprusside did not significantly increase 
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cGMP production. The high degree of variance in results from the cGMP assay (Figs. 
4.11 and 4.12) may be due to the low quantity of soluble guanylyl cyclase enzyme 
present in HUVECs. 
 
 
Figure 4.11: Mean levels of cGMP produced in HUVECs after treatment with 100 μg 
GAE/ml plant extracts, sodium nitroprusside (+ve) or a vehicle control, after inhibition of 
cGMP-degrading enzymes, ± standard deviation, where replicates allow. n=3 (culture 
well replicates) for the kale, dill and Sideritis treatments, n=2 for the pomegranate, nettle, 
positive control and vehicle control treatments, and n=1 for the persimmon treatment 
 
 
Figure 4.12: Mean levels of cGMP produced in HUVECs after treatment with 50 μM 
pure compounds, sodium nitroprusside (+ve) or a vehicle control, after inhibition of 
cGMP-degrading enzymes, ± standard deviation, where replicates allow. n=3 (biological 
replicates) for the sinigrin treatment, n=2 for the quercetin, quercetin metabolites, allyl-
ITC and vehicle control treatments, and n=1 for the sulforaphane and sulforaphane 
metabolites treatments. 
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4.5.6. Nitrates/nitrites released into culture media from endothelial cells treated 
with plant extracts and pure compounds 
Treatment of cell cultures with 5 μM of the pure compounds over 24 hours had no effect 
on levels of nitrates/nitrites released into cell culture media when compared to the vehicle 
control treatment (Fig. 4.13).  
 The dill, nettle and kale extracts all released very high concentrations of 
nitrates/nitrites when dissolved in EBM-2 (data not shown). To control for extract 
nitrate/nitrites, cell-free experiments were also performed with the extracts alongside a 
vehicle control and a blank media control. This also revealed a basal level of 
nitrate/nitrite already present in cell culture media (data not shown). Nitrate/nitrite values 
from the cell-free experiments were subtracted from the cell experiment values. Cell 
cultures treated with pomegranate and persimmon extract at 20 μg GAE/ml for 24 hours 
resulted in a significant increase of nitrates/nitrites released into cell culture media (p < 
0.01) compared to the vehicle control treatment, while no difference was observed in 
media from cells treated with the Sideritis extract (Fig. 4.14), or the dill, nettle or kale 
extracts (Fig. 4.15). 
 
 
Figure 4.13: Mean levels of nitrate/nitrite in culture media after incubation of HUVECs 
with pure compounds (5 µM) for 24 hours, ± standard deviation. n=3 (culture well 
replicates) for each treatment. 
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Figure 4.14: Changes to mean levels of nitrate/nitrite in culture media (compared to cell-
free experiments) after incubation of HUVECs with Sideritis, pomegranate or persimmon 
extracts (20 µg GAE/ml) for 24 hours, ± standard deviation. n=3 (culture well replicates) 
for each treatment. * - p < 0.05 vs the vehicle control. 
 
 
Figure 4.15: Changes to mean levels of nitrate/nitrite in culture media (compared to cell-
free experiments) after incubation of HUVECs with dill, nettle or kale (20 µg GAE/ml) 
for 24 hours, ± standard deviation. n=3 (culture well replicates) for each treatment. 
 
4.5.7. Effect of PI3K inhibition on the increase of Akt and eNOS phosphorylation 
by extracts of pomegranate and persimmon 
Incubation of HUVECs with the PI3K chemical inhibitor LY294002 prior to incubation 
with the pomegranate or persimmon extract reduced the levels of both p-Akt and p-
eNOS, compared to cells treated without the PI3K inhibitor (Fig. 4.16). 
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Figure 4.16: Western blots of p-Akt/Akt and p-eNOS/eNOS from lysates of HUVECs 
treated for 60 minutes with or without the PI3K inhibitor LY294002 (LY), prior to 
treatment with vehicle control, 50 µg GAE/ml of the pomegranate extract (Pom.) or 50 
µg GAE/ml of the persimmon extract (Pers.) for a further 60 minutes. Blots 
representative of n=2 (culture well replicates) for each treatment. Ratio of blot 
densitometry (p-Akt/Akt and p-eNOS/eNOS) is shown in the two lower panels. * - p < 
0.05 vs vehicle control treatment. # - p < 0.05 vs vehicle control treatment and respective 
plant extract treatment (i,e. Pom. + LY vs Pom.) 
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4.5.8. Effects of plant extracts and pure compounds on WST-1 metabolism and cell 
morphology 
The rate of WST-1 metabolism by HUVECs after treatment with plant extracts at a dose 
of 100 µg GAE/ml for 60 minutes was significantly (p < 0.05) reduced in all cases except 
for kale (Fig. 4.17), compared to the vehicle control. The rate was reduced to 85% by dill, 
to 59% by pomegranate, to 28% by persimmon, to 14% by nettle and to 1% by Sideritis. 
In contrast, 20 µg GAE/ml doses of each extract caused significant (p < 0.05) increases in 
metabolism of WST-1 for dill, kale and Sideritis (Fig. 4.18). Nettle was still reduced 
(46% of the vehicle control), as was pomegranate (91%) and persimmon (88%). 24 hours 
incubations of 10 µg GAE/ml doses of the extracts reduced the rate of WST-1 
metabolism to less than 20% in all cases except Sideritis, which reduced the rate to 50% 
(Fig. 4.19).  
 Treatment of cells with 50 µM of sulforaphane and allyl-ITC for 60 minutes had 
no effect on WST-1 metabolism compared to the vehicle control (Fig. 4.20). Similar 
treatments with quercetin, quercetin metabolites, sinigrin and sulforaphane metabolites all 
significantly (p < 0.001) increased WST-1 metabolism (by 16%, 7%, 6% and 10% 
respectively). 24 hour incubations of each pure compound treatment at 50 µM reduced 
the rate of WST-1 metabolism in all cases (data not shown). Cells treated with sinigrin 
and quercetin metabolite treatments were the least affected in this respect. Following this, 
cells were treated with the pure compounds at 1, 5 and 10 µM doses (10 µM was the 
lowest concentration used for the sinigrin and quercetin metabolite treatments due to the 
relatively weak effects on metabolism of WST-1 mentioned above). Allyl-ITC and 
sinigrin had no effect at these concentrations compared to the vehicle control (Fig. 4.21). 
Sulforaphane and a mix of its metabolites both caused significant (p < 0.001) increases to 
metabolism of WST-1 (by 14% and 30% respectively, 5 µM dose). 10 µM of quercetin 
metabolites still reduced metabolism of WST-1 slightly, but significantly (p < 0.001), to 
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93%. Quercetin dose-dependently reduced metabolism of WST-1 to 59% at 10 µM, to 
78% and 5 µM and to 97% at 1 µM, compared to the vehicle control. 
  
 
Figure 4.17: Rate, normalised to the vehicle control, at which WST-1 reagent was 
metabolised by HUVECs, after treatment of cells for 60 minutes with a 100 μg GAE/ml 
of each extract, ± standard error. n=6 (culture well replicates) for each treatment. * - p < 
0.05 vs vehicle control treatment. 
 
 
Figure 4.18: Rate, normalised to the vehicle control, at which WST-1 reagent was 
metabolised by HUVECs, after treatment of cells for 60 minutes with 20 μg GAE/ml of 
each extract, ± standard error. n=6 (culture well replicates) for each treatment. * - p < 
0.05 vs vehicle control treatment. 
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Figure 4.19: Rate, normalised to the vehicle control, at which WST-1 reagent was 
metabolised by HUVECs, after treatment of cells for 24 hours with 10 μg GAE/ml of 
each extract, ± standard error. n=6 (culture well replicates) for each treatment. * - p < 
0.05 vs vehicle control treatment. 
  
 
Figure 4.20: Rate, normalised to the vehicle control, at which WST-1 reagent was 
metabolised by HUVECs, after treatment of cells for 60 minutes with 50 μM of pure 
compounds, ± standard error. n=6 (culture well replicates) for each treatment. * - p < 0.05 
vs vehicle control treatment. 
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* 
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Figure 4.21: Rate, normalised to the vehicle control, at which WST-1 reagent was 
metabolised by HUVECs, after treatment of cells for 24 hours with indicated 
concentrations of pure compounds, ± standard error. n=6 (culture well replicates) for each 
treatment. * - p < 0.05 vs vehicle control treatment 
 
It was observed that addition of pomegranate extract to cell culture media changed the 
culture media‘s pH indicator from pink to yellow. Measurement of the pH of solutions 
free of cell cultures showed a change of 7.6 to 6.7 after addition of pomegranate extract 
(at 50 µg GAE/ml). It is likely the extract contained organic acids (such as citric or malic 
acid (Melgarejo et al. 2000)) from the fruit arils. 
 Microscope images of cells (40X magnification) after exposure to 20 µg GAE/ml 
of the plant extract treatments (Figs. 4.22 to 4.28), or 5 µM of the pure compound 
treatments (Figs. 4.29 to 4.34), for 24 hours provided little evidence of toxicity. For 
example, while all treatments resulted in large numbers of detached, floating cells (as 
demonstrated in Figs. 4.22 and 4.23, where photographs were taken before floating cells 
were washed away), including the vehicle control treatment, there was little evidence of 
increased detachment of HUVECs from culture plates in comparison to the vehicle 
control, except in the case of quercetin and the nettle extract, where large cell-free areas 
were clearly visible, and persimmon, where smaller gaps were visible. The proportion of 
cells missing due 5 µM quercetin treatment for 24 hours appeared to correspond with the 
reduction in metabolism of WST-1 for the corresponding quercetin treatment (78%). 
* 
* 
* 
* 
* 
* 
* 
* 
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Figure 4.22: Photograph of HUVECs (40X magnification) after incubation with 20 µg 
GAE/ml of dill extract for 24 hours. 
 
 
Figure 4.23: Photograph of HUVECs (40X magnification) after incubation with 20 µg 
GAE/ml of kale extract for 24 hours. 
 
 
Figure 4.24: Photograph of HUVECs (40X magnification) after incubation with 20 µg 
GAE/ml of nettle extract for 24 hours. 
Dill 
Kale 
Nettle 
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Figure 4.25: Photograph of HUVECs (40X magnification) after incubation with 20 µg 
GAE/ml of Sideritis extract for 24 hours. 
 
 
Figure 4.26: Photograph of HUVECs (40X magnification) after incubation with 20 µg 
GAE/ml of pomegranate extract for 24 hours. 
 
 
Figure 4.27: Photograph of HUVECs (40X magnification) after incubation with 20 µg 
GAE/ml of persimmon extract for 24 hours. 
Sideritis 
Pomegranate 
Persimmon 
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Figure 4.28: Photograph of HUVECs (40X magnification) after incubation with vehicle 
control (0.1% DMSO) for 24 hours. 
 
 
Figure 4.29: Photograph of HUVECs (40X magnification) after incubation with 5 µM 
quercetin for 24 hours. 
 
 
Figure 4.30: Photograph of HUVECs (40X magnification) after incubation with 5 µM 
quercetin metabolites for 24 hours. 
Vehicle 
Quercetin 
Q. metabolites 
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Figure 4.31: Photograph of HUVECs (40X magnification) after incubation with 5 µM 
sulforaphane for 24 hours. 
 
 
Figure 4.32: Photograph of HUVECs (40X magnification) after incubation with 5 µM 
sulforaphane metabolites for 24 hours. 
 
 
Figure 4.33: Photograph of HUVECs (40X magnification) after incubation with 5 µM 
sinigrin for 24 hours. 
Sulforaphane 
S. metabolites 
Sinigrin 
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Figure 4.34: Photograph of HUVECs (40X magnification) after incubation with 5 µM 
allyl-ITC for 24 hours. 
Allyl-ITC 
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4.6. Discussion  
Assays measuring changes to signalling molecules involved with endothelial nitric oxide 
production and the regulation of vascular tone were used to test the affects of extracts 
prepared from traditional foods characteristic of countries surrounding the Black Sea. 
Phosphorylation (activation) of Akt and eNOS, and culture media nitrate/nitrite levels 
were significantly increased, and ET-1 secretion was significantly decreased, by an 
extract of persimmon and pomegranate, but not by extracts of nettle, Sideritis, kale or 
dill. There were no significant effects in response to treatment with quercetin, quercetin 
metabolites, sulforaphane, sulforaphane metabolites, sinigrin or allyl-isothiocyanate. 
 
4.6.1. Treatment of endothelial cells with plant extracts and pure compounds for 
the study of signalling molecules relevant to vasodilation  
The effects on Akt and eNOS phosphorylation, total eNOS protein, ET-1 secretion and 
culture media nitrate/nitrite levels in endothelial cells treated with bioactive-rich extracts 
of dill, kale, nettle, Sideritis and persimmon (edible parts) are reported here for the first 
time. This is also the first report describing the effects of a persimmon fruit extract on 
Akt and eNOS phosphorylation (Figs. 4.2, 4.5 and 4.6), the effects of pomegranate 
extract on phosphorylated and total eNOS protein in endothelial cells cultures (Fig. 4.9), 
and the first to show increased nitrate/nitrite levels, and decreased ET-1 secretion due to 
pomegranate or persimmon extract (Figs. 4.10 and 4.14). The significant, though smaller, 
decrease in the secretion of ET-1 to cell culture media due to treatment with quercetin or 
a mix of its metabolites (Fig. 4.8) is in agreement with previous reports (Lodi et al. 2012; 
Zhao et al. 1999), although this appears to be the first report of quercetin and its 
metabolite lowering ET-1 secretion in resting endothelial cells, and the first to show a 
significant decrease (p < 0.05) in response to sulforaphane or its human metabolites. The 
stability of ET-1 in biological buffers has been previously demonstrated (Zhang & Luo 
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1999), and so it is likely that the pomegranate and persimmon extracts either strongly 
inhibit ET-1 secretion, perhaps as a direct consequence of the increased production of 
nitric oxide (Bourque et al. 2011), or promote its degradation through another signalling 
mechanism or by chemical means. 
 Persimmon and pomegranate have been previously reported to effect markers of 
endothelial function and CVD. Gorinstein et al. (2011) reported decreased plasma lipid 
levels and reduced aortic atherosclerotic lesions in rats compared to control treatments, 
after feeding dried persimmon fruits to rats on a high cholesterol diet. An extract prepared 
from the leaves of persimmon (but not the fruit) was also able to increase Akt and eNOS 
phosphorylation in HUVECs, within 15 minutes of exposure to cells (and at a dose 
approximately 200 times weaker than that used in this study) (Kawakami et al. 2011), and 
furthermore improved dilation of rat aortic tissue ex vivo in an endothelium- and NO-
dependent manner (Yin et al. 2005). de Nigris et al. (2007a; 2007b) reported that a 
pomegranate extract could increase eNOS expression and slow down the progression of 
atherosclerosis in atherogenic models of rats and mice, and increase eNOS enzyme 
activity in human endothelial cells. Ignarro et al. (2006) reported similar effects of 
pomegranate on eNOS activity in bovine endothelial cells. The concentrations of 
quercetin used in these experiments matched those which caused a significant decrease to 
eNOS phosphorylation in Chapter 3 (Fig. 3.1). For the work in that chapter, cells were 
pre-treated with EGCG to stimulate eNOS phosphorylation. No such pre-treatment was 
performed in this study, however, which may explain why no effect on eNOS 
phosphorylation after treatment of cells with quercetin was observed. 
 Despite a lack of effect in the other assays performed, the nettle extract was able 
to significantly (p < 0.05) decrease total eNOS protein in cells over 24 hours (Fig 4.9) 
(but not over 60 minutes (Fig. 4.4)). While treatment with pomegranate extract also 
caused a significant reduction (p < 0.001) in total eNOS protein, treatment of cells with 
the persimmon extract did not. It could not, therefore, be concluded that the decrease in 
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total eNOS protein over 24 hours was in response to increased nitric oxide production. If 
increased nitric oxide production does indeed reduce intracellular levels of eNOS protein 
in the 24 hour period following Akt and eNOS phosphorylation, this could be confirmed 
by pre-treatment of cells with a chemical inhibitor of Akt activation, such as LY294002. 
 Nitric oxide binds to soluble guanylyl cyclase, greatly increasing the rate that the 
enzyme produces cGMP in smooth muscle cells, which ultimately leads to the relaxation 
of the smooth muscle tissue. There are numerous other pathways dependent on cGMP for 
activity (Francis et al. 2010), and sGC protein and activity have been reported in most 
cells and tissues, including endothelial cells (Takeuchi et al. 2004; Boulanger et al. 1990; 
Potter 2011). Therefore it should have been possible to measure cGMP increase in 
HUVECs, after inhibition of phosphodiesterases using IBMX, though this was obviously 
not the case. It is possible that nitric oxide produced by HUVECs was either not reaching 
sGC in the cells, perhaps due to its diffusion to cell culture media, or the sGC content was 
too low in the cells to produce measurable levels of cGMP. Where cGMP levels were 
recorded, they were higher than those obtained by Donnini et al. (2006) (pM cGMP/µg 
HUVEC lysate protein compared to pM cGMP/mg HUVEC lysate protein). It is likely 
that the cGMP measurements presented here were false positives, especially considering 
the inability of the positive control to produce a consistent response, and that a more 
sensitive assay is required. It has also been reported that vascular smooth muscle cells 
become desensitised to sGC activation by sodium nitroprusside once they have been 
passaged five or more time (Boulanger et al. 1990), though such effects have not yet been 
reported for passaged endothelial cells. 
 Despite the lack of bioactivity from the dill, nettle, Sideritis and kale extracts, and 
the pure compound treatments, it is still possible that compounds in these food plants 
could modulate signalling molecules related to vasodilation in vivo. Likewise, it is not 
possible to conclude that the compounds which provide the bioactivity of the 
pomegranate and persimmon extracts would cause similar effects in vivo, due to 
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metabolism and resulting structural changes to the compounds, and possible limits to 
their absorption in the gastrointestinal system. The composition of the plant extracts used 
in the in vitro work described here is likely to be quite different from the profile of 
compounds which would reach the endothelium in vivo. after preparation of the plants 
(including storage and cooking), and consumption in the diet. Polyphenols also tend to be 
susceptible to oxidation in cell culture media, more so than when they are circulating in 
plasma. This results in their degradation while incubating with cell cultures, which may 
attenuate or augment particular bioactive effects. Furthermore, the solubility of 
compounds can affect they're efficacy in vitro compared to their in vivo activity. While 
none of the extracts were observed to produce precipitates when they were first 
introduced to the cell culture media, observations made under the microscope at the 
conclusion of cell culture treatments confirmed the presence of particulate matter floating 
in the media. While this matter would have included dead cell debris, it is also likely that 
compounds in the plant extracts will have come out of solution over time, possibly due to 
their degradation. No experiments were performed to determine the solubility over time 
of the plant extract compounds in the cell culture media used, though it may be more 
useful to perform such experiments with individual compounds that have been identified 
as bioactive. 
 HUVECs were used here as an in vitro cell model for endothelial signalling, with 
the respective in vivo situation being the signalling which occurs in the endothelium 
lining human arteries. While umbilical vein endothelial cells will experience oxygenated 
blood flow similar to the arteries, the blood pressure in umbilical veins is much lower (6 
mmHg at term (Pesola et al. 2001), compared to ~112 mmHg systolic/~64 mmHg 
diastolic in healthy adults (Spurway et al. 2012)). The smooth muscle tissue surrounding 
the endothelium of umbilical veins is also much thinner compared to adult human 
arteries. Therefore it is unlikely that these cells behave exactly as endothelial cells do in 
adult arteries in vivo. This should be taken into consideration when drawing conclusions 
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on the molecular outcomes in HUVECs that have been used to assay polyphenol 
bioactivity, even when the polyphenols used are the physiologically relevant human 
metabolites. 
 
4.6.2. Effect of plant extracts and pure compounds on cell adhesion to culture plate 
surfaces and metabolism of WST-1 
It was clear that some of the treatments (notably the 24 hour incubations of quercetin, 
nettle and probably persimmon) were cytotoxic at the concentrations used to measure 
effects on endothelial vasomodulatory factors, and this was taken into account when 
analysing results from these assays. Both microscope observations and results from the 
WST-1 assay suggested that these treatments were causing decreases to the number of 
cells attached to the culture plates, compared to vehicle controls (Figs. 4.17 - 4.19, 4.21, 
4.24, 4.27 and 4.29). It is interesting to note that the cytotoxicity of quercetin is reduced 
when quercetin's structure is altered to that of its phase II metabolites. Based on the 
WST-1 results, 5 µM doses of the pure compounds were used for subsequent 24 hour cell 
culture experiments. 24 hour cell culture experiments with the plant extracts were 
performed using a 20 µg GAE/ml dose, as despite large decreases to WST-1 metabolism, 
microscope images of cells did not suggest that there were significantly detrimental 
effects to cell cultures due to these treatments. 
 WST-1 is one of a number of tetrazolium dyes that are used to determine effects 
on cell viability and metabolism. Upon metabolism by viable cells, WST-1 forms water 
soluble formazan compounds that are yellow/orange in colour (Assalian & Francoeur 
1996). Experiments such as the LDH assay, which measures lactate dehydrogenase 
released into culture media from burst cells, require the experimental media for proper 
measurement. As the WST-1 reagent was dissolved in fresh media before application to 
cells, potential inference in light absorption measurements caused by the pigments of the 
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plant extracts was avoided. The absorbance of the yellow colour produced can be 
correlated with the metabolic activity of the cells, though not always with cell viability. 
For example, it is possible for metabolism of WST-1 to continue, even after cell death 
(Quent et al. 2010). Metabolism most likely occurs at the cell surface or the plasma 
membrane via trans-plasma membrane transport, due to the cell-impermeable nature of 
the formazan compounds produced (Assalian & Francoeur 1996).  
 It is possible that compounds in the extracts were attaching to the surface of cell 
cultures, or interfering with cell membrane biology in a manner than allowed cells to 
remain attached to the culture plate but still reduce metabolism of WST-1 independent of 
cytotoxic/non-cytotoxic effects. As the plasma membrane is the most probable location 
for metabolism of WST-1 (Liu et al. 1997; Berridge et al. 2005), interference by 
compounds here would impede the conversion of WST-1 to formazan dye, and explain 
reductions seen in the WST-1 assay for cells treated with plant extracts for 24 hours, 
despite the lack of obvious differences seen between cell cultures viewed down the 
microscope.  
 
4.6.3. Preparation of plant extracts 
So as to give no bias to a particular type of compound when extracting polyphenols and 
other bioactives from the plant material, the same extraction method was used for each 
food plant. Aqueous methanol has been previously shown to act as a good solvent for 
leaching a wide variety of phytochemicals from plant material in a non-selective manner 
(Tsao 2010; Robards 2003). While care was taken to keep the majority of the extraction 
method the same for each plant, the nature of each plant‘s material meant that plant-
specific changes to the protocol, such as omittance of the drying steps for the 
pomegranate arils, were necessary. In this case, as the material was already in a form that 
could be easily extracted, degradation of bioactive compounds was assumed unlikely due 
to the short preparation time. During the removal of water from the extract supernatants, 
 155 
the pomegranate and persimmon extracts required a more intensive evaporation 
procedure than the kale extract. This was most likely due to the high quantity of sugars 
extracted from the fruits (reports of > 10 g/100g fresh weight (Glew et al. 2005; 
Melgarejo et al. 2000), compared to, for example, < 0.1 g/100g fresh weight for kale 
(Noichinda et al. 2007)), which would make the extracts more hygroscopic. Care was 
taken to ensure minimal exposure of the pomegranate and persimmon extracts to air, to 
avoid uptake of additional water into the extracts. The higher moisture/sugar content of 
these extracts is highlighted by their low TPC values (Table 4.2). Sugars such as sucrose 
and fructose have been previously reported to react with the Folin-Ciocalteu reagent. 
Such increases, however, are likely to be negligible (Waterhouse 2001; Everette et al. 
2010; Lester et al. 2012).  
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4.7. Conclusion 
Of the selected plant extract and pure compound treatments, only the pomegranate and 
persimmon extracts provided consistent evidence that they could positively affect 
vasomodulatory factors in a manner consistent with increased nitric oxide production. 
They increased Akt and eNOS phosphorylation in a PI3K-dependent manner, elevated 
nitrate and nitrite concentrations in cell culture media and sharply decreased levels of 
secreted ET-1. It is clear that pomegranate and persimmon both contain compounds able 
to affect nitric oxide signalling and ET-1 secretion. Further investigation is required, 
however, to elucidate the effective compounds and the mechanisms involved in the 
activation of Akt and eNOS by these extracts. 
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Chapter 5: An investigation of the compounds and mechanisms 
responsible for pomegranate extract bioactivity 
 
5.1. Abstract 
In vitro studies to measure molecules involved in nitric oxide signalling and vasodilation, 
as detailed in the previous chapter, showed that methanolic extracts of pomegranate and 
persimmon were able to affect these molecules in a manner associated with increased 
nitric oxide production. As these extracts are complex mixture of compounds, it is not 
known which were responsible for the extracts' bioactivity, nor how they were able to 
increase PI3K/Akt activity. The aim of the research described in this chapter was to 
identify the compounds responsible and the underlying mechanisms by which the 
pomegranate extract induced nitric oxide signalling.  
 Activity-guided fractionation in combination with LC-MS analyses were used to 
identify the compounds responsible for bioactivity of the extract. The molecular 
signalling mechanisms underlying the bioactivity were investigated using (1) an antibody 
microarray spotted with antibodies complementary for a selection of receptor tyrosine 
kinases (RTK) that lie upstream of the Akt/eNOS pathway and (2) western blotting and 
enzyme activity assays to determine affects on the phosphatase PTEN (which reverses the 
effects of PI3K, therefore suppressing Akt activation). 
 It was shown that procyanidins, of size and concentration similar to those 
observed in the pomegranate extract, were able to elicit a strong induction of Akt and 
eNOS phosphorylation. No evidence could be found, however, that this was due to either 
an increase in the phosphorylation and activation of RTKs upstream of Akt, or a rapid 
inhibition of PTEN activity. Further research is required to establish the mechanisms 
responsible for activation of Akt and eNOS by pomegranate polyphenols. 
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5.2. Introduction 
5.2.1. Polyphenol content of pomegranate arils 
Pomegranates contain a variety of different phenolic compounds. In terms of those found 
specifically in the edible arils, most fall into one of three subclasses:  
 flavan-3-ols (and oligomers of flavan-3-ols, proanthocyanidins) (de Pascual-
Teresa et al. 2000; Sentandreu et al. 2010),  
 ellagitannins (Borges et al. 2010; Mertens-Talcott et al. 2006) 
 and anthocyanins (Alighourchi et al. 2008; Mousavinejad et al. 2009; Robert et al. 
2010; Sepulveda et al. 2010).  
A number of phenolic acids, lignans and flavonols may also be present in relatively small 
quantities, as evidenced by a recent study utilising ultra-HPLC-MS
n
 analysis (Mena et al. 
2012). While these polyphenols are common across most cultivars of pomegranate, the 
quantities present in each can vary substantially. 
 Three ellagitannins - punicalagin (Fig. 5.1), punicalin and granatin - have been 
identified in pomegranate aril juice, in both their α- and β- anomeric forms. A galloylated 
ester of punicalagin has also been described (Borges et al. 2010; Gil et al. 2000), as well 
as ellagic acid and ellagic acid-O-hexoside. 
 There are six main anthocyanins which give pomegranate fruit juice its deep red 
and purple colours, these being 3-O-glucosides and 3,5-di-O-glucosides of cyanidin (Fig. 
5.2), delphinidin and pelargonidin (Mousavinejad et al. 2009; Alighourchi et al. 2008). 
Recently, a pentoside and rutinoside of cyanidin were also identified in pomegranate 
(Fischer et al. 2011), as well as 3-O-glucosides of peonidin, malvidin and petunidin 
(Borges & Crozier 2012), though no details of the material from which the pomegranate 
juice was prepared were given. Peonidin has been identified as a component of 
pomegranate peel (Zhao et al. 2012), and inclusion of peel phenolics in pomegranate 
juices, depending on the process used, would not be unusual. 
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Figure 5.1: (A) Punicalagin, an ellagitannin found in pomegranates and (B) cyanidin-3,5-
di-O-glucoside, an anthocyanin found in pomegranates. 
 
Despite a number of general and specific methods for the identification of 
proanthocyanidins, the complex nature of their structure can complicate such analyses 
(Hümmer & Schreier 2008). Though catechin, epicatechin, gallocatechin and 
epigallocatechin have all been identified in pomegranate, at present what is known of 
their proanthocyanidin content is limited to procyanidin dimers and trimers (de Pascual-
Teresa et al. 2000; Borges et al. 2010). The membranous sacs of pomegranate arils are a 
A 
B 
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likely source of procyanidins (Dr Francisco A. Tomás-Barberán, personal 
communication, 24 March 2013), although in preparation of pomegranate juices, 
particularly in commercial circumstances, proanthocyanidins and other polyphenols from 
additional parts of the fruit, such as the peel (Saad et al. 2012), are likely to be included in 
the resulting product (Wang et al. 2010; Türkyılmaz et al. 2013). 
 
5.2.2. Upstream mechanisms for Akt induction 
Data presented in Chapter 4 showed that the increased Akt phosphorylation was PI3K-
dependent (Fig. 4.16), i.e. dependent on sufficient levels of PIP3 so that Akt may be 
present at the plasma membrane to be phosphorylated. Therefore, increased Akt activity 
is dependent on either increased class 1 PI3K activity or a reduction in the activity of a 
PIP3 phosphatase. 
 Class 1A PI3Ks are activated by either receptor tyrosine kinases (RTKs) or 
guanine nucleotide-binding (G) protein coupled receptors (GPCRs), whereas class 1B 
PI3Ks can only be activated by GPCRs (Shiojima & Walsh 2002; Morello et al. 2009). 
Over 200 GPCRs and their activating ligands have been described in humans. They have 
a seven-transmembrane structure and couple with G-proteins consisting of α, β and γ 
subunits upon activation. Gα can activate PI3K indirectly and Gβγ directly (New et al. 
2007; Strotmann et al. 2011). Activation of RTKs is accomplished by interaction of 
growth factors with extracellular domains. RTKs are phosphorylated upon activation and 
may autophosphorylate further. With assistance from adaptor proteins, RTK pYXXM 
motifs are able to bind PI3K's regulatory domain, and expose its catalytic domain, so that 
it may act on phosphoinositides. Their activation leads to the recruitment of proteins such 
as Lyn, Fyn and Src, which can phosphorylate additional tyrosine residues or act to 
recruit additional substrate molecules such as PI3K (Engelman et al. 2006). There are 58 
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RTKs reported in humans, divided into 20 families, with the most extensive families 
being VEGF, PDGF, ErbB, Eph and FGF (Lemmon & Schlessinger 2010). 
 While PI3K acts to increase levels of PIP3, this behaviour is countered by the 
phosphatases SHIP and PTEN. SHIP has two isoforms, SHIP1 and SHIP2. The former is 
expressed mostly in haemopoietic cell lineages and in unlikely to be found in endothelial 
cells (Liu et al. 1998), whereas SHIP2 is more broadly expressed (Erneux et al. 2011). 
After activation, likely by phosphorylation of tyrosine residues on SHIP, they convert 
PI(3,4,5)P3 to PI(3,4)P2. PTEN, on the other hand, converts PIP3 to PI(4,5)P2. PTEN is 
held in an inactive state in the cytosol through modifications such as phosphorylation at 
Ser380, Thr382 and Thr383 or acetylation at Lys158 and Lys138 (Singh & Chan 2011). 
Removal of these modifications allows for its translocation to the plasma membrane, 
where it performs its phosphatase activity (Das et al. 2003). PTEN is also regulated 
through ubiquitination in the cytosol and at the plasma membrane, leading to its 
degradation (Maccario et al. 2010). The removal of PTEN from healthy cells is known to 
lead to increased levels of Akt phosphorylation (Stambolic et al. 1998). Indeed, PTEN 
has been well studied in models for cancer where the lack of its expression promotes 
dysregulation of the cell cycle and activation of Akt (Chetram & Hinton 2012). It would 
not be unreasonable to assume the basal level of Akt phosphorylation is maintained in 
resting endothelial cells by the activity of PTEN. 
 As described above, there are a several ways in which the pomegranate extract 
used in this work might act on endothelial cells to increase Akt phosphorylation. In this 
chapter, two of the possible mechanisms that could give rise to increased Akt activity 
were investigated. The activity of PTEN has been well characterised in HUVECs and 
other endothelial cell models. Here, a number of assays were performed to measure 
activity-related changes to PTEN protein. The possibility that exposure of the endothelial 
cells to the pomegranate extract activates cell surface receptors upstream of PI3K was 
also investigated. The relatively small number of human RTKs and ease of determining 
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their activation through their phosphorylation levels made them suitable for study in the 
context of this project. On top of this, to determine which of the compounds in the 
pomegranate extract might be responsible for increasing Akt phosphorylation and nitric 
oxide production in endothelial cells, the extract was separated into fractions representing 
the main phenolic compounds likely to be found in the extract. These were then tested, 
alongside individual compounds identified in the extract, to determine their ability to 
increase Akt phosphorylation. 
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5.3. Aims 
The main objectives of the work described in this chapter were to 
(i) determine which chemical class(es) of compounds were responsible for the 
bioactive effects of the pomegranate extract observed in Chapter 4 and  
(ii) to elucidate receptors or mechanisms upstream of Akt that may be mediating 
these effects. 
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5.4. Methods 
5.4.1. Materials 
C-18 columns were purchased from Biotage (Isolute Flash C18, 25 g). LH-20 sephadex 
was purchased from GE Healthcare. Malachite green solution, phosphate standard, 
purified PTEN (supplied as lyophilised stock formulated with various salts and buffer 
compounds) and PIP3 (#P-3908) were purchased from Echelon Biosciences. Antibodies 
for ubiquitin (#3936), p-PTEN (Ser380/Thr382/383) (#9549), PTEN (#9188) and PTEN 
conjugated to sepharose beads (#4326) were purchased from Cell Signalling 
Technologies. Antibodies for p-Akt, Akt, p-eNOS and eNOS (Cell Signalling 
Technologies) were the same as those used in Chapter 4. TBS buffer was prepared with 
20 mM tris-base, 137 mM NaCl and 10 mM dithiothreitol (DTT), adjusted to pH 7.6 
using HCl. The procyanidin-rich apple extract (Evesse™ OPC, referred to in this chapter 
as simply OPC) was kindly provided by Coressence Ltd (UK). A sample of isolated apple 
procyanidin tetramers was prepared from OPC extract by Dr Ana B. Cerezo (IFR, UK). 
Urolithins were chemically synthesised in-house by Dr Paul Needs. Anthocyanins and 
procyanidin dimer B1 were purchased from Extrasynthese (France). Punicalagin was 
purchased as a mixture of its α- and β- anomers from Phytolab (Germany). (-)-
Epicatechin and all other chemicals were purchased from Sigma-Aldrich and were of 
analytical-grade purity, unless otherwise specified. All water used was of MilliQ-grade 
purity. 
 
5.4.2. Cell culture experiments 
General materials and methods for culture of HUVECs, and the analysis of their lysates 
by BCA assay and western blotting, are described in Chapter 2, Sections 2.2.1 - 2.2.3. 
The vehicle control in all cell culture experiments was 0.1% DMSO. 
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5.4.3. Pomegranate extract fractionation 
The fractionation process was based on the method by García-Estévez et al. (2010), 
which was developed to separate classes of polyphenol compounds from a red wine 
extract. Pomegranate extract was dissolved in water/2.5% acetic acid to 100 mg/ml, aided 
by sonication. Aliquots were centrifuged (13000g, 5 minutes) to clarify the solution, 
which was then loaded onto a polytetrafluoroethylene (PTFE) sample loop by glass 
syringe, connected to a 6-port injection valve (set in the 'load' position). A 25 g C-18 
cartridge was placed in line with a Gilson 306 pump (set for a flow rate of 30 ml/min), a 
Gilson 805 manometric module and a Gilson 117 UV detector measuring absorbance at 
205 and 270 nm. The Gilson pump was also connected to a container of water/2.5% 
acetic acid (the first elution solvent). The Gilson modules were controlled by a PC 
running the Gilson Unipoint software, which was also set up to record traces of UV 
absorbance over time. The cartridges were activated with methanol for approximately 5 
minutes before equilibration with water/2.5% acetic acid until UV absorbance stabilised. 
The pump was stopped and the injection valve set to ‗inject‘ to bring the sample loop in 
line with the cartridge and Gilson system, and then restarted to load the pomegranate 
extract onto the cartridge. The flow of water/2.5% acetic acid was maintained to elute 
ellagitannins, sugars and other small polar molecules into a glass container (eluent A), 
until the UV absorbance was stable for at least 5 minutes. The pump was stopped and the 
elution solvent changed from acidified water to ethyl acetate. The pump was restarted to 
elute flavonols, small phenolics, catechins and procyanidins (eluent B) into a new 
container until the UV absorbance had stabilised once more for at least 5 minutes, and the 
pump was stopped again. The elution solvent was changed to methanol, and the pump 
restarted to elute anthocyanins (eluent C) into a new container. Any other compounds still 
bound to the column would likely be eluted at this point as well. 
 Eluent A was dispensed into 500 ml round-bottom flasks to approximately 1/3 
total volume, and snap-frozen by rotating the flask in an acetone bath chilled with dry-
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ice. The ethyl acetate in eluent B and ethyl acetate/methanol in eluent C were first 
removed by rotary evaporation over a 30 °C water bath, replacing evaporated solvent 
with water periodically, before snap-freezing. Flasks were placed on dry-ice and flask 
mouths were covered with muslin cloth secured by parafilm wrapped around flask necks. 
Flasks were then placed in freeze-driers for 2-5 days to remove water. Fractions were 
redissolved in acidified water and fractionated again, using the above method, to improve 
the separation of polyphenol classes. These eluents were freeze-dried and then 
fractionated a third time before pooling sub-fractions of eluents A, B and C.  
 Sephadex LH-20 beads, activated in an excess of methanol at room temperature 
for 2-3 hours, were packed into a glass column connected to an AKTA FPLC system (GE 
Healthcare) for 24 hours (flow rate of 3 ml/min). After packing, LH-20 was equilibrated 
with water/2.5% acetic acid for 2 column volumes (1 volume = 35 ml) at a flow rate of 3 
ml/min. The dried fraction from eluent A was dissolved in water/2.5% acetic acid and 
loaded onto a sample loop via syringe and then onto the column. The flow was reduced to 
0.1-0.2 ml/min and maintained to elute sugars and other small molecules into a glass 
container until the UV absorbance (270 nm) had stabilised for approximately 0.5 
volumes. The pump was stopped and the solvent changed to methanol. The pump was 
restarted to elute ellagitannins into a fresh container. Methanol in the second eluent was 
removed by rotary evaporation, similar to eluents B and C, and then both eluents were 
snap-frozen and freeze-dried as described above. The resulting C-18 column fractions 
(PPF (Pomegranate Procyanidin Fraction) from eluent B and PAF (Pomegranate 
Anthocyanin Fraction) from eluent C) and sephadex column fractions (PSF (Pomegranate 
Sugar Fraction) from the first elution and PEF (Pomegranate Ellagitannin Fraction) from 
the second) were prepared for analysis by HPLC and for testing in cell culture 
experiments. The pellet produced from centrifugation of the pomegranate extract solution 
at the clarification step was air-dried, weighed, and dissolved in DMSO. It was labelled 
as PIF (Pomegranate Insoluble Fraction). 
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Fractions were dissolved in 1-2 ml of water and pipetted into eppendorfs weighed before 
and after addition of the dissolved fractions. 200 μl aliquots of each (n=2) were pipetted 
into pre-weighed 2-ml screw-cap eppendorfs, and then frozen on dry-ice, with caps left 
on loose. The remaining volume of each fraction was then calculated. Once dry, the 
eppendorfs were weighed again and the mass of aliquoted fraction was calculated. From 
the total volume of dissolved fraction, the mass of each fraction was calculated. Further 
aliquots were taken to (i) calculate the total phenolic content (TPC) of each fraction, 
using the Folin-Ciolcateau method (details in Chapter 4, Section 4.4.5: Measurement of 
phenolic content by Folin-Ciocalteu assay) and (ii) to analyse their content by HPLC 
(detailed below), alongside standards of punicalagin for PEF, (-)-epicatechin (EC) and 
procyanidin tetramers (DP4) for PPF and cyanidin-3-O-Glc (C3Glc), delphinidin-3-O-
Glc (D3Glc) and cyanidin-3,5-di-O-Glc (C35diGlc) for PAF. The presence of these 
compounds, excluding DP4, was confirmed using mass spectrometry analysis, which was 
carried out by Dr Shikha Saha (IFR, UK), using an Agilent 1100 HPLC-DAD-MSD 
system, as detailed in Hollands et al. (2013). 
 
5.4.4. HPLC analysis of pomegranate extract and fractions 
Before injection onto HPLC columns, samples of crude pomegranate extract and PAF 
were dissolved in 70% methanol (30% water) acidified with 2.5% acetic acid. PEF and 
punicalagin were dissolved in water acidified with 2.5% acetic acid, as ellagitannins have 
been reported to be more stable dissolved in low-pH water as opposed to low-pH 
methanol (Lei 2002). Stocks of all other samples and standards were prepared in DMSO. 
A preparation of the vehicle solvent used for each sample was used as the blank standard 
in each case. For reverse-phase (RP) analysis, samples were injected onto a Luna C18(2) 
5 μm column (250 x 4.6 mm; Phenomenex, #00G-4252-E0) connected to an Aglient 1100 
HPLC system and eluted at a flow rate of 1 ml/min. The solvents used for elution were 
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acetonitrile/0.1% trifluoroacetic acid (solvent A) and water/0.1% trifluoroacetic acid 
(solvent B). A linear solvent gradient was used, varying in terms of solvent A as follows: 
0-5 mins: 0%; 15-17 mins: 17%; 22 mins: 25%; 30 mins: 35%; 35 mins: 50%; 40-50 
mins: 100%; 55-65 mins: 0%. 
 For normal-phase (NP) analysis, samples were injected onto a Luna Silica(2) 5 
μm column (250 x 4.6 mm; Phenomenex, #00G-4274-E0) connected to an Aglient 1100 
HPLC system and eluted at a flow rate of 1 ml/min. The solvents used for elution were 
dichloromethane (solvent A), methanol (solvent B) and water/50% acetic acid (solvent 
C). Solvent C formed 4% of the total solvent composition for NP-HPLC analysis; its 
elution was isocratic. A linear gradient was used for solvents A and B, varying in terms 
of solvent A as follows: 0 mins: 82%; 30 mins: 67.6%; 45 mins: 56.8% 50 mins: 10%; 
55-65 mins: 82%. Where comparison of similar compounds between samples was 
intended, such samples were injected into the HPLC system within the same run of 
analyses, in sequence where possible. 
 To quantify standard compounds in the extract and fractions, increasing 
concentrations of the respective compounds were analysed alongside extract/fractions so 
that the concentration of the compounds in the samples could be interpolated from the 
standard curve produced. Samples of the extract/fractions, spiked with the standard 
compounds at three increasing concentrations, were also analysed to determine if there 
were any matrix effects associated with the quantification of the compounds. Analysis of 
procyanidins and other compounds associated with PPF were performed by NP-HPLC, 
using fluorescence detection for quantification. All other compounds were analysed by 
RP-HPLC, with quantification of compounds associated with PEF performed using UV 
absorbance at 370 nm, and quantification of compounds associated with PAF performed 
using UV absorbance at 520 nm. The peaks of both punicalagin anomers were used for its 
quantification. 
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5.4.5. Akt phosphorylation induced by pomegranate fractions and pure compounds 
Confluent monolayers of HUVECs cultured in 6-well plates were treated for 60 minutes 
with:  
(i) doses of pomegranate extract fractions equivalent to 50 μg gallic acid 
equivalent (GAE)/ml dose of the crude extract 
(ii) doses of compounds identified in the extract (Table 5.5) equivalent to what 
would be expected (from HPLC analysis) in the concentrations of extract 
fractions in (i) or in 50 μg GAE/ml of whole extract 
(iii) doses of compounds identified in the extract (at supra-extract-equivalent 
concentrations) or metabolites of these compounds, including ellagic acid and 
urolithins A, B and C. 
Cell lysates were prepared and the total protein concentration of each sample was 
determined by BCA assay. Analysis of Akt and eNOS phosphorylation was performed by 
western blotting. 
 
5.4.6. Inhibition of PI3K and the modulation of vasodilatory signalling molecules 
by the crude pomegranate extract 
Repeats of the total eNOS, ET-1 and media nitrates/nitrites assays from Chapter 4 were 
performed using cells treated for 8 or 24 hours with either 20 μg GAE/ml of the crude 
extract or a vehicle control, with or without the PI3K inhibitor LY294002 (Cell 
Signalling Technologies) (added to cell culture media 60 minutes prior to addition of 
pomegranate or vehicle treatments). In this case, the media nitrate/nitrite assay was 
performed without cell-free experiments, as the results from Chapter 4 show that the 
pomegranate extract by itself does not significantly increase levels of nitrate/nitrite in 
culture media. Unpaired 2-tailed student t-tests were used to determine differences 
between cell culture treatments, with significance taken as p < 0.05. 
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5.4.7. Phosphorylation of RTKs in endothelial cells treated with pomegranate 
extract 
Confluent monolayers of HUVECs cultured in 6cm
2
 dishes were treated with either 
pomegranate extract (50 μg GAE/ml), punicalagin (20 μM), PF-P (5.5 μg GAE/ml) or 
vehicle control (0.1% DMSO) (n=2, biological replicates). Cell lysates were prepared and 
the total protein concentration of each sample measured by BCA. Antibody microarrays 
(Cell Signalling Technologies, #7949) spotted with antibodies (n=2, technical replicates) 
(Fig. 5.2) corresponding to pan Tyr-phosphorylated RTKs (Table 5.1), and related 
signalling molecules (Table 5.2, where antibodies correspond to pan-Tyr phosphorylated 
proteins unless the phosphorylated residue is specified), were used according to the 
manufacturer‘s instructions. After the final wash buffer step, a flow of compressed 
nitrogen at 20 psi was used to remove remaining buffer from the surface of the slide, 
which was then stored in a plastic holder, protected from light. 
 
 
Figure 5.2: Layout of antibodies for phospho-RTKs and related proteins on microarray 
slide, taken from product data-sheet. Details of targets are given in Tables 5.1 and 5.2. 
 
Slides were scanned fluorescently, using a Genepix 4000B microarray scanner, connected 
to a computer running Genepix software (version 6.1), at a resolution of 5 μm/pixel with 
a 635 nm excitation laser coupled with a 650-690 nm emission filter. The photo-
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multiplier tube (PMT) gain was adjusted so less than 1% of the scanned image‘s pixels 
were saturated, Images produced from the slide scanning were saved as .tiff files, and 
microarray slides were then placed into storage at room temperature, protected from light. 
Slides were also scanned using an 532 nm excitation laser coupled with a 557.7-592.5 nm 
emission filter. Images produced from scanning at 532 nm were assessed visually to 
determine if there had been any signal produced through artifacts such as scratches on the 
slide, so that these could be taken into account when analysing the images produced by 
excitation at 635 nm. 
 
Table 5.1: Receptor tyrosine kinases, their RTK family, and corresponding spot number, 
as featured in the microarray layout of Fig. 5.2.  
Spot No. Target Family Spot No. Target Family 
1 EGFR/ErbB1 EGFR 15 PDGFR PDGFR 
2 HER2/ErbB2 EGFR 16 c-Kit/SCFR PDGFR 
3 HER3/ErbB3 EGFR 17 FLT3/Flk2 PDGFR 
4 FGFR1 FGFR 18 M-CSFR/CSF-1R PDGFR 
5 FGFR3 FGFR 19 EphA1 EphR 
6 FGFR4 FGFR 20 EphA2 EphR 
7 InsR Insulin R 21 EphA3 EphR 
8 IGF-IR Insulin R 22 EphB1 EphR 
9 TrkA/NTRK1 NGFR 23 EphB3 EphR 
10 TrkB/NTRK2 NGFR 24 EphB4 EphR 
11 Met/HGFR HGFR 25 Tyro-3/Dtk Axl 
12 Ron/MST1R HGFR 26 Axl Axl 
13 Ret Ret 27 Tie2/TEK Tie 
14 ALK LTK 28 VEGFR2/KDR VEGFR 
 
Table 5.2: RTK-related phospho-proteins, their kinase family, and corresponding spot 
number, as featured in the microarray layout of Fig. 5.2. 
Spot 
No. 
Target Family Spot 
No. 
Target Family 
29 Akt (Thr308) Akt 35 Zap-70 Zap-70 
30 Akt (Ser473) Akt 36 Src Src 
31 ERK1/2 (Thr202/Tyr204) MAPK 37 Lck Src 
32 S6 Ribosomal Protein (Ser235/236) RSK 38 Stat1 (Tyr701) Stat 
33 c-Abl Abl 39 Stat3 (Tyr 705) Stat 
34 IRS-1 IRS    
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The image produced from scanning at 635 nm was analysed with the software GenePix 
Pro v6.1, using a manually aligned spot overlay, and the median spot fluorescence 
intensities (MSFIs) were calculated. Microsoft Excel 2007 spreadsheets were used to 
organise data-points, and statistical analysis was carried out using the limma package for 
the R software environment (Smyth 2004; Smyth 2005; R Development Core Team 
2010). The data was fitted to a linear model, an empirical Bayes method was applied to 
the data to reduce statistical errors (Smyth 2004), and p-values were calculated, adjusting 
for multiple testing (MT) using the Benjamini-Hochberg method, for per-target 
comparison of MSFIs between each polyphenol/extract treatment and the vehicle 
treatment. 
 
5.4.8. Changes to PTEN structure and activity in endothelial cells treated with 
pomegranate extract 
5.4.8.1. Phosphorylated and total PTEN 
Confluent monolayers of HUVECs cultured in 6-well plates were treated with 
pomegranate extract at either 50 μg GAE/ml for 60 mins or 20 μg GAE/ml for 8 and 24 
hours. Cell lysates were prepared and the total protein concentration of each sample 
measured by BCA assay. Lysates from HUVECs treated for 60 mins with the 
pomegranate extract were assayed for changes to phosphorylated PTEN, and lysates from 
HUVECs treated for 8-24 hours with the extract were assayed for changes for total PTEN 
protein, both by western blotting. 
 
5.4.8.2. Ubquitinated PTEN 
Confluent monolayers of HUVECs cultured in 6cm
2
 dishes were treated with 50 μg 
GAE/ml pomegranate extract or vehicle control for 60 mins. Cell lysates were prepared 
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and the total protein concentration of each sample was measured by BCA assay. 200 μg 
of cell lysate protein was diluted in 1X cell lysis buffer (Cell Signalling Technologies) 
containing 1X protease inhibitor (Roche) to 1 μg/μl. Samples were incubated with anti-
PTEN antibody conjugated to sepharose beads, according to the manufacturer's 
instructions, overnight at 4 °C with gentle agitation. Samples were centrifuged (13000 g 
for 30 s) and the pellets washed 5 times with fresh cell lysis buffer containing protease 
inhibitor, with centrifugation between washes.  
 In preparation for loading onto SDS-PAGE gels, the final wash of cell lysis buffer 
was aspirated to leave approximately 13 μl of buffer along with the pellet of sepharose 
beads. 2 μl of a 250 mM stock of DTT and 5 μl of 4X LDS sample buffer (Expedeon) 
were added and the sample was spun briefly to mix before incubation at 100 °C for 4 
minutes. Lysates were assayed for changes to ubiquitinated PTEN by western blotting, 
using anti-ubiquitin and anti-PTEN antibodies as the primary antibodies. An HRP-linked 
anti-mouse IgG antibody (CST #7076) was used as the secondary antibody to the anti-
ubiquitin antibody. For imaging PTEN protein in this assay, two secondary antibodies 
were used: a mouse-derived anti-rabbit IgG (conformation specific) antibody (CST 
#3678) was used first, followed by the HRP-linked anti-mouse antibody was described 
above. The anti-rabbit IgG (conformation specific) antibody is raised so that it will not 
detect denatured or reduced rabbit IgG heavy chain, which would be found in western 
blots from this assay due to the anti-PTEN antibody contained in the immunoprecipitated 
samples loaded onto the SDS-PAGE gels. Use of the conformation-specific antibody 
avoids masking of PTEN protein by rabbit IgG heavy chain (both are approximately 50 
kDa). 
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5.4.8.3. Measurement of PTEN phosphatase activity 
Confluent monolayers of HUVECs cultured in 6cm
2
 dishes were treated with 50 μg 
GAE/ml pomegranate extract or vehicle control for 30 minutes. Cell lysates were 
prepared and the total protein concentration of each sample was measured by BCA. 260 
μg of cell lysate protein was diluted in cell lysis buffer (CST) to 1 μg/μl. Samples were 
incubated with sepharose beads conjugated to an anti-PTEN antibody, according to 
manufacturer's instructions, overnight at 4 °C with gentle agitation. Samples were 
centrifuged (13000 g for 30 s) and pellets washed 4 times with TBS, centrifuging in 
between washes. After the final wash, pellets were re-suspended in 27 μl TBS and 
aspirated into wells of a 96-well plate, alongside blank controls of 30 μl TBS, and 
substrate only controls of 27 μl TBS plus 3 μl of a 1 mM solution (in TBS) of PIP3 
(PTEN substrate). 3 μl PIP3 was added to the wells containing HUVEC lysate 
immunoprecipitate, and the plate was covered and incubated at 37 °C for 120 minutes.  
 Alongside these samples, microplate wells were prepared that contained 2 μl of a 
15 ng/μl solution (in water) of purified PTEN enzyme and 20 μl of procyanidin tetramers 
diluted in TBS to concentrations of 0, 4, 10, 16, 24, 32 and 40 μM (n=3 for each sample). 
Samples were incubated immediately at 37 °C for 5 mins, before addition of 3 μl of a 1 
mM solution of PIP3, followed by a further 30 mins incubation at 37 °C. During the 
substrate incubations, dilutions of a 1 mM phosphate solution were prepared, of 
concentrations ranging from 4 to 48 μM. Following substrate incubations, aliquots of 
each standard were pipetted into plate wells (n=2) and 100 μl of malachite green solution 
was added to each sample, blank or standard. The plate was incubated at room 
temperature for 20 minutes, protected from light, after which the absorbance of each well 
at 620 nm was measured using a microplate reader. 
 Unpaired 2-tailed student t-tests were used to determine differences between cell 
culture treatments, with significance taken as p < 0.05. To determine significant 
correlation between the concentration of procyanidin tetramers and PTEN enzyme 
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activity, Pearson's correlation coefficient was calculated, along with its corresponding p-
value. 
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5.5. Results 
5.5.1. Fractionation of pomegranate extract 
 
Figure 5.3: Flow chart depicting the steps taken to fractionate the pomegranate extract. 
 
Table 5.3: List of acronyms used for each of the fractions produced from the crude 
pomegranate extract. 
Fraction Acronym 
Pomegranate Ellagitannin Fraction PEF 
Pomegranate Procyanidin Fraction PPF 
Pomegranate Anthocyanin Fraction PAF 
Pomegranate Insoluble Fraction PIF 
Pomegranate Sugar Fraction PSF 
Pomegranate Water Soluble Fraction PWSF 
 
Pomegranate extract, dissolved in H2O and centrifuged 
Elute with H2O 
 
Elute with ethyl acetate 
Pomegranate Procyanidin Fraction (PPF) 
Elute with methanol 
Pomegranate Anthocyanidin Fraction (PAF) 
Pomegranate Water Soluble Fraction (PWSF), 
loaded onto Sephadex LH-20 column 
Elute with H2O 
Pomegranate Sugar Fraction (PSF) 
Elute with methanol 
Pomegranate Ellagitannin Fraction (PEF) 
Supernatant aspirated and filtered, loaded 
onto C-18 column 
 
Pellet air-dried: Pomegranate 
Insoluble Fraction (PIF) 
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The steps taken to fractionate the crude pomegranate extract are shown in Fig. 5.3 with 
the names and acronyms used for each fraction given in Table 5.3. The mass of the final 
fractions produced and their corresponding TPC values are given in Table 5.4. 
Originally, only use of a C-18 column had been planned for separation of the 
pomegranate extract. However, the ellagitannin fraction that was produced, despite an 
ability to increase Akt phosphorylation (data not shown), caused detachment of a large 
proportion of the endothelial cell cultures from the culture plate surface (data not shown). 
This was likely due to the decrease in pH, shown by the discolouration of the pH 
indicator in the culture medium. The inability to evaporate the fraction to dryness due to 
its hygroscopic nature, likely caused by the sugar content of the extract, in turn would 
have been causing fruit acids and acetic acid dissolved in the extract solution to be 
retained, so decreasing the pH of the fraction (PWSF). Sephadex LH-20 material was 
used to remove this interference, resulting in the high sugar/acid content fraction PSF, in 
addition to PEF. Centrifugation of the pomegranate extract, dissolved in acidified water, 
was required to clarify the solution before it was loaded onto the C-18 column. Thus, the 
pellet produced (PIF) would be expected to contain compounds that, while soluble under 
the original extraction conditions (70% methanol at 70 ºC), are not soluble in acidified 
water. 
 
Table 5.4: Weight/yields of fractions prepared from pomegranate extract 
Sample Weight (mg) Yield (w/w % of 
crude extract) 
TPC (mg 
GAE/mg) 
TPC as % of crude 
extract TPC) 
Crude extract 1482.8 ± 0.10 n/a 14.61 ± 0.30 n/a 
PIF 10.74 ± 0.12 0.7 0.01 ± 0.001 0.1 
PSF 882.35 ± 1.58 55.4 1.33 ± 0.01 9.1 
PEF 2.80 ± 0.21 0.2 0.42 ± 0.02 2.9 
PPF 8.47 ± 0.21 0.6 1.61 ± 0.05 11.0 
PAF 8.55 ± 0.58 0.6 1.86 ± 0.07 12.7 
Fraction total 842.17 ± 1.71 56.8 5.22 ± 0.09 35.8 
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5.5.2. HPLC analysis of pomegranate fractions and crude extract 
Peaks from compounds identified in the crude pomegranate extract by mass spectrometry 
are labelled in HPLC chromatograms of the crude extract and extract fractions. The 
fractionation of ellagitannins (the absorbance spectrum of which shows a characteristic 
peak around 370 nm, as opposed to 520 nm for anthocyanins) into PEF is shown in Fig. 
5.4, demonstrated by the prominent peaks for punicalagin. Peaks in the chromatogram 
from PAF are of a magnitude of size smaller than those from PEF, with both fractions 
injected in similar quantities (10 µg). Absorbance of PPF at 370 nm and 520 nm after 
similar chromatographic analysis to PAF and PEF did not result in any peaks 
 
Figure 5.4: Chromatograms of absorbance at 370 nm from RP-HPLC-UV analysis of the 
pomegranate fractions PEF and PAF, alongside the crude extract. Labelled peaks are (1) 
punicalagin-α, (2) punicalagin-β and (3) ellagic acid. 
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discernable from background noise (data not shown). Chromatograms for 520 nm 
absorbance of PEF showed peaks a magnitude of size smaller than those of PAF (Fig. 
5.5), again with both fractions injected in similar quantities (10 µg).  
 
 
Figure 5.5: Chromatograms of absorbance (measured as absorbance units (AU)) at 520 
nm from RP-HPLC-UV analysis of the pomegranate fractions PEF and PAF, alongside 
the crude extract. Labelled peaks are (1) C35diGlc, (2) D3Glc, (3) C3Glc, (4) 
delphinidin-3,5-di-O-Glc, (5) pelargonidin-3,5-di-O-Glc and (6) pelargonidin-3-O-Glc.  
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Figure 5.6: Chromatograms of emitted fluorescence (measured as relative fluorescence 
units (RFU)) from NP-HPLC analysis of the pomegranate fractions PEF, PAF and PPF, 
alongside the crude extract. Peaks labelled as #, *, ** and *** are presumed to each be 
produced by similar compounds due to the shape of surrounding peaks. 
 
Normal phase HPLC analysis of PEF presented relatively small peaks, with stronger 
responses from PAF and PPF (Fig. 5.6). There did not appear to be consistent retention 
times between peaks from different samples. This could possibly be due to differences in 
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their matrices, i.e. the additional compounds present in each besides flavan-3-ols and 
procyanidins. The crude extract was initially dissolved in acidified water before injection 
onto the HPLC system. PPF, however, required DMSO for it to solubilise so that it could 
be analysed by HPLC. While DMSO was also tested as a solvent for the crude extract, 
there was a large loss of colour (purple to brown) in the extract, even when DMSO was 
acidified with HCl. This is likely to indicate a change in structure of anthocyanins, and so 
DMSO was not used as a solvent for the crude extract. It would be interesting to 
determine whether a DMSO solution of the crude extract would produce NP-HPLC 
retention times similar to those seen for PPF. Given the current appearance of the PPF 
and crude extract NP chromatograms, it could be concluded that compounds in PPF have 
come off the HPLC column quicker than those in the crude extract. Assuming this to be 
the case, peaks representing similar compounds in each chromatogram have been labelled 
accordingly.  
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Figure 5.7: Chromatograms of emitted fluorescence (measured as relative fluorescence 
units (RFU)) from NP-HPLC analysis of the crude pomegranate extract, Evesse™ OPC 
extract and isolated procyanidin tetramers. Labelled peaks are (1) epicatechin and (2) 
procyanidin tetramers. 
 
Procyanidins do not ionise particularly well, and so are difficult to identify by mass 
spectrometry, unless present in high concentrations (Dr Shikha Saha, personal 
communication, August 2012). NP-HPLC analysis of the crude extract alongside the 
procyanidin-rich Evesse™ OPC extract and a purified fraction of procyanidin tetramers 
(DP4) (Fig. 5.7) was conducted to provide evidence for the presence of procyanidins in 
the extract. The pattern of peak retention produced by the crude extract was similar to 
that produced by the OPC extract, with one cluster of peaks showing very similar 
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retention time to the procyanidin tetramers of the other samples. The peak pattern of the 
OPC extract would also suggest the identification of the peaks in Fig. 5.6 as (*) 
procyanidin trimers, (**) tetramers and (***) pentamers.  
 Using a response factor obtained from the peak for the isolated tetramer standard, 
the concentration of procyanidin tetramers in the extract was calculated as 2.7 μM per 50 
μg GAE/ml dose of pomegranate extract. The concentration of other compounds 
quantified in the extract fractions was also found to be reduced (to varying degrees) 
compared to the crude extract. The quantification of other polyphenols identified in the 
extract are shown in Table 5.5, where their concentration in quantities of the extract 
fractions is shown in most cases to be lower than their concentrations in equivalent 
quantities of the crude extract, indicating the fractionation process caused losses of 
polyphenols in a number of cases (most prominently for punicalagin). 
 
Table 5.5: Compounds identified in pomegranate extract and fractions, and their 
equivalent concentrations (i) in the crude extract (μM/[mg/ml]), (ii) in 50 μg GAE/ml of 
the crude extract (μM) and (iii) in their respective fractions (μM), where the quantity of 
each fraction is equivalent to 50 μg GAE/ml of the crude extract Column (iv) shows the 
reduction (% w/w) of compounds after fractionation.  
Polyphenol (i) (ii) (iii) (iv) 
Punicalagin (α + β) 1.7 ± 0.1 9.3 ± 0.4 0.9 ± 0.01 10 
Ellagic acid 0.16 ± 0.02 0.8 ± 0.1 n/a n/a 
C35diGlc 0.21 ± 0.03 1.1 ± 0.1 0.8 ± 0.01 73 
D3Glc 0.37 ± 0.05 1.9 ± 0.3 0.5 ± 0.01 26 
C3Glc 0.26 ± 0.01 1.3 ± 0.04 0.5 ± 0.04 38 
(-)-Epicatechin 0.06 ± 0.01 0.3 ± 0.07 0.4 ± 0.01 - 
Procyanidin tetramers 0.53 2.7 n/a n/a 
 
 
RP- and NP-HPLC analysis of PIF (Fig. 5.8) showed the presence of phenolic 
compounds. However, considering the concentration the sample of PIF was prepared at 
for HPLC analysis (100 mg/ml), and the size of peaks produced in contrast to those of the 
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crude extract (prepared at 50 mg/ml) in Figs. 5.4, 5.5 and 5.6, the concentration of 
phenolic compounds in this fraction are likely to be very small. 
 
 
Figure 5.8: Chromatograms of absorbance at 370 and 520 nm from RP-HPLC-UV 
analysis and emitted fluorescence (from NP-HPLC analysis of the pomegranate fraction 
PIF. AU - Absorbance Units; RFU - Relative Fluorescence Units. 
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5.5.3. Increase in p-Akt due to extract fractions or individual compounds 
HUVECs were treated with the pomegranate polyphenol fractions at doses equivalent to 
50 μg GAE/ml of the whole pomegranate extract. Each fraction was shown to increase 
Akt phosphorylation in HUVECs, with PPF producing the strongest effect (Fig. 5.9).  
 
 
 
Figure 5.9: Western blots of p-Akt/Akt from lysates of HUVECs treated for 60 minutes 
with pomegranate fractions PEF, PPF and PAF at doses equivalent to 50 μg GAE/ml of 
crude pomegranate extract (based on results shown in Table 5.4), and cells treated with 
individual compounds representative of these fractions, at concentrations equivalent to 
what would be present in the fraction doses used (based on results shown in Table 5.5), 
alongside the crude extract and vehicle controls. Abbreviations: Pnclgn = punicalagin; 
EC = (-)-epicatechin. n=2 (culture well replicates) for each treatment. Ratio of blot 
densitometry (p-Akt/Akt) is shown in the lower panel. * - p < 0.05 vs vehicle control 
treatment. 
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Cells were also treated with individual compounds identified in the extract at doses 
equivalent to concentrations in the fraction and crude extract treatments (Figs. 5.9 - 5.11). 
Of these, only DP4 was able to strongly increase p-Akt (and p-eNOS). Punicalagin and 
ellagic acid increased Akt phosphorylation, but only at concentrations that were much 
higher than those present in the crude extract treatments (Figs. 5.12 and 5.13). The 
resulting strong stain for phosphorylated protein in a number of western blots appeared to 
interfere with subsequent imaging for levels of total protein (resulting in a weak or absent 
stain), despite the inclusion of extra stripping buffer washes. In these cases, imaging of 
GAPDH in lysates was also included to demonstrate the relative levels of protein that had 
been assayed in each sample. Urolithins, human metabolites of punicalagin and ellagic 
acid were unable to increase p-Akt at similar concentrations. Urolithins A and B were 
likely in solution at a slightly lower concentration than that stated in Fig. 5.13, however, 
as precipitate was observed after they were diluted into cell culture media. 
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Figure 5.10: Western blots of p-Akt/Akt/GAPDH from lysates of HUVECs treated for 
60 minutes with a mix of anthocyanins (ACN = 1.0 μM C3Glc + 1.9 μM D3Glc + 1.3 μM 
C35dG), punicalagin (Pnclgn), a mix of anthocyanins and punicalagin, or procyanidin 
B1, alongside the crude extract and a vehicle control. n=2 (culture well replicates) for 
each treatment. Ratio of blot densitometry (p-Akt/GAPDH) is shown in the lower panel. 
* - p < 0.05 vs vehicle control treatment. 
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Figure 5.11: Western blots of p-Akt/Akt/p-eNOS/eNOS/GAPDH from lysates of 
HUVECs treated for 60 minutes with PSF at a dose equivalent to 50 μg GAE/ml crude 
extract, DP4, and OPC extract (at a concentration containing approximately 2.7 µM 
procyanidin tetramers), alongside the crude extract and a vehicle control. n=2 (culture 
well replicates) for each treatment. Ratio of blot densitometry (p-Akt/GAPDH and p-
eNOS/eNOS) is shown in the two lower panels. * - p < 0.05 vs vehicle control treatment. 
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Figure 5.12: Western blots of p-Akt/Akt from lysates of HUVECs treated for 60 minutes 
with high concentrations of punicalagin (Pnclgn) and anthocyanins found in the crude 
extract, alongside the extract and a vehicle control. n=2 (culture well replicates) for each 
treatment. Ratio of blot densitometry (p-Akt/Akt) is shown in the lower panel. * - p < 
0.05 vs vehicle control treatment. 
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Figure 5.13: Western blots of p-Akt/Akt/GAPDH from lysates of HUVECs treated for 
60 minutes with high concentrations of ellagic acid or urolithins, alongside the crude 
extract and a vehicle control. n=2 (culture well replicates) for each treatment. Ratio of 
blot densitometry (p-Akt/Akt) is shown in the lower panel. * - p < 0.05 vs vehicle control 
treatment. 
 
Treatment of cells with PSF at a concentration equivalent to 50 μg GAE/ml of the crude 
extract did not cause an increase in Akt phosphorylation (Fig. 5.11). HUVECs were not 
treated with a sample of PIF, due to the precipitation of this fraction when dissolved in 
cell culture media. However, a sample of pomegranate extract with PIF removed was 
prepared and used to treat cells. No difference in the levels of phosphorylated Akt were 
observed between lysates from cells treated with the crude extract and cells treated with 
the PIF-removed extract (Fig. 5.14). It was also shown that adjustment of the culture 
media pH, down to the same level measured after dilution in media of 50 μg GAE/ml of 
the crude extract, did not increase basal levels of phosphorylated Akt.  
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Figure 5.14: Western blots of p-Akt/Akt from lysates of cells treated for 60 minutes with 
the crude extract after removal of PIF, the vehicle control with cell media pH adjusted 
using HCl and the whole crude extract, alongside a vehicle control. n=3 (culture well 
replicates) for each treatment. Ratio of blot densitometry (p-Akt/Akt) is shown in the 
lower panel. * - p < 0.05 vs vehicle control treatment. 
 
5.5.4. Role of PI3K in the modulation of additional vasodilatory signalling 
molecules by the crude pomegranate extract 
The crude pomegranate extract was again shown to significantly reduce both total eNOS 
protein and ET-1 secreted into culture media, and to increase levels of media 
nitrate/nitrite. Inhibition of PI3K significantly reversed both the increase of media 
nitrate/nitrite and the decrease in secreted ET-1 (Figs. 5.15 and 5.16). This was in spite 
of the PI3K inhibitor on its own causing a significant reduction in secreted ET-1, possibly 
due to the increase in the number of cells detached from the culture plate surface that was 
observed post-treatment, which also appeared to be reversed when cells were treated with 
the crude extract alongside the inhibitor (data not shown). The PI3K inhibitor 
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significantly reduced the decrease in eNOS protein by the crude extract even further, an 
effect also seen in cells treated with the inhibitor on its own (Fig. 5.18). 
 
 
Figure 5.15: Concentration of culture media nitrate/nitrite after treatment of cells for 24 
hours with crude pomegranate extract (Pom.) alongside a vehicle control, with or without 
a PI3K inhibitor (LY). Data representative of mean ± SD. n=3 (culture well replicates) 
for each treatment. * - p < 0.05 vs the vehicle control. # - p < 0.05 vs crude extract treated 
cells.  
 
 
Figure 5.16: Concentration of secreted ET-1 after treatment of cells for indicated times 
with crude pomegranate extract (Pom.) alongside a vehicle control, with or without a 
PI3K inhibitor (LY). Data representative of mean ± SD. n=3 (culture well replicates) for 
each treatment. *** - p < 0.001 vs the vehicle control. ### - p < 0.001 vs crude extract 
treated cells. 
 
 194 
 
Figure 5.17: Concentration of intracellular eNOS protein after 24 hour treatment of cells 
with crude pomegranate extract (Pom.) alongside a vehicle control, with or without a 
PI3K inhibitor (LY). Data representative of mean ± SD. n=3 (culture well replicates) for 
each treatment. *** - p < 0.001 vs the vehicle control. ** - p < 0.01 vs vehicle control. 
 
5.5.5. Analysis of RTK phosphorylation in cells treated with pomegranate extract 
An antibody microarray slide, spotted with antibodies complimentary for a number of 
pan-tyrosine-phosphorylated RTKs, was used to analyse cells treated with the 
pomegranate extract, PPF or punicalagin for 10 minutes. No increase in phosphorylation 
of any of the multiple RTKs was observed in response to the treatments compared to the 
vehicle control. Comparison of the pomegranate extract against the vehicle control 
treatment showed a significant (p < 0.05) decrease in the phosphorylation of a number of 
RTKs featured on the slide, as well as three RTK adaptor proteins, Src, IRS-1 and c-Abl 
(Table 5.6). The only increases to protein phosphorylation in this comparison were to p-
Akt (Ser473), p-Akt (Thr308) and p-ERK1/2 (Thr202/Tyr204). There were no significant 
changes to protein phosphorylation in comparisons of PPF vs. vehicle control or 
punicalagin vs. vehicle control. 
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Table 5.6: Kinases with significant differences in their levels of phosphorylation (p < 
0.05) from cells treated with pomegranate extract, compared to cells treated with a 
vehicle control. Positive fold change values describe increased phosphorylation, while 
negative values describe decreased phosphorylation. n = 2 (culture well replicates) for 
each treatment. 
Phospho-protein Fold Change p-value (adjusted for MT) 
p-ERK1/2 (Thr202/Tyr204) 3.61 7.2E-06 
p-Akt (Thr308) 3.50 9.7E-05 
p-Akt (Ser473) 5.25 1.3E-04 
p-ALK (pan-Tyr) -1.37 2.8E-03 
p-Src (pan-Tyr) -1.95 4.2E-03 
p-EphA3 (pan-Tyr) -1.24 5.7E-03 
p-EphB4 (pan-Tyr) -1.27 1.4E-02 
p-FGFR3 (pan-Tyr) -1.24 1.5E-02 
p-IRS-1 (pan-Tyr) -1.29 1.5E-02 
p-FGFR4 (pan-Tyr) -1.17 1.7E-02 
p-c-Abl (pan-Tyr) -1.22 2.2E-02 
p-FGFR1 (pan-Tyr) -1.18 2.7E-02 
p-TrkA (pan-Tyr) -1.19 2.7E-02 
p-ErbB2 (pan-Tyr) -1.16 2.8E-02 
p-c-Kit (pan-Tyr) -1.15 3.7E-02 
p-Ron (pan-Tyr) -1.15 3.7E-02 
p-EphA1 (pan-Tyr) -1.13 4.7E-02 
p-IGF-IR (pan-Tyr) -1.13 4.7E-02 
 
5.5.6. Effects of pomegranate extract treatment on endothelial cell PTEN protein 
and enzyme activity 
To determine if PTEN was being prevented from translocating to the plasma membrane 
and dephosphorylating PIP3, lysates from cells treated with pomegranate extract were 
assayed to determine if phosphorylation or ubiquitination of PTEN was increased due to 
the treatment, and if there were decreases in total intracellular PTEN protein. Western 
blots showed no change to PTEN phosphorylation (Fig. 5.18) or ubiquitination (Fig. 
5.19) in cells treated with pomegranate extract for 60 mins compared to a vehicle control. 
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A reduction in total PTEN protein levels was observed following a 24 hour treatment 
with pomegranate extract (Fig. 5.20). To determine if PTEN enzyme activity itself was 
inhibited by the pomegranate extract, samples of immunoprecipitated PTEN from 
HUVECs treated with the extract for 30 minutes were incubated with a phosphoinositide 
substrate for 2 hours, and the concentration of the phosphate released was quantified. No 
difference was observed between treatments with the pomegranate extract and a vehicle 
control (Fig. 5.21). However, when purified PTEN was incubated for 5 mins with the 
procyanidin tetramers fraction, its phosphatase activity was significantly reduced (p = 
2.9E-9) in a dose-dependent manner (0-40 μM) (Fig. 5.22). 
 
 
 
Figure 5.18: Western blots of p-PTEN/PTEN from lysates of HUVECs treated for 60 
minutes with 50 μg GAE/ml of the crude pomegranate extract, alongside a vehicle 
control. n=2 (culture well replicates) for each treatment, representative of two 
independent experiments. Ratio of blot densitometry (p-PTEN/PTEN) is shown in the 
lower panel. 
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Figure 5.19: Western blots of PTEN/ubiquitin from anti-PTEN immunoprecipitated 
lysates of HUVECs treated for 60 minutes with 50 μg GAE/ml of the crude pomegranate 
extract, alongside a vehicle control. Molecular weight marker (MW) bands: 20, 30, 40, 
50, 60, 80, 100, 120 and 220 kDa (bottom to top). n=3 (culture well replicates) for each 
treatment, representative of two independent experiments. 
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Figure 5.20: Western blots of PTEN/GAPDH from lysates of HUVECs treated for the 
indicated time periods with the crude pomegranate extract and punicalagin (Pnclgn), 
alongside a vehicle control. n=2 (culture well replicates) for each treatment, 
representative of two independent experiments. Ratio of blot densitometry 
(PTEN/GAPDH) is shown in the lower panel. * - p < 0.05 vs vehicle control treatment. 
 
 
Figure 5.21: Enzyme activity of PTEN from cells treated with pomegranate extract (50 
μg GAE/ml, 30 mins) is unchanged compared to a vehicle control treatment. Data 
representative of mean ± SD. n=3 (culture well replicates) for each treatment. 
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Figure 5.22: Inhibition of PTEN activity (from 30 ng PTEN) by increasing doses of 
procyanidin tetramers. Data representative of mean ± SD. n=3 (culture well replicates) 
for each treatment. 
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5.6. Discussion 
Fractionation of the crude pomegranate extract, and subsequent HPLC and in vitro 
analyses, showed the extract's bioactivity to be mostly due to its procyanidin content. The 
increase to Akt and eNOS activity in endothelial cells was not due to changes to the 
phosphatase PTEN or receptor tyrosine kinases, leading to the question of what the true 
nature of the underlying mechanism for this bioactivity was. 
 
5.6.1. Procyanidins as key polyphenols for pomegranate bioactivity 
The crude pomegranate extract had been shown to increase Akt phosphorylation in 
Chapter 4. Being a mixture of mostly ellagitannins, anthocyanins, procyanidins and 
flavan-3-ols, fractions enriched with these compounds were prepared from the extract. 
The procyanidin/flavan-3-ol fraction (PPF) produced the strongest response with respect 
to Akt phosphorylation (Fig. 5.9). NP-HPLC analysis also suggested the presence of 
procyanidin tetramers in the crude extract (Fig. 5.7), though their presence in PPF could 
not be confirmed due to apparent drifts in peak retention times, which may require further 
work to resolve (Fig. 5.6). Neither the insoluble fraction. the sugar fraction, nor the 
decrease in pH caused by the acidity of the extract, were responsible for any considerable 
part of the extract's bioactivity (Figs. 5.11 and 5.14). Though smaller increases to p-Akt 
were seen from the ellagitannin and anthocyanin fractions, assays conducted using 
individual compounds showed a strong increase to Akt phosphorylation after treatment of 
HUVECs with procyanidin tetramers, but not with procyanidin dimer B1, (-)-epicatechin, 
punicalagin or delphinidin/cyanidin glucosides (Figs. 5.9 - 5.11). This is the first case in 
which a fractionation method has been used to identify the compounds responsible for 
pomegranate bioactivity. 
 While procyanidin tetramers in the pomegranate extract appear to play a 
significant role in increasing Akt phosphorylation in HUVECs, they are unlikely to 
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account for all of the extract's bioactivity. It has been reported that there is a correlation 
between the degree of polymerisation (DP) of procyanidins and their bioactivity (Byun et 
al. 2012; Kimura et al. 2011; Osborne & McNeill 2001; Kondo et al. 2006). This would 
suggest that if larger procyanidin oligomers, such as pentamers or hexamers, were 
present, only relatively small quantities of these would be needed to account for the rest 
of the extract-induced p-Akt response. Running the pomegranate extract on a preparative 
NP-HPLC method, to isolate the peak presumed to be procyanidin tetramers, would be a 
sensible means for collecting further evidence of the procyanidins as the key polyphenols 
responsible for the extracts ability to increase p-Akt. 
 
5.6.2. Fractionation of pomegranate polyphenols 
No previous reports were found which described the use of activity-guided fractionation 
to separate pomegranate into its major polyphenol sub-classes. Though the method used 
was originally described for the separation of a red wine extract, it was effective for the 
completion of this study's objectives, with RP- and NP-HPLC showing good separation 
of the relevant compounds. It appeared that there were short-comings in terms of yields 
for a number of compounds, comparing the fractions to the whole extract, though the 
efficiency of the method was not reported in the study in which it was originally 
described (García-Estévez et al. 2010). As ellagitannins are less stable dissolved in 
methanol (Lei 2002), its use for the second fractionation with the Sephadex LH-20 
material may have been a factor in the loss seen for punicalagin after fractionation. As a 
further explanation of lost yields, it was observed that during the evaporation of ethyl 
acetate, small quantities of a cloudy-white precipitate formed around the top of the round-
bottom flasks. Attempts were made to redissolve and reclaim this precipitate but they 
were unsuccessful.  
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5.6.3. Additional bioactive compounds from the pomegranate extract 
Besides procyanidin tetramers, other compounds found in pomegranate arils were able to 
increase Akt phosphorylation, though the concentration required was too high to 
conclude that they were responsible for a major part of the observed bioactivity of the 
crude extract. The increase of p-Akt by punicalagin (Fig. 5.12) and ellagic acid (Fig. 
5.13) is in concurrence with reports from Chen et al. (2008), where a 50 μM dose of 
punicalagin and a 25 μM dose of 1-O-galloylpunicalagin increased eNOS (Ser1177) and 
Akt (Ser473) phosphorylation and Ou et al. (2010) where ellagic acid was similarly 
shown to increase Akt and eNOS phosphorylation. This was with a smaller dose of 5 µM, 
though cells were also challenged with oxidised low-density lipoprotein which decreased 
Akt phosphorylation prior to ellagic acid treatment (the basal level of Akt 
phosphorylation in this report also appears to be much higher than that observed in the 
studies performed here). The study by Chen et al. also highlights that other ellagitannins 
besides punicalagin may be present in the pomegranate extract, and these may be more 
effective at increasing p-Akt.  
 Although it was not seen here, (-)-epicatechin has been reported to increase Akt 
phosphorylation in HUVECs (Ramirez-Sanchez et al. 2012). It has been similarly shown 
that the flavan-3-ol epigallocatechin-gallate can increase p-Akt as well (Yamakuchi et al. 
2008), though this particular flavan-3-ol has not yet been identified in pomegranate. 
Anthocyanins from black currants, including D3Glc, were also shown to increase Akt 
phosphorylation (Edirisinghe et al. 2011), again an effect again not seen in this study. 
There are recent reports of flavan-3-ol-anthocyanin adducts, identified by LC–ESI/MSn 
analysis (Sentandreu et al. 2011; Sentandreu et al. 2010). Whether condensation of 
flavan-3-ols with anthocyanins could affect the potential bioactivity of the individual 
compounds remains to be investigated.  
 Pomegranates also contain a number of other secondary metabolites, such as 
alkaloids, organic acids, fatty acids and a number of volatile organic compounds 
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(Bonzanini et al. 2009; Wang et al. 2010; Viuda-Martos et al. 2010; Johanningsmeier & 
Harris 2011; Kumar & Vijayalakshmi 2011; Medjakovic & Jungbauer 2013; Lansky & 
Newman 2007). No studies could be found, however, that report an increase to Akt or 
eNOS phosphorylation in endothelial cells due to these compounds. 
 
5.6.4. Evidence of beneficial effects of pomegranate on human health 
Many reports have described the potential benefits of pomegranate, for a wide range of 
aspects of human health. While much has been concluded from in vitro and animal 
studies, such as effects on lipid metablism or gastric ulcer formation, a number of human 
clinical trials, specially for prostate cancer therapy/prevention, are reportedly now in 
progress (Colombo et al. 2013; Miguel et al. 2010). In the context of vascular health, a 
recent human study that measured effects on pulse wave velocity (PWV) and blood 
pressure after consumption of pomegranate juice for four weeks found that, while PWV 
was unaffected, systolic and diastolic blood pressure both significantly decreased 
compared to the control drink, as did mean arterial pressure, though no underlying 
mechanisms were proposed in this study (Lynn et al. 2012). Such effects are consistent 
with in vitro results showing changes to markers of reduced vascular tone, such as those 
reported here. 
 The presence of procyanidins, of sizes large enough to be bioactive towards nitric 
oxide signalling (i.e. DP4) has still to be confirmed, however, and cannot yet be 
concluded as the mechanism by which pomegranate exerts health benefits in the 
cardiovascular system. Procyanidin dimers (i.e. DP2) have been reported in human 
plasma (Holt et al. 2002), but further development of analytical technologies may be 
required before the presence or lack of presence of larger procyanidins can be proven. 
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5.6.5. Underlying mechanisms of pomegranate bioactivity - PTEN protein 
Despite the potential for pomegranate arils to provide beneficial effects to human 
vascular health, little has been reported on the underlying mechanisms in endothelial 
cells. The effect of pomegranate on eNOS activity has been well reported (Ignarro et al. 
2006; de Nigris et al. 2005), but besides this, evidence is limited to an ability to improve 
levels of antioxidant enzymes in endothelial cells (de Nigris et al. 2007; Nishigaki et al. 
2008). The dependence of PI3K for the increase of endothelial nitric oxide production by 
pomegranate extract, shown in the context of Akt activation in Chapter 4, was further 
underlined in this chapter shown by the reversal to increased media nitrate levels after 
incubation of cells with a PI3K inhibitor (Fig. 5.15). The reversal of decreased ET-1 
secretion by the crude extract by this inhibitor also provides strong evidence that the 
inhibition of ET-1 is a direct result of the increase in nitric oxide production (Fig. 5.16). 
After studying a number of markers, there was no evidence to suggest that inhibition of 
PTEN, a phosphatase which acts to limit Akt activity, was behind the PI3K-dependent 
pomegranate bioactivity. Though there was a reduction in total PTEN protein (Fig. 5.20), 
the relatively long period for this effect to occur would not help to explain the much 
quicker increase of Akt phosphorylation. The marked reduction in PTEN enzyme activity 
that was seen after incubation of the protein with procyanidin tetramers (Fig. 5.22) is in 
agreement with previous studies that have reported the capacity for procyanidins to bind 
to proteins and inhibit enzyme activity (Cho et al. 2009; Huang et al. 2011), however, this 
observation could not be repeated with an in-cell experiment. This is the first reported use 
of immunoprecipitation to allow study of the activity of enzymes from endothelial cells 
treated with polyphenols or polyphenol-rich extracts. It should be noted that while the 
experiments testing enzyme activity of immunoprecipitated PTEN featured controls for 
the cell lysis buffer, no controls were used that took account of the immunoprecipitation 
beads used in the assay. To ensure that the levels of free phosphate measured are certain 
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to be a result of active PTEN from endothelial cells, this second control should be 
included in the assay design in any future repeats of this experiment. 
 While PTEN is a key regulator of Akt activity, SHIP1/2 proteins share similar 
phosphatase activity. Therefore, study of markers for SHIP2 inhibition (as the presence of 
SHIP1 in endothelial cells is not well recorded) may be necessary, to rule out the 
inhibition of phosphatase activity as an underlying mechanism.  
 
5.6.6. Underlying mechanisms of pomegranate bioactivity - RTKs 
An investigation into the involvement of endothelial cell surface receptors in the 
mediation of pomegranate extract bioactivity has not been previously reported. There are 
previous reports, however, that show the effects of procyanidins on individual RTKs, 
including reduced expression of ErbB2 (Kenny et al. 2004), the dephosphorylation of 
which was reported in this study, and the inhibition of VEGFR2 activity (Lu et al. 2010). 
As the phosphorylation of a number of RTKs was shown to significantly decrease (p < 
0.05), the extract appears to interfere with either the activating ligands of RTKs or RTK 
autophosphorylation. It is a key feature of RTKs that their activation is facilitated by 
increased tyrosine phosphorylation (Lemmon & Schlessinger 2010). If indeed there is a 
trend of the pomegranate extract decreasing the phosphorylation of RTKs, or even 
inhibiting their phosphorylation via other signalling molecules, then this suggests that 
increased PI3K activity through RTK activation is not the key mechanism for 
pomegranate extract-induced Akt/eNOS phosphorylation. Alongside the decreased 
phosphorylation of RTKs, the phosphorylation of three RTK cofactors, IRS-1, Src and c-
Abl, was also reduced. This phosphorylation decrease may be another indication of 
interference by the pomegranate extract in the resting activity of RTKs. It is of course 
still possible that an RTK expressed in human endothelial cells, but not represented by 
the microarray, is responsible for increasing PI3K activity. Only 12 of the 20 human RTK 
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families are represented on the microarray slide, though there is evidence that all but one 
of these are expressed in endothelial cells (Cantarella et al. 2002; Kamiyama et al. 2008; 
O‘Donnell et al. 1999; Song et al. 2012; Suhardja & Hoffman 2003; You & McDonald 
2008; Lanckohr et al. 2010). Additionaly, it may be that compounds from the extract can 
bind to the cell surface and cause RTK activation by interfering with the processes which 
keep RTKs in a state of low phosphorylation.  
 As expected, the crude extract increased phosphorylation of Ser473 and Thr308 of 
Akt. It is surprising that the PPF treatment did not also increase p-Akt in this experiment, 
but this may be due to the short treatment time, and the likelihood that the relative 
concentration of bioactive compounds was reduced (through the fractionation process - 
see Section 5.5.2), in comparison to the crude extract. The crude extract also increased 
phosphorylation of ERK1/2. These proteins are involved with a number of cellular 
processes, including proliferation, cell survival and cell adhesion (Roskoski 2012), and 
have been characterised as a signalling molecule regulated by PI3K activity. Therefore, in 
this case the increase to its phosphorylation does not appear to provide further 
information as to the crude extract's underlying signalling mechanisms. 
 GPCR activation cannot be ruled out as the mechanism for increasing PI3K 
activity. There are numerous reports detailing the activation of PI3K and Akt through 
GPCRs, and the stimuli responsible for such activation (New et al. 2007; Oudit & 
Penninger 2009). Investigation of any dependence of Akt activation on GPCRs could be 
performed by inhibiting the interaction between G-protein subunits, through the use of, 
for example, targetted peptides (Chen et al. 1997). As the activity of PI3K, PTEN, Akt 
and eNOS, in the context of nitric oxide production, takes place at the plasma membrane, 
it is also possible that exposure of endothelial cells to procyanidins results in changes to 
the membrane itself, independent of individual signalling receptors, which interfere with 
signalling processes. For example, the translocation of PTEN to the plasma membrane 
relies on electrostatic interactions between the membrane and cationic protein residues 
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(Das et al. 2003). Depolarisation of the membrane to a positive potential could potentially 
disrupt this interaction, and procyanidins have been reported to cause depolarisation of 
mitochondrial membranes in breast cancer cells (Ramljak et al. 2005), however, most 
results in endothelial cells show a hyperpolarisation effect due to procyanidin treatment 
(Byun et al. 2012; Matsui et al. 2009). It is possible that hyperpolarisation of the 
membrane may be an underlying mechanism for the activation of Akt and eNOS, but 
exactly how, and in what manner, remains to be investigated. 
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5.7. Conclusion 
The bioactivity of the pomegranate extract is reported here as being primarily due to its 
procyanidin content, though further work is necessary to confirm the presence of specific 
procyanidin oligomers in the pomegranate extract. Phosphorylation, ubiquitination or 
phosphatase activity of PTEN was not affected by the pomegranate extract treatment, and 
the activity-related phosphorylation of a number of human RTKs did not increase, prior 
to the phosphorylation of Akt and eNOS by the extract. Activation of a GPCR or an RTK 
not covered in this study may explain the observed bioactivity. Alternatively, interference 
with the stasis of the plasma membrane, possibly through binding of procyanidins to the 
membrane surface, may be behind the increased production of nitric oxide in endothelial 
cells by pomegranate procyanidins. 
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Chapter 6: Concluding remarks and directions for 
future work 
 
6.1. Identification and analysis of bioactive procyanidins 
The studies detailed in this thesis sought to determine the effects of dietary polyphenols 
on markers of endothelial function, and to understand the underlying mechanisms behind 
these effects. To accomplish this, a number of biochemical techniques were used to 
analyse molecular changes in endothelial cell cultures after exposure to phenolic 
compounds. Western blotting and ELISAs provided simple and practical means for 
analysis of specific markers, while antibody microarrays allowed analyses of a wide 
range of targets and consequently provided large sets of data from which to draw 
conclusions. The flavonoid quercetin was a common phenolic amongst the food plants 
selected in Chapter 2, being present to varying extents in dill, nettle, kale and persimmon 
according to previous reports, and confirmed by in-house analysis performed by Shikha 
Saha (IFR, UK) (Hollands et al. 2013b). However, it was procyanidins, identified after 
fractionation of the crude pomegranate extract, which had the greatest effect on 
endothelial cell signalling. As with the crude extract, procyanidins increased both Akt 
and eNOS phosphorylation in HUVECs, while incubation of cells with pomegranate 
extract also increased levels of nitrate/nitrite in cell culture media, inhibited ET-1 
secretion in a PI3K-dependent manner, and decreased total eNOS protein over 24 hours. 
As procyanidins and flavan-3-ols constitute a large proportion of persimmon phenolics 
(Hollands et al. 2013b), it is likely that the persimmon extract's ability to effect markers 
of endothelial function in a manner similar to the pomegranate extract is also due to the 
presence of procyanidins or other oligomeric proanthocyanidins (OPACs). 
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Identification of the particular procyanidins responsible for pomegranate bioactivity 
remains to be investigated. There are likely to be features of the procyanidin structure that 
contribute towards its ability to increase endothelial nitric oxide production, and so it 
would be useful to determine the structure of the bioactive procyanidins so that these 
features could be better understood. For example, besides the degree of polymerisation 
(DP), the types of flavanol monomer from which proanthocyanidins are composed may 
affect their bioactivity. It has been reported in animal studies that gallocatechins and 
epigallocatechins can be more effective at producing vasorelaxant effects, compared to 
their catechin and epicatechin counterparts (Huang et al. 1998; Sanae et al. 2002), though 
no studies could be found which show marked differences between epicatechin and 
catechin monomers in the context of effects on endothelial function and CVD risk. There 
are also different manners in which monomer units may be linked, such as A- or B-type 
OPAC bonds (Fig. 6.1), which at the very least may affect their rate of absorption 
(Appeldoorn et al. 2009). Separation of procyanidins by DP can be achieved using 
normal-phase (NP) HPLC. Preparation of pomegranate extract fractions by NP-HPLC 
would allow each set of procyanidin oligomers to be assayed for bioactivity towards p-
  
Figure 6.1: Procyanidin dimers demonstrating (A) A-type interflavan bonds (C2→O-
C5/7, and C4→C6/8) and (B) B-type interflavan bonds (C4→C6/8). 
A B 
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Akt in isolation from other procyanidins and pomegranate phenolics. The particular DP 
of procyanidins that are responsible for the majority of the crude pomegranate extract's 
bioactivity could be determined by this method. NP-HPLC is often limited by poor 
reproducibility of peak retention time between runs, however, which could create issues 
during preparative HPLC runs, as the time points set for collecting each fraction would be 
based on peak retention times of previous runs. An alternative approach would be to use 
hydrophilic interaction liquid chromatography (HILIC). As with NP-HPLC, HILIC 
makes use of a polar stationary phase, often with additional polar functional groups such 
as diols, but also uses polar solvents such as acetonitrile, similar to reverse phase (RP) 
HPLC (Buszewski & Noga 2012). Compared to NP-HPLC, however, HILIC analysis 
provides improved peak resolutions and a high level of reproducibility between 
chromatography runs. Whereas NP-HPLC is adequate for separation of OPACs by DP 
alone (Shoji et al. 2006a; Sarnoski et al. 2012; Kelm et al. 2006), and in cases can 
separate also by A- or B-type interflavan linkage (Gu et al. 2002), recent reports 
demonstrating HILIC analysis suggest that the technique is powerful enough to not only 
separate peaks by A- or B-type interflavan linkage (Karonen et al. 2011; Robbins et al. 
2009; Wallace & Giusti 2010), but in cases can separate individual OPAC isomers 
(Furuuchi et al. 2011). It was also demonstrated by Kalili et al. (2012) that 
chromatography run times can be greatly reduced while retaining peak resolution. Faster 
HPLC runs alongside improved reproducibility make the repeated collection of fractions 
highly practical, allowing production of quantities of each fraction to the extent required 
for incubation with cell cultures. There is potential for further increases to productivity if 
ultra-pressure liquid chromatography (UPLC) equipment is used, as shown by the 
comparative study by Ortega et al. (2010). While this study used NP silica columns, the 
compatibility of HILIC with UPLC equipment has been previously demonstrated 
(Spagou et al. 2011). 
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Chromatograms presented in Chapter 5 (Fig. 5.8) demonstrate the presence of 
compounds in the pomegranate anthocyanin and ellagitannin fractions which have similar 
retention times to the peaks representative of procyanidins in the pomegranate 
procyanidin fraction and crude extract. It would be expected, therefore, that fractionation 
of the crude extract to isolate procyanidins of specific DP would also isolate non-
procyanidin compounds in the same fractions. Sephadex LH-20 (Cuevas-Rodríguez et al. 
2010; Gu et al. 2002; Wei et al. 2011) and Toyalpearl HW-50 (Xu et al. 2012a; Li et al. 
2010; Stringano et al. 2011) have been previously shown to be suitable materials for 
preparing OPAC rich fractions from crude plant extracts. It was noted in Chapter 5, 
however that fractionation steps can result in losses of certain phenolic compounds and so 
it would be preferable to keep the number of fractionation steps to a minimum. If the 
crude extract was to be fractionated by preparative HILIC, without prior purification 
using LH-20 or HW-50 material, the HILIC fractions could be subsequently separated by 
RP-HPLC, as has been recently demonstrated. This method has proved to be efficient at 
separating isomers which share similar NP-HPLC or HILIC retention times (Montero et 
al. 2013; Kalili & de Villiers 2009; Kalili & de Villiers 2013). The combination of HILIC 
fractionation with subsequent RP-HPLC analysis would allow identification of individual 
compounds within the fractions by mass spectrometry, especially if reasonable quantities 
of each fraction could be collected. 
 Characterisation of OPACs can be performed by thiolysis (Jerez et al. 2009; 
Saucier et al. 2001; Xu et al. 2012a) or phloroglucinolysis (Hanlin et al. 2011; Bordiga et 
al. 2011; Drinkine et al. 2007), where acid-catalysed cleavage of interflavan bonds 
releases flavanol monomer units. The released flavanols can then be analysed by HPLC 
and mass spectrometry, so as to identify and quantify the terminal units, the extension 
units (which become conjugated on release, allowing them to be differentiated from the 
terminal units) and the mean DP. Electrospray ionisation mass spectrometry (MS-ESI) 
provides a more certain means of identification for OPACs in concentrated samples. 
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Besides measurement of the degree of polymerisation, the fragmentation pattern can also 
provide clues as to the flavanol composition of individual OPAC compounds. (Sendker et 
al. 2013; Tarascou et al. 2011; Sarnoski et al. 2012). If individual OPACs can be isolated, 
nuclear magnetic resonance spectroscopy and circular dichroism spectroscopy can be 
employed for confirming details of the interflavan bonds between monomer units, such as 
whether linkages are of A- or B-type conformation (Li et al. 2010, Hümmer & Schreier 
2008). 
 HILIC coupled with RP-HPLC-MS-ESI is one of the most powerful means for 
separation and subsequent identification of OPACs currently available. Such a method 
may be improved by initial isolation of OPACs using LH-20 or HW-50 columns, and the 
length of time to perform chromatography would certainly be reduced using a UPLC 
system, though such an approach may not be currently feasible due to the cost of such 
equipment. Isolation of groups of OPACs according to their DP from the pomegranate 
and persimmon extracts, with subsequent preparation of these compounds in reasonable 
quantities, would allow more detailed analyses of their ability to increase Akt and eNOS 
phosphorylation. There are currently no commercially available OPACs of DP > 3, and 
so the production of stocks of individual OPAC oligomers/isomers would be of high 
value. Concentrated solutions of pomegranate/persimmon OPAC fractions would make 
identification by MS-ESI more practical, and if successful, may allow conclusions to be 
drawn on the importance of specific structural features, such as the types of flavanols 
from which they are composed, or whether galloylation of flavanol units is important for 
OPAC bioactivity. 
 
6.2. The mechanism by which procyanidins regulate Akt activity 
The regulation of PI3K/Akt activity by pomegranate procyandins was shown to be 
independent of a number of changes to PTEN protein, and of increased activity of a 
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subset of receptor tyrosine kinases. To date, there are no reports which investigate 
endothelial signalling upstream of Akt and eNOS phosphorylation, in relation to 
incubation of cell cultures with pomegranate or persimmon extracts. There are, however, 
a number of reports that show increased Akt phosphorylation in endothelial cells after 
incubation with OPACs or flavanols extracted from other sources. Increased 
phosphorylation of Akt and eNOS has been reported after treatment of endothelial cells 
with procyanidin-rich fractions of a red wine extract (Auger et al. 2010), and with an 
OPAC-rich grape seed extract (Edirisinghe et al. 2008). The grape-seed extract also 
caused relaxation of rabbit aortic rings, but these effects were inhibited after methylation 
of phenolic hydroxyl groups. The importance of specific flavanol hydroxyl groups for 
eliciting their bioactivity has been previously demonstrated. The 3'' hydroxyl group of 
epigallocatechin-gallate (i.e. the 3-OH group of the galloyl moiety) was found to be 
required for its ability to increase Akt and eNOS phosphorylation, whereas methylation 
of the 4'' hydroxyl group caused no reduction of protein phosphorylation (Kurita et al. 
2013). As the hydroxyl groups are largely responsible for phenolic antioxidant activity 
(Rice-Evans et al. 1996), it is probable that OPAC antioxidant activity plays some part in 
its activation of Akt. The activity of a number of signalling proteins, including AMPK, 
eNOS and ET receptor B, can be regulated by localised redox changes (Maron & Michel 
2012). For example, increased eNOS phosphorylation in endothelial cells has been shown 
to rely on the availability of non-glutathione oxidant-reducing cysteine thiols inside cells 
and at the cell surface (Tanaka et al. 2005). The increase to eNOS mRNA in endothelial 
cells by an OPAC-rich purple grape juice was shown to be partly dependent on 
intracellular ROS generation, through the incubation of cells with membrane permeable 
antioxidant enzymes (Alhosin et al. 2013).  
 As was suggested in Chapter 5, it is possible that the exposure of cells to 
procyanidins influences the chemistry of the plasma membrane in a manner which 
activates Akt. OPAC-rich extracts have been reported to cause hyperpolarisation (a 
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decrease in the membrane electric potential) of endothelial cells and arterial tissue 
(DalBó et al. 2008; Byun et al. 2012a), and this change to membrane potential has been 
shown to be reliant on K
+ 
channels and was induced in less than three minutes after 
treatment with an epicatechin trimer (procyanidin C1) (Byun et al. 2012b). The increased 
levels of cell culture media nitrite/nitrate induced by procyanidin C1 treatment was also 
shown to be partly due to K
+ 
channel activity. Akt phosphorylation may not necessarily 
be induced primarily by hyperpolarisation, however. Hyperpolarisation of HUVECs by 
β2-adrenoceptor treatment was discovered to be in response to increased nitric oxide 
production, through increased uptake of the eNOS substrate L-arginine from cell culture 
media, and so changes to membrane potential may help to sustain eNOS activity, rather 
than initiate it (Queen et al. 2006). However, increased Akt activity has also been shown 
to be initiated by depolarisation of endothelial cell plasma membranes (Chatterjee et al. 
2012) and endothelial cell mitochondrial membranes (Katakam et al. 2013).  
 It would be interesting to determine whether the pomegranate or persimmon 
extract, or their isolated OPACs, are able to hyperpolarise or depolarise the cell culture 
membrane potential. Measurement of membrane hyper-/depolarisation can be measured 
using a number of potential sensitive fluorophores, including bis-(1,3-dibutylbarbituric 
acid) trimethine oxonol, bisoxonol and rhodamine 123, which can be introduced into cells 
during a pre-incubation period before treatment with phenolic compounds. K
+ 
channel 
blocking can be performed by treating cells with iberiotoxin, which could be used to 
confirm that hyperpolarisation is necessary for Akt activation. C-natriuretic peptide may 
be used in such experiments as a positive control, as it has been previously shown to 
hyperpolarise endothelial cell membranes (Simon et al. 2009). The involvement of cell 
surface cysteine thiols could be investigated using the fluorophore ALM-488, followed 
by analysis using flow cytometry. It would also be interesting to determine if similar 
effects to nitric oxide production are seen in these experiments when using inflamed 
HUVECs, such as through pre-treatment with TNF-α (Sawa et al. 2007). Inflamed 
 217 
HUVECs are a more commonly reported model, in relation to resting HUVECs, and so 
such experiments could provide more useful data for comparing to other previously 
published studies. 
 It has been shown that S-nitrosylation of PTEN leads to increased Akt activity 
(Numajiri et al. 2011). This particular modification to PTEN protein was not studied as 
part of Chapter 5, and so it may be useful to determine levels of PTEN S-nitrosylation to 
clarify whether or not PTEN protein is responsible for increasing Akt activity after 
treatment of cells with pomegranate extract. This can be achieved through reduction of S-
nitrosothiols to thiols, incubation with a biotin-conjugate followed by subsequent pull-
down, and analysis by western blotting. Alternatively, the sub-cellular location of PTEN 
at various time-points could be tracked using fluorescently tagged recombinant PTEN. As 
PTEN is required at the plasma membrane to inhibit Akt activity, such an experiment 
would provide strong evidence of PTEN's involvement in pomegranate extract 
bioactivity. 
 
6.3. Bioavailability of proanthocyanidins 
To date, procyanidins larger than dimers are still to be reported in human plasma, though 
studies with rats have identified procyanidin trimers in plasma after feeding doses of 
cocoa or other procyanidin-rich extracts (Serra et al. 2013; Serra et al. 2009; Prasain et al. 
2009). Reports of procyanidin dimers and trimers in rat plasma have also shown them to 
be unaffected by phase II metabolism (Appeldoorn et al. 2009; Serra et al. 2010; Tsang et 
al. 2007). Human studies have reported the presence of procyanidin dimer B2 after 
consumption of cocoa, as well as a lack of phase II metabolism of procyanidins (Holt et 
al. 2002; Kahle et al. 2011). Even though increased size of procyanidins has been shown 
to correlate inversely with their transport across Caco-2 cell cultures, it is still possible for 
procyanidins as large as tetramers to pass through these cells (Ou et al. 2012). The study 
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by Zumdick et al. (2012) reported that the transport of tetramers is comparable to that of 
procyanidin dimers, indicating the possibility that tetramers could be found in human 
plasma. It has been hypothesised that procyanidins bind to proteins in plasma, and that 
this can interfere with their identification after feeding studies (Shoji et al. 2006b). To test 
this hypothesis, plasma samples from rats fed with apple procyanidins were treated with 
urea, to reverse the binding of procyanidins to plasma proteins. Following urea treatment, 
procyanidins up to and including DP5 were then identified. It is likely, though, that the 
size of OPACs can limit their absorption in the gut. It would be interesting to determine 
whether the rate of their absorption could be improved. The formulation of liposome 
vesicles for improved transport of molecules has been demonstrated previously 
(Parmentier et al. 2010), and as liposome encapsulation has been demonstrated for 
epigallocatechin-gallate (Gülseren & Corredig 2013), it may be possible to prepare such 
formulations for OPACs as well. To date, though. there is little evidence to suggest that 
proanthocyanidins are relatively bioavailable to humans. Any bioactive effects seen from 
OPACs in in vitro experiments cannot yet, therefore, be concluded as likely mechanisms 
for their in vivo health effects, with further human studies still required to conclusively 
understand the absorption and metabolism of these compounds. In future, technological 
developments may allow labelling of phenolic compounds such that they can be tracked 
as native and metabolised compounds in vivo. Such advancements would allow the 
destination of phenolics to be recorded with greater accuracy, and provide a better 
understanding of the specific metabolites that reach certain tissues. 
 
6.4. Health benefits from consumption of proanthocyanidin-rich foods 
Identifying the compounds responsible for the reduction of cardiovascular risk observed 
in the patients and volunteers of epidemiological and human intervention studies focused 
on polyphenol-rich diets, as well as determining the underlying molecular mechanisms 
for their bioactivity, can improve advice for prevention of CVD, and guide drug design 
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for therapies. Continued investigation of the signalling pathways which are activated or 
inhibited due to exposure of cells to phenolic compounds provides development of new 
biomarkers for future human studies. It is important that the physiologically relevant 
forms of phenolic compounds remain the focus of such studies. While phase II 
metabolites of quercetin were used to treat cells in Chapters 3 and 4, metabolites 
produced by gut microflora are also present in plasma after consumption of quercetin 
glycosides. To date, there do not appear to be any reports of studies which investigate the 
effects of quercetin microbial metabolites on endothelial signalling. Microbial 
metabolites of quercetin have been recovered in human urine at 22% of the original dose 
(Jaganath et al. 2006), and so represent a significant proportion of bioavailable quercetin 
metabolites. There appears to be very few additional studies which quantify levels of 
quercetin-derived microbial metabolites in human plasma or urine, though validated 
methods for performing such analyses are now available (Urpi-Sarda et al. 2009; Chen et 
al. 2012). Future studies could make use of our increasingly greater understanding of the 
profile of bacterial species which inhabit our gut, and use in vitro cultures to determine 
the microbial metabolites likely to be produced from certain polyphenols in vivo, coupled 
with preparations of microbial metabolite mixes to then be used on human cell cultures, 
to determine their bioactivity. 
 Data from appropriate in vitro studies in conjunction with human trials can serve 
as strong supporting evidence in cases of health claims for food products (Aggett et al. 
2005). Based on the results of studies described in this thesis, foods rich in procyanidins 
and other OPACs would be strong candidates for studies focused on markers of 
endothelial function and reduced CVD risk. Cocoa has been shown to be rich in OPACs 
(Kalili & de Villiers 2013) and its consumption can effect a number of markers of CVD 
risk in human studies (Arranz et al. 2013), including improvement of flow-mediated 
dilation (Monahan et al. 2011) and reduced levels of oxidised low density lipoprotein 
(Khan et al. 2012). It is of note that cocoa products (and likely other OPAC-rich foods) 
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are also rich in (-)-epicatechin (Jiménez et al. 2012), which has a higher rate of absorption 
in the gut than OPACs (Spencer et al. 2001). (-)-Epicatechin has also been shown to 
increase nitric oxide production, as well as inhibit NADPH oxidase in vitro (Ramirez-
Sanchez et al. 2012; Steffen et al. 2007) and improve FMD in vivo (Schroeter et al. 
2006). In future studies that report the bioactivity of an OPAC-rich food or extract, it 
would be of interest to determine the proportion of activity due to the food's flavanol 
monomers, in comparison to the activity due to the procyanidin oligomer content. 
 It is likely that there are food plants besides pomegranate and persimmon, which 
form part of traditional diets of countries surrounding the Black Sea, that are rich in 
OPACs. It would be useful to identify such foods, and conduct in vitro and human studies 
which assess markers of endothelial function such as Akt and eNOS phosphorylation, and 
seek to measure levels of procyanidins or their metabolites in human plasma. Results 
from these studies could potentially provide good evidence for the ability of the selected 
foods to lower CVD risk, and would encourage their continued use as part of local and 
national diets. 
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Appendix I 
 
List of protein targets featured as pairs of anti-phosphorylated/unphosphorylated 
antibodies on the PEX-100 antibody microarray: 
 
Uniprot ID  Protein and phosphorylated residue(s) 
P27348  14-3-3 theta/tau (Phospho-Ser232) 
P63104  14-3-3 zeta (Phospho-Ser58) 
P63104  14-3-3 zeta/delta (Phospho-Thr232) 
Q13541  4E-BP1 (Phospho-Thr36)  
Q13541  4E-BP1 (Phospho-Thr45)  
Q13541  4E-BP1 (Phospho-Ser65) 
Q13541  4E-BP1 (Phospho-Thr70) 
O60825  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2) 
(Phospho-Ser483) 
P00519  Abl1 (Phospho-Tyr204) 
P00519  Abl1 (Phospho-Thr754/735) 
Q13085  ACC1 (Phospho-Ser79) 
Q13085  ACC1 (Phospho-Ser80) 
P68032  ACTIN Pan(α/β/γ) (Phospho-Tyr55/53) 
P98177  AFX/FOXO4 (Phospho-Ser197)  
P31749  AKT (Phospho-Thr308)  
P31749  AKT (Phospho-Tyr326) 
P31749  AKT (Phospho-Ser473)  
P31749  AKT1 (Phospho-Ser124) 
P31749  AKT1 (Phospho-Ser246) 
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P31749  AKT1 (Phospho-Thr450) 
P31749  AKT1 (Phospho-Tyr474) 
P31749  AKT1 (Phospho-Thr72) 
Q96B36  AKT1S1 (Phospho-Thr246) 
P31751   AKT2 (Phospho-Ser474)  
Q9UM73  ALK (Phospho-Tyr1507) 
Q9UM73  ALK (Phospho-Tyr1604) 
Q13131  AMPK1 (Phospho-Thr174) 
Q13131  AMPK1/AMPK2 (Phospho-Ser485/491)  
Q9Y478  Ampkβ1 (Phospho-Ser182) 
P05067  Amyloid β A4 (Phospho-Thr743/668) 
P10275  Androgen Receptor (Phospho-Ser213)  
P10275  Androgen Receptor (Phospho-Ser650)  
P10398  A-RAF (Phospho-Tyr301/302) 
P49407  Arrestin-1 (Phospho-Ser412) 
Q99683  ASK1 (Phospho-Ser83)  
Q99683  ASK1 (Phospho-Ser966)  
P18846  ATF-1 (Phospho-Ser63) 
P15336  ATF2 (Phospho-Ser112/ 94)  
P15336  ATF2 (Phospho-Ser62/ 44)  
P15336  ATF2 (Phospho-Thr69/51)  
P15336  ATF2 (Phospho-Thr71/53)  
P15336  ATF2 (Phospho-Thr73/55)  
P18848  ATF4 (Phospho-Ser245)  
P05023  ATP1A1/Na+K+ atpase1 (Phospho-Ser23) 
P05023  Atpase (Phospho-Ser16) 
P53396  ATP-Citrate Lyase (Phospho-Ser454) 
 223 
Q8WXE1  ATRIP (Phospho-Ser68/72) 
Q96GD4  AurB (Phospho-Tyr12) 
Q96GD4  AurB (Phospho-Thr232) 
O14965  AURORA KINASE (Phospho-Thr288) 
Q92934  BAD (Phospho-Ser112)  
Q92934  BAD (Phospho-Ser134) 
Q92934  BAD (Phospho-Ser136)  
Q92934  BAD (Phospho-Ser155)  
Q92934  BAD (Phospho-Ser91/128) 
P10415  BCL-2 (Phospho-Thr56)  
P10415  BCL-2 (Phospho-Thr69) 
P10415  BCL-2 (Phospho-Ser70)  
Q07817  BCL-XL (Phospho-Thr47) 
Q07817  BCL-XL (Phospho-Ser62)  
P11274  BCR (Phospho-Tyr177)  
P11274  BCR (Phospho-Tyr360) 
P55957  BID (Phospho-Ser78) 
O43521  BIM (Phospho-Ser69/65)  
Q8WV28  BLNK (Phospho-Tyr96) 
P15056  B-RAF (Phospho-Ser446) 
P15056  B-RAF (Phospho-Thr598) 
P15056  B-RAF (Phospho-Ser601) 
P38398  BRCA1 (Phospho-Ser1423)  
P38398  BRCA1 (Phospho-Ser1457) 
P38398  BRCA1 (Phospho-Ser1524)  
Q06187  BTK (Phospho-Tyr222) 
Q9NYB9  C-Abl (Phospho-Tyr412)  
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P62158  Calmodulin (Phospho-Thr79/Ser81) 
Q9Y2W7  Calsenilin/KCNIP3 (Phospho-Ser63) 
Q14012  Camk1-α (Phospho-Thr177) 
Q13554  Camk2-β/γ/δ (Phospho-Thr287) 
Q16566  Camk4 (Phospho-Thr196/200) 
Q9UQM7  CaMKII (Phospho-Thr286)  
P29466  CASP1 (Phospho-Ser376) 
P42575  CASP2 (Phospho-Ser140) 
P55212  CASP6 (Phospho-Ser257) 
Q14790  CASP8 (Phospho-Ser347) 
P55212  CASP9 (Phospho-Thr125) 
P42574  Caspase-3 (Phospho-Ser150) 
P55211  Caspase 9 (Phospho-Ser144) 
P55211  Caspase 9 (Phospho-Tyr153) 
P55211  Caspase 9 (Phospho-Ser196) 
P04040  Catalase (Phospho-Tyr385) 
P35222  Catenin β (Phospho-Ser33)  
P35222  Catenin β (CTNNB) (Phospho-Tyr489) 
P35222  Catenin β (Phospho-Ser37)  
P35222  Catenin β (Phospho-Thr41/Ser45)  
P35222  Catenin β (Phospho-Tyr654) 
O60716  Catenin delta-1 (Phospho-Tyr228) 
Q03135  Caveolin-1 (Phospho-Tyr14)  
P15391  CD19 (Phpspho-Tyr531) 
P15941  CD227/mucin 1 (Phospho-Tyr1243) 
P20963  CD3Z (Phospho-Tyr142) 
P01730  CD4 (Phospho-Ser433) 
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P06127  CD5 (Phospho-Tyr453) 
P06493  CDC2 (Phospho-Tyr15)  
P30304  CDC25A (Phospho-Ser124) 
P30304  CDC25A (Phospho-Ser75)  
P30305  CDC25B (Phospho-Ser323) 
P30305  CDC25B (Phospho-Ser353) 
P30307  CDC25C (Phospho-Ser216)  
P24941  CDK1/CDC2 (Phospho-Thr14) 
P24941  CDK2 (Phospho-Thr160)  
Q00535  CDK5 (Phospho-Tyr15) 
P50613  CDK7 (Phospho-Thr170) 
O14757  Chk1 (Phospho-Ser280)  
O14757  Chk1 (Phospho-Ser286) 
O14757  Chk1 (Phospho-Ser317)  
O14757  Chk1 (Phospho-Ser345)  
O96017  Chk2 (Phospho-Thr383) 
O96017  Chk2 (Phospho-Thr387) 
O96017  Chk2 (Phospho-Ser516)  
O96017  Chk2 (Phospho-Thr68)  
P05412  C-Jun (Phospho-Tyr170)  
P05412  C-Jun (Phospho-Thr239)  
P05412  C-Jun (Phospho-Ser243)  
P05412  C-Jun (Phospho-Ser63)  
P05412  C-Jun (Phospho-Ser73)  
P05412  C-Jun (Phospho-Thr91)  
P05412  C-Jun (Phospho-Thr93)  
P48729  CK1-α (Phospho-Thr321) 
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P67870  CK2-β (Phospho-Ser209) 
P10721  C-Kit (Phospho-Tyr721)  
O15551  Claudin 3 (Phospho-Tyr219) 
O95471  Claudin 7 (Phospho-Tyr210) 
P08581  C-met (Phospho-Tyr1003) 
P23528  Cofilin (Phospho-Ser3)  
P17302  Connexin 43 (Phospho-Ser367)  
Q14247  Cortactin (Phospho-Tyr421)  
Q14247  Cortactin (Phospho-Tyr466)  
P41279  COT (Phospho-Thr290) 
Q96A00  CPI17 (Phospho-Thr38)  
P47712  C-PLA2 (Phospho-Ser505) 
P04049  C-Raf (Phospho-Ser296) 
P04049  C-Raf (Phospho-Ser43) 
P16220  CREB (Phospho-Thr100) 
P16220   CREB (Phospho-Ser121) 
P16220  CREB (Phospho-Ser129)  
P16220  CREB (Phospho-Ser133)  
P16220  CREB (Phospho-Ser142) 
P46108  Crkii (Phospho-Tyr221) 
P07333  CSFR (Phospho-Tyr561) 
P14635  Cyclin B1 (phospho-Ser126) 
P14635  Cyclin B1 (phospho-Ser147)) 
P24385  Cyclin D1 (Phospho-Thr286) 
P30281  Cyclin D3 (Phospho-Thr283) 
P24864  Cyclin E1 (Phospho-Thr395) 
P24864  Cyclin E1 (Phospho-Thr77)) 
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P05783  Cytokeratin 18 (Phospho-Ser52) 
P05787  Cytokeratin 8 (Phospho-Ser431) 
O75553  DAB1 (Phospho-Tyr220)  
O75553  Dab1 (Phospho-Tyr232)  
Q9UHF2  DAPP1 (Phospho-Tyr139) 
Q9UD71  DARPP-32 (Phospho-Thr34)  
Q9UD71  DARPP-32 (Phospho-Thr75) 
Q9UER7  DAXX (Phospho-Ser668) 
P17844  DDX5/DEAD-box protein 5 (Phospho-Tyr593) 
P78527  DNA-PK (Phospho-Thr2638) 
P78527  DNA-PK (Phospho-Thr2647) 
Q99704  Dok-1 (Phospho-Tyr362)  
Q99704  Dok-1 (Phospho-Tyr398)  
O60496  Dok-2 (Phospho-Tyr299)  
Q05193  DYN1 (Phospho-Ser774) 
Q01094  E2F1 (Phospho-Thr433) 
P13639  EEF2 (Phospho-Thr56) 
O00418  EEF2K (Phospho-Ser366) 
P00533  EGFR (Phospho-Tyr1016) 
P00533  EGFR (Phospho-Tyr1069) 
P00533  EGFR (Phospho-Ser1070)  
P00533  EGFR (Phospho-Tyr1092)  
P00533  EGFR (Phospho-Tyr1110)  
P00533  EGFR (Phospho-Tyr1172)  
P00533  EGFR (Phospho-Tyr1197)  
P00533  EGFR (Phospho-Thr678) 
P00533  EGFR (Phospho-Thr693) 
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P00533  EGFR (Phospho-Tyr869)  
P05198  EIF2a (Phospho-Ser51)  
P06730  EIF4e (Phospho-Ser209)  
Q04637  EIF4g (Phospho-Ser1108) 
P19419  Elk-1 (Phospho-Ser383)  
P19419  Elk1 (Phospho-Ser389)  
P19419  Elk1 (Phospho-Thr417)  
P29474  eNOS (Phospho-Ser1177)  
P29474  eNOS (Phospho-Thr495)  
P29474  eNOS (Phospho-Ser615) 
P11171  EPB41 (Phospho-Tyr418/660) 
P29317  EPHA2/3/4 (Phospho-Tyr588/596) 
P54762  EPHB1/2 (Phospho-Tyr594/604) 
P52799  Ephrin B (Phospho-Tyr330) 
P98172  Ephrin-B1 (Phospho-Tyr317) 
P19235  Epo-R (Phospho-Tyr368) 
Q16659  ERK3 (Phospho-Ser189) 
P03372  Estrogen Receptor-a (Phospho-Ser104)  
P03372  Estrogen Receptor-a (Phospho-Ser106)  
P03372  Estrogen Receptor-a (Phospho-Ser118)  
P03372  Estrogen Receptor-a (Phospho-Ser167)  
P51813  ETK (Phospho-Tyr40) 
P51813  ETK (Phospho-Tyr566) 
P15311  Ezrin (Phospho-Tyr353)  
P15311  Ezrin (Phospho-Tyr478) 
P15311  Ezrin (Phospho-Thr566)  
Q13158  FADD (Phospho-Ser194) 
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Q05397  FAK (Phospho-Tyr397) 
Q05397  FAK (Phospho-Tyr407) 
Q05397  FAK (Phospho-Tyr576) 
Q05397  FAK (Phospho-Tyr861)  
Q05397  FAK (Phospho-Ser910) 
Q05397  FAK (Phospho-Tyr925)  
P16591  FER (Phospho-Tyr402) 
P11362  FGFR1 (Phospho-Tyr154)  
P11362  FGFR1 (Phospho-Tyr654) 
P11362  FGFR1 (Phospho-Tyr766) 
P21333  Filamin A (Phospho-Ser2152) 
Q12778  FKHR (Phospho-Ser256)  
Q12778  FKHR (Phospho-Ser319)  
O43524  FKHRL1/FOXO3A (Phospho-Ser253)  
P01100  Fos (Phospho-Thr232) 
P53539  Fosb (Phospho-Ser27) 
Q12778  FOXO1/3/4-PAN (Phospho-Thr24/32) 
Q12778   FOXO1A (Phospho-Ser329) 
Q13283  G3BP-1 (Phospho-Ser232)  
Q13480  GAB1 (Phospho-Tyr627)  
Q13480  GAB1 (Phospho-Tyr659) 
P18505  GABA-RB (Phospho-Ser434) 
P17677  GAP43 (Phospho-Ser41)  
P15976  GATA1 (Phospho-Ser142)  
P15976  GATA1 (Phospho-Ser310)  
P42261  Glur1 (Phospho-Ser849)  
P42261  Glur1 (Phospho-Ser863)  
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P42262  Glur2 (Phospho-Ser880)  
Q13322  GRB10/Growth factor receptor-bound protein 10 (Phospho-Tyr67) 
Q9UQC2  GRB2 (Phospho-Ser159) 
Q15835  GRK1 (Phospho-Ser21) 
P25098  GRK2 (Phospho-Ser29) 
P49840  GSK3b (Phospho-Ser21)  
P49841  GSK3β (Phospho-Ser9)  
P49840  GSK3α-β (Phospho-Tyr216/279) 
Q9H0H5  GTPase activating protein (Phopspho-Ser387) 
P08631  HCK (Phospho-Tyr410) 
Q13547  HDAC1 (Phospho-Ser421) 
Q92769  HDAC2 (Phospho-Ser394) 
O15379  HDAC3 (Phospho-Ser424) 
P56524  HDAC4 (Phospho-Ser632)  
Q9UQL6  HDAC5 (Phospho-Ser259) 
Q9UQL6   HDAC5 (Phospho-Ser498)  
Q9UBN7  HDAC6 (Phospho-Ser22) 
Q9BY41  HDAC8 (Phospho-Ser39)  
P04626  HER2 (Phospho-Tyr1221/Tyr1222)  
P04626  HER2 (Phospho-Tyr1248)  
P04626  HER2 (Phospho-Tyr877)  
P21860  HER3/erbb3 (Phospho-Tyr1222) 
P21860  HER3/erbb3 (Phospho-Tyr1289) 
Q15303  HER4/erbb4 (Phospho-Tyr1284) 
P16104  Histone H2A.X (Phospho-Ser139)  
P68431  Histone H3.1 (Phospho-Ser10)  
P41235  HNF4α (Phospho-Ser304)  
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O14964  HRS (Phospho-Tyr334) 
Q00613  HSF1 (Phospho-Ser303)  
Q05469  HSL (Phospho-Ser552/563) 
Q05469  HSL (Phospho-Ser554) 
P04792  HSP27 (Phospho-Ser15)  
P04792  HSP27 (Phospho-Ser78)  
P04792  HSP27 (Phospho-Ser82)  
P08238  HSP90β (Phospho-Ser254) 
P08238  HSP90β (Phospho-Ser226) 
Q16543  Hsp90 co-chaperone Cdc37 (Phospho-Ser13) 
P05362  ICAM-1 (Phospho-Tyr512)  
P08069  IGF-1R (Phospho-Tyr1161)  
P08069  IGF-1R (Phospho-Tyr1165/1166)  
P11717  IGF2R (Phospho-Ser2409) 
P25963  Ikb-α (Phospho-Ser32/36)  
P25963  Ikb-α (Phospho-Tyr42)  
Q15653  Ikb-β (Phospho-Thr19) 
O00221  Ikb-ε (Phospho-Ser22) 
O15111  IKK-α/β (Phospho-Ser180/181) 
O15111  IKK-α (Phospho-Thr23)  
O14920  IKK-β (Phospho-Tyr188) 
O14920  IKK-β (Phospho-Tyr199) 
Q9Y6K9  IKK-GAMMA (Phospho-Ser31) 
Q9Y6K9  IKK gamma (Phospho-Ser85) 
Q13651  IL-10R-A (Phospho-Tyr496) 
P78552  IL-13R/CD213a1 (Phospho-Tyr405) 
P01589  IL-2RA/CD25 (Phospho-Ser268) 
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P26951  IL3R (Phospho-Tyr593) 
P24394  IL-4R/CD124 (Phospho-Tyr497) 
P05556  Integrin β-1 (phospho-Thr788) 
P05106  Integrin β-3 (Phospho-Tyr773)  
P05106  Integrin β-3 (Phospho-Tyr785)  
P15260  Interferon-γ receptor α chain precursor (Phospho-Tyr457) 
P06213  IR (Phospho-Tyr1361) 
P35568  IRS-1 (Phospho-Ser307)  
P35568  IRS-1 (Phospho-Ser312)  
P35568  IRS-1 (Phospho-Ser323) 
P35568  IRS-1 (Phospho-Ser636)  
P35568  IRS-1 (Phospho-Ser639)  
P35568  IRS-1 (Phospho-Ser794) 
P16144  ITGB4 (Phospho-Tyr1510) 
P23458  JAK1 (Phospho-Tyr1022)  
P23458  JAK2 (Phospho-Tyr1007)  
P23458  JAK2 (Phospho-Tyr221)  
P45983  JNK1/2/3 (Phospho-Thr183/Tyr185) 
P17275  Junb (Phospho-Ser259)  
P17275  Junb (Phospho-Ser79)  
P17535  Jund (Phospho-Ser255)  
P05783  Keratin 18 (Phospho-Ser33) 
P05787  Keratin 8 (Phospho-Ser73) 
P10721  KIT (Phospho-Tyr936) 
Q8IVT5  KSR (Phospho-Ser392) 
P22001  Kv1.3/KCNA3 (Phospho-Tyr135) 
P02545  Lamin A (Phospho-Ser22) 
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P02545  Lamin A/B(lamin A/C) (Phospho-Ser392) 
O43561   LAT (Phospho-Tyr171) 
O43561  LAT (Phospho-Tyr191) 
P06239  LCK (Phospho-Tyr192) 
P06239  Lck (Phospho-Tyr393)  
P06239  LCK (Phospho-Tyr504) 
P06239  LCK (Phospho-Ser59) 
P53667  LIMK1 (Phospho-Thr508)  
Q15831  LKB1 (Phospho-Thr189) 
Q15831  LKB1 (Phospho-Ser428) 
P07948  LYN (Phospho-Tyr507) 
P49137  MAPKAPK2 (Phospho-Ser272) 
P49137  MAPKAPK2 (Phospho-Thr334) 
P29966  MARCKS (Phospho-Ser158)  
P29966  MARCKS (Phospho-Ser162)  
P07333  M-CSF Receptor (Phospho-Tyr809) 
Q00987  MDM2 (Phospho-Ser166) 
Q02078  MEF2A (Phospho-Thr312)  
Q02078  MEF2A (Phospho-Thr319)  
Q02078  MEF2A (Phospho-Ser408) 
Q06413  MEF2C (Phospho-Ser396) 
Q02750  MEK1 (Phospho-Ser217)  
Q02750  MEK1 (Phospho-Ser221)  
Q02750  MEK1 (Phospho-Thr286) 
Q02750  MEK1 (Phospho-Thr291)  
Q02750  MEK1 (Phospho-Ser298) 
P36507  MEK-2 (Phospho-Thr394)  
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P35240  Merlin (Phospho-Ser10) 
P35240  Merlin (Phospho-Ser518)  
P08581  Met (Phospho-Tyr1234)  
P08581  Met (Phospho-Tyr1349)  
O75030  MITF (Phospho-Ser73) 
P46734  MKK3 (Phospho-Ser189  
P46734  MKK3/MAP2K3 (Phospho-Thr222) 
P52564  MKK6 (Phospho-Ser207) 
O14733  MKK7/MAP2K7 (Phospho-Ser271) 
P28562  MKP-1 (Phospho-Ser359) 
P28562  MKP-1/2 (Phospho-Ser296) 
Q9BUB5  Mnk1 (Phospho-Thr385) 
O75582  MSK1 (Phospho-Ser360) 
O75582  MSK1 (Phospho-Ser376)  
O75582  MSK1 (Phospho-Thr581) 
Q13043  Mst1/Mst2 (Phospho-Thr183) 
P42345  MTOR (Phospho-Thr2446) 
P42345  MTOR (Phospho-Ser2448)  
P42345  MTOR (Phospho-Ser2481) 
P01106  Myc (Phospho-Thr358)  
P01106  Myc (Phospho-Ser373)  
P01106  Myc (Phospho-Thr58)  
P01106  Myc (Phospho-Ser62) 
P24844  Myosin regulatory light chain 2 (Phospho-Ser18) 
Q12968  NFAT4 (Phospho-Ser165) 
Q04206  Nfkb-p100/p52 (Phospho-Ser865)  
Q04206  Nfkb-p100/p52 (Phospho-Ser869)  
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P19838  Nfkb-p105 (Phospho-Ser927) 
P19838  Nfkb-p105/p50 (Phospho-Ser337)  
P19838  Nfkb-p105/p50 (Phospho-Ser893)  
P19838  Nfkb-p105/p50 (Phospho-Ser907)  
P19838  Nfkb-p105/p50 (Phospho-Ser932)  
Q04206  Nfkb-p65 (Phospho-Thr254)  
Q04206  Nfkb-p65 (Phospho-Ser276)  
Q04206  Nfkb-p65 (Phospho-Ser311)  
Q04206  Nfkb-p65 (Phospho-Thr435)  
Q04206  Nfkb-p65 (Phospho-Ser468)  
Q04206  Nfkb-p65 (Phospho-Ser529)  
Q04206  Nfkb-p65 (Phospho-Ser536)  
Q05586  NMDAR1 (Phospho-Ser897)  
Q13224  NMDAR2B (Phospho-Tyr1472) 
P35372  Opioid Receptor (Phospho-Ser375) 
P56945  p130Cas (Phospho-Tyr165) 
P56945  p130Cas (Phospho-Tyr410) 
P38936  p21Cip1 (Phospho-Thr145)  
P46527  p27Kip1 (Phospho-Ser10)  
P46527  p27Kip1 (Phospho-Thr187)  
Q16539  p38 MAPK (Phospho-Thr180)  
Q16539  p38 MAPK (Phospho-Tyr182)  
Q16539  p38 MAPK (Phospho-Tyr322) 
P27361  p44/42 MAP Kinase (Phospho-Thr202)  
P27361  p44/42 MAP Kinase (Phospho-Tyr204)  
P04637  p53 (Phospho-Ser15)  
P04637  p53 (Phospho-Thr18)  
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P04637  p53 (Phospho-Ser20) 
P04637  p53 (Phospho-Ser315)  
P04637  p53 (Phospho-Ser33)  
P04637  p53 (Phospho-Ser37)  
P04637  p53 (Phospho-Ser378) 
P04637  p53 (Phospho-Ser392) 
P04637  p53 (Phospho-Ser46)  
P04637  p53 (Phospho-Ser6)  
P04637  p53 (Phospho-Ser9)  
P23443  P70S6K (Phospho-Thr229) 
P23443  P70S6K (Phospho-Ser371) 
P23443  P70S6K (Phospho-Ser411)  
P23443  P70S6K (Phospho-Ser418) 
P23443  P70S6k (Phospho-Thr421) 
P23443  P70S6K (Phospho-Ser424)  
Q9UBS0  P70s6k-β (Phospho-Ser423) 
O15350  P73 (Phospho-Tyr99)  
Q15418  P90RSK (Phospho-Thr359/Ser363) 
Q15418  P90RSK (Phospho-Ser380) 
Q15418  P90RSK (Phospho-Thr573) 
O60934  P95/NBS1 (Phospho-Ser343)  
Q13153  PAK1 (Phospho-Ser204) 
Q13153  PAK1 (Phospho-Thr212) 
Q13153  PAK1/2 (Phospho-Ser199) 
Q13153  PAK1/2/3 (Phospho-Ser141) 
Q13153  PAK1/2/3 (Phospho-Thr423/402/421) 
Q13177  PAK2 (Phospho-Ser192) 
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O75914  PAK3 (Phospho-Ser154) 
P49023  Paxillin (Phospho-Tyr118)  
P49023  Paxillin (Phospho-Tyr31)  
P16234  PDGF R α (Phospho-Tyr849) 
P09619  PDGF R β (Phospho-Tyr1021) 
P09619  PDGF R β (Phospho-Tyr740) 
P09619  PDGF R β (Phospho-Tyr751)  
O15530  PDK1 (Phospho-Ser241)  
Q15121  PEA-15 (Phospho-Ser116) 
P16284  PECAM-1 (Phospho-Tyr713) 
P27986  PI3-kinase p85-subunit alpha/gamma (Phospho-Tyr467/Tyr199) 
P06803  Pim-1 (Phospho-Tyr309) 
P17612  PKA CAT (Phospho-Thr197) 
P17252  PKC α (Phospho-Tyr657) 
P17252  PKC α/β II (Phospho-Thr638) 
P05771  PKC β/PKCB (Phospho-Ser661) 
Q05655  PKC δ (Phospho-Thr505) 
Q05655  PKC δ (Phospho-Ser645)  
Q02156  PKC ε (Phospho-Ser729) 
P17252  PKC pan activation site (Phospho) 
Q04759  PKC theta (Phospho-Thr538) 
Q04759  PKC theta (Phospho-Ser676)  
Q05513  PKC zeta (Phospho-Thr410) 
Q05513  PKC zeta (Phospho-Thr560) 
Q15139  PKD1/PKC mu (Phospho-Ser205) 
Q15139  PKD1/PKC mu (Phospho-Tyr463) 
Q15139  PKD1/pkcmu (Phospho-Ser910) 
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Q9BZL6  PKD2 (Phospho-Ser876) 
P19525  PKR (Phospho-Thr446)  
P19525  PKR (Phospho-Thr451)  
Q01970  PLC-β (Phospho-Ser1105) 
Q01970  PLC-β (Phospho-Ser537) 
P19174  PLCG1 (Phospho-Tyr771) 
P19174  PLCG1 (Phospho-Tyr783) 
P16885  PLCG2 (Phospho-Tyr1217) 
P16885  PLCG2 (Phospho-Tyr753) 
Q13393  PLD1 (Phospho-Tyr561) 
P62136  PP1alpha (Phospho-Thr320) 
P67775  PP2A-α (Phospho-Tyr307) 
Q15648  PPAR-β (Phospho-Thr1457) 
P37231  PPAR-r (Phospho-Ser112) 
P06401  Progesterone Receptor (Phospho-Ser190)  
P60484  PTEN (Phospho-Ser370)  
P60484  PTEN (Phospho-Ser380)  
P60484  PTEN (Phospho-Ser380/Thr382/Thr383)  
Q14289  Pyk2 (Phospho-Tyr402)  
Q14289  Pyk2 (Phospho-Tyr580) 
Q14289  Pyk2 (Phospho-Tyr881) 
P63000  Rac1/cdc42 (Phospho-Ser71)  
P43351  RAD52 (Phospho-Tyr104) 
P04049  Raf1 (Phospho-Ser259)  
P04049  Raf1 (Phospho-Ser338)  
P04049  Raf1 (Phospho-Tyr341) 
P04049  Raf1(Phospho-Ser621) 
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Q13972  Ras-GRF1 (Phospho-Ser916) 
P06400  Rb (Phospho-Ser608) 
Q13972  Rb (Phospho-Ser780)  
P06400  Rb (Phospho-Ser795)  
P06400  Rb (Phospho-Ser807)  
P06400  Rb (Phospho-Ser811) 
Q04864  Rel (Phospho-Ser503)  
Q01201  Relb (Phospho-Ser552)  
P07949  Ret (Phospho-Tyr905)  
Q8TDA3  Rho/Rac guanine nucleotide exchange factor 2 (Phospho-Ser885) 
Q15418  RSK1/2/3/4 (Phospho-Ser221/227/218/232) 
Q92736   Ryr2 (Phospho-Ser2808) 
P62753  S6 Ribosomal Protein (Phospho-Ser235)  
P45983  SAPK/JNK (Phospho-Thr183)  
P45983  SAPK/JNK (Phospho-Tyr185)  
P45985  SEK1/MKK4 (Phospho-Thr261)  
P45985  SEK1/MKK4 (Phospho-Ser80)  
P45985  SEK1/MKK4/JNKK1 (Phospho-Ser257) 
P29353  Shc (Phospho-Tyr349) 
P29353  Shc (Phospho-Tyr427) 
Q06124  SHP-2 (Phospho-Tyr542) 
Q06124  SHP-2 (Phospho-Tyr580) 
Q13094  SLP-76 (Phospho-Tyr128) 
Q15797  Smad1 (Phospho-Ser187) 
Q15797  Smad1 (Phospho-Ser465) 
Q15796  Smad2 (Phospho-Thr220) 
Q15796  Smad2 (Phospho-Ser250) 
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Q15796  Smad2 (Phospho-Ser467) 
P84022  Smad2/3 (Phospho-Thr8) 
P84022  Smad3 (Phospho-Thr179) 
P84022  Smad3 (Phospho-Ser204) 
P84022  Smad3 (Phospho-Ser213) 
P84022  Smad3 (Phospho-Ser425) 
Q14683  SMC1 (Phospho-Ser957)  
P08047  SP1 (Phospho-Thr739)  
P12931  Src (Phospho-Tyr418)  
P12931  Src (Phospho-Tyr529)  
P12931  Src (Phospho-Ser75) 
P36956  SREBP-1 (Phospho-Ser439) 
P11831  SRF (Phospho-Ser77) 
P11831  SRF (Phospho-Ser99) 
O75886  STAM2 (Phospho-Tyr192) 
P42224  STAT1 (Phospho-Tyr701)  
P42224  STAT1 (Phospho-Ser727)  
P52630  STAT2 (Phospho-Tyr690) 
P40763  STAT3 (Phospho-Tyr705)  
P40763  STAT3 (Phospho-Ser727)  
Q14765  STAT4 (Phospho-Tyr693)  
P42229  STAT5A (Phospho-Tyr694)  
P42229  STAT5A (Phospho-Ser780)  
P51692  STAT5B (Phospho-Ser731) 
P42226  STAT6 (Phospho-Tyr641)  
P42226  STAT6 (Phospho-Thr645)  
P16949  Stathmin 1(Phospho-Ser15)  
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P16949  Stathmin 1(Phospho-Ser24)  
P16949  Stathmin 1(Phospho-Ser37)  
O15392   Survivin (Phospho-Thr117) 
P43405  SYK (Phospho-Tyr348) 
P43405  SYK (Phospho-Tyr525) 
P17600  SYN1-Synapsin1 (Phospho-Ser62) 
P17600  Synapsin (Phospho-Ser9)  
P21579  Synaptotagmin (Phospho-Thr202) 
P21579  Synaptotagmin (Phospho-Ser309) 
P37840  Synuclein alpha (Phospho-Tyr125)  
P37840  Synuclein alpha (Phospho-Tyr133)  
O43318  TAK1 (Phospho-Thr184) 
P10636  Tau (Phospho-Thr181)  
P10636  Tau (Phospho-Thr205)  
P10636  Tau (Phospho-Thr212)  
P10636  Tau (Phospho-Ser214)  
P10636  Tau (Phospho-Thr231)  
P10636  Tau (Phospho-Ser235)  
P10636  Tau (Phospho-Ser262)  
P10636  Tau (Phospho-Ser356)  
P10636  Tau (Phospho-Ser396)  
P10636  Tau (Phospho-Ser404)  
P10636  Tau (Phospho-Ser422)  
Q9NYV6  TIF-IA (Phospho-Ser649) 
P11388  TOP2A/DNA topoisomerase II (Phospho-Ser1106) 
Q16620  Trk B (Phospho-Tyr515) 
P49815  Tuberin/TSC2 (Phospho-Thr1462) 
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P49815  Tuberin/TSC2 (Phospho-Ser939) 
P29597  TYK2 (Phospho-Tyr1054)  
P07101  Tyrosine Hydroxylase (Phospho-Ser19) 
P07101  Tyrosine Hydroxylase (Phospho-Ser31) 
P07101  Tyrosine Hydroxylase (Phospho-Ser40) 
P07101  Tyrosine Hydroxylase(TH) (Phospho-Ser8) 
P50552  VASP (Phospho-Ser157)  
P50552  VASP (Phospho-Ser238)  
P15498  VAV1 (Phospho-Tyr174)  
P52735  VAV2 (Phospho-Tyr142) 
P17948  VEGFR1 (Phospho-Tyr1333) 
P35968  VEGFR2 (Phospho-Tyr1054) 
P35968  VEGFR2 (Phospho-Tyr1059) 
P35968  VEGFR2 (Phospho-Tyr1175)  
P35968  VEGFR2 (Phospho-Tyr1214)  
P35968  VEGFR2 (Phospho-Tyr951)  
P18206  Vinculin (Phospho-Tyr821) 
P42768  WASP (Phospho-Tyr290) 
Q92558  WAVE1 (Phospho-Tyr125) 
P98170  XIAP (Phospho-Ser87) 
P43403  Zap-70 (Phospho-Tyr292) 
P43403  Zap-70 (Phospho-Tyr319)  
P43403  Zap-70 (Phospho-Tyr493)  
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List of protein targets featured as either an anti-phosphorylated or an anti-
unphosphorylated antibody on the PEX-100 antibody microarray: 
 
Uniprot ID  Protein and phosphorylated/unphosphorylated residue(s) 
P63104  14-3-3 zeta/β (Ab-184/186) 
P00519  Abl1 (Phospho-Tyr412) 
Q07912  ACK1 (Phospho-Tyr284) 
P35611  ADD1 (Ab-726)  
P31749  AKT1 (Ab-129) 
P31749  AKT1 (Ab-308) 
P31749  AKT1/2/3 (Ab-315) 
Q13315  ATM (Ab-1981)  
O14965  Aura (Ab-342) 
Q9UQB9  Aurb/C (Ab-202/175) 
P30530  AXL (Phospho-Tyr691) 
Q07812  BAX (Ab-167) 
P10415  BCL-2 (Phospho-Ser87) 
P41182  BCL-6 (Ab-333) 
Q8WV28  BLNK (Phospho-Tyr84) 
Q13882  Breast tumor kinase (Phospho-Tyr447) 
Q06187  BTK (Phospho-Tyr550) 
P00519  C-Abl (Phospho-Tyr245) 
Q9UQM7  Camk2 (Phospho-Thr305) 
P22681   CBL (Phospho-Tyr700) 
P22681   CBL (Phospho-Tyr774) 
P20273  CD22/BL-CAM (Phospho-Tyr807) 
P10747  CD28 (Phospho-Tyr218) 
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P31994   CD32 (fcgammariib) (Ab-292) 
P08575  CD45 (Phospho-Ser1007) 
P30304  CDC25A (Ab-178) 
P30307  CDC25C (Phospho-Thr48) 
O14757  Chk1 (Phospho-Ser296) 
O14757  Chk1 (Phospho-Ser301) 
P48729  CK1-A/A2 (Phospho-Tyr294) 
P56747  Claudin 6 (Phospho-Tyr219) 
P13726  Coagulation Factor III (Phospho-Ser290) 
P46109  Crkl (Phospho-Tyr207) 
P61073  CXCR4 (Phospho-Ser339) 
P24863  Cyclin C (Phospho-Ser275) 
P24385  Cyclin D1 (Ab-90) 
P30279  Cyclin D2 (Ab-280) 
O96020  Cyclin E2 (Ab-392) 
P78527  DNA-PK (Ab-2056) 
P00533  EGFR (Ab-998) 
P23588  EIF4b (Phospho-Ser422) 
P29474  eNOS (Ab-1179) 
P98172  Ephrin B1/B2/B3 (Phospho-Tyr324) 
Q8TD08  ERK8 (Phospho-Thr175/Tyr177) 
P25445  FAS (Ab-291) 
P36888  FLT3 (Ab-599) 
P36888  FLT3 (Phospho-Tyr842) 
P36888  FLT3 (Phospho-Tyr969) 
P01100  Fos (Ab-374) 
P01100  Fos (Phospho-Ser362) 
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Q12778  FOXO1A/3A (Phospho-Ser322/325) 
Q8WU20  FRS2 (Phospho-Tyr436) 
P06241  Fyn (Phospho-Tyr530) 
Q9UQC2  Gab2 (Ab-623) 
Q9UQC2  Gab2 (Phospho-Tyr643) 
Q9NRY4  GRF-1 (Phospho-Tyr1105) 
P25098  GRK2 (Phospho-Ser685) 
P04626  HER2 (Ab-1112) 
P04626  HER2/erbb2 (Ab-686) 
Q9UPZ9  ICK (Phospho-Tyr159) 
P17936  IGFBP-3 (Ab-183) 
P25963  Ikb-α (Phospho-Tyr305) 
Q15653  Ikb-β (Phospho-Ser23) 
O15111  IKK-α/β (Ab-176) 
P16871  IL7R/CD127 (Phospho-Tyr449) 
P05556  Integrin β-1 (Ab-789) 
P17181  Interferon-α/β receptor α chain (Ab-466) 
P06213  IR (Phospho-Tyr1355) 
P35568  IRS-1 (Phospho-Ser1101) 
P35568  IRS-1 (Phospho-Ser612) 
P10721  KIT (Phospho-Tyr703) 
Q14721  Kv2.1/Kcnb1 (Phospho-Tyr128) 
O43561   LAT (Ab-161) 
P53667  LIMK1/2 (Ab-508/505)  
Q15831  LKB1 (Ab-334) 
Q13233  MAP3K1/MEKK1 (Phospho-Thr1381) 
O43318  MAP3K7/TAK1 (Ab-187) 
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O43318  MAP3K7/TAK1 (Ab-439) 
P41279  MAP3K8/COT (Ab-400) 
P49137  MAPKAPK-2 (Phospho-Thr222) 
O15151  MDM4 (Phospho-Ser367) 
Q14814  MEF2D (Phospho-Ser444) 
Q12866  MER/SKY (Phospho-Tyr749/Tyr681) 
Q09YK0  Met (Phospho-Tyr1356) 
O14733  MKK7/MAP2K7 (Phospho-Thr275) 
O75582  MSK1 (Phospho-Ser212) 
O75676  MSK2 (Phospho-Thr568) 
O14974  MYPT1 (Phospho-Thr696) 
O14974  MYPT1 (Phospho-Thr-853) 
Q99640  MYT1 (Ab-83) 
Q14934  NFAT3 (Ab-168/170) 
Q14934  NFAT3 (Ab-676) 
Q00653  Nfkb-p100 (Phospho-Ser872) 
Q04206  Nfkb-p65 (Ab-281) 
Q04206  Nfkb-p65 (Ab-505) 
Q12879  NMDA NR2A/B (Phospho-Tyr1246/1252) 
Q09472  P300 (Ab-89) 
P04637  P53 (Ab-376) 
P04637  P53 (Ab-387) 
P04637  P53 (Phospho-Ser366) 
P04637  P53 (Phospho-Thr81) 
Q9H3D4  P63(Phospho-Ser455) 
P23443  P70S6K (Ab-427) 
P23443  P70S6K (Phospho-Thr389) 
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Q13177  PAK2 (Ab-197) 
Q13177  PAK2 (Phospho-Ser20) 
O96013  PAK4/PAK5/PAK6 (Ab-474) 
P09619  PDGF R β (Ab-1009) 
Q15121  PEA-15 (Phospho-Ser104) 
P27986  PI3-kinase p85-alpha (Phospho-Tyr607) 
Q9Y2I7  PIP5K (Phospho-Ser307) 
P31323  PKA-R2B (Phospho-Ser113) 
Q05655  PKC delta (Phospho-Tyr52) 
Q05655  PKC delta (Phospho-Tyr313) 
Q05655  PKC delta/PKCD (Phospho-Tyr64) 
Q15139  PKD1/2/3/PKC mu (Ab-744/748) 
P19174  PLCG1 (Phospho-Tyr1253) 
O14939  PLD2 (Phospho-Tyr169) 
P53350  PLK1 (Ab-210) 
P18433   PTPRA (Phospho-Tyr798) 
Q14289  Pyk2 (Phospho-Tyr579) 
Q06609  RAD51 (Ab-309) 
Q06609  RAD51 (Phospho-Tyr315) 
P04049  Raf1 (Ab-289) 
Q13905  Rapgef1 (Phospho-Tyr504) 
P06400  Rb (Phospho-Thr821) 
Q08999  Rb-like-2 (RBL2) (Ab-952) 
O15492  RGS16 (Phospho-Tyr168) 
P61586  Rhoa (Ab-188) 
P29350  SHP-1 (Phospho-Tyr536) 
Q15796  Smad2 (ab-245) 
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Q15796  Smad2 (Ab-255) 
P84022  Smad3 (Phospho-Ser208) 
P12931  Src (Phospho-Tyr216) 
P42229  STAT5A (Phospho-Ser725) 
P43405  SYK (Phospho-Tyr323) 
P37840  Synuclein alpha (Phospho-Tyr136)  
P78347  TFII-I (Phospho-Tyr248) 
P36897  TGFBR1 (Ab-165) 
P37173  TGFBR2 (Ab-250) 
Q02763  TIE2 (Phospho-Tyr1108) 
Q9Y4F6  TLK1 (Ab-764) 
P04629  Trk A (Ab-496) 
P04629  Trk A (Phospho-Tyr680/681) 
P04629  Trk A (Phospho-Tyr701) 
P04629  Trk A (Phospho-Tyr791) 
Q16620  Trk B (Phospho-Tyr705) 
P49815  Tuberin (Ab-981) 
P15498  VAV1 (Ab-160) 
P33151  VE-Cadherin (Phospho-Tyr731) 
P30291  WEE1 (Ab-53) 
P30291  WEE1 (Phospho-Ser642) 
Q96KM3  WWOX (Phospho-Tyr33) 
P43403  Zap-70 (Phospho-Tyr315) 
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Appendix II 
 
To correct for the high variance in spot values on the first microarray slide processed for 
the main microarray study of Chapter 3, estimation of unspecific binding was performed 
using the values of the negative control spots. This calculation (equation given at the 
bottom of page) was performed for each of the protein targets on the first microarray:   
 Firstly, the difference between the background of protein target's spot (Sb) and 
the mean background of the left negative control spots (LNb) was calculated, alongside 
the difference between the mean background of the right negative control spots (RNb) 
and the mean background of the left negative control spots (LNb). The ratio between 
these two differences was then calculated [(Sb – LNb )/(RNb – LNb)]. This ratio was 
then used to multiply the difference between the mean foreground of the right negative 
control spots and the mean foreground of the left negative control spots (RNf – LNf). 
This calculation, therefore, uses the differences in background fluorescence of the 
aforementioned spots to the estimate the proportion of the fluorescence at the location of 
the protein target in question that is due to unspecific binding. The value of this 
unspecific binding is then subtracted from the protein target's spot fluorescence (Sf). The 
mean foreground of the left negative control spots (LNf) is also subtracted, and a value of 
300 is added to ensure that all values calculated by this method remain over 0. The 
equation used is shown here: 
CSf = Sf – ([(Sb – LNb)/(RNb – LNb)] x (RNf - LNf)) – LNf +300 
Abbreviations: Corrected Spot foreground (CSf); Spot foreground (Sf); Spot background (Sb); 
average left negative control spot background (LNb); average right negative control spot 
background (RNb); average left negative control spot foreground (LNf); average right 
negative control spot foreground (RNf). 
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Abbreviations 
Ac   Acetyl 
ACN  Anthocyanin 
Alo   Allosyl 
AMPK  5' adenosine monophosphate-activated protein kinase 
BH4   Tetrahydrobiopterin 
BKCa  Large conductance Ca(2+)- and voltage-activated potassium channel 
BSA  Bovine serum albumin 
C35diGlc  Cyanidin-3,5-diglucoside 
C3Glc  Cyanidin-3-glucoside 
CaMKII  Ca2+/calmodulin-dependent protein kinase II 
cGMP  Cyclic guanosine monophosphate 
Coum  Coumaryl 
CST   Cell Signalling Technologies 
Cy3   Cyanine 3 
D3Glc  Delphinidin-3-glucoside 
dH2O  Deionised water 
DMSO  Dimethyl sulfoxide 
DP4   Degrees of polymerisation 4 (procyanidin) 
DTT  Dithiothreitol 
E. acid  Ellagic acid 
EA   Epiafzelechin 
EBM-2  Endothelial basal media 
EC   Epicatechin 
ECG  Epicatechin-gallate 
EDTA  Ethylenediaminetetraacetic acid 
EGC  Epigallocatechin 
EGCG  Epigallocatechin-gallate 
EGM-2  Endothelial growth media 
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EGTA  Ethylene glycol tetraacetic acid 
eNOS  Endothelial nitric oxide synthase 
ET-1  Endothelin-1 
EU   European Union 
EuroFIR  European Food Information Resource Network 
Fer   Feruloyl 
FMB  Full Moon Biosystems 
FMD  Flow Mediated Dilation 
FP7   Framework Programme 7 
FPLC  Fast protein liquid chromatography 
GAE  Gallic acid equivalent 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
Glc   Glucose 
GlcA  Glucuronic acid 
Gnb   Gentiobioside 
GPCR  G-protein coupled receptor 
GPX  Glutathione peroxidase 
GST   Glutathione S-transferase 
Hex   Hexose 
hFer   Hydroxyferuloyl 
HHDP  3,4,5,3',4',5'-hexahydroxydiphenoyl 
HILIC  Hydrophilic interaction liquid chromatography 
HPLC  High pressure liquid chromatograpy 
HPLC-DAD-MSD High pressure liquid chromatograpy-diode array detection-mass 
spectrometry detection 
HPLC-MSn  High pressure liquid chromatograpy-mass spectrometry in series 
HRP  Horse-radish peroxidase 
HUVEC  Human umbilical vein endothelial cells 
I-CAM  Intracellular adhesion molecule 
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IFR   Institute of Food Research (UK) 
IMR   Institute of Medical Research (Serbia) 
IP3   Inositol trisphosphate 
IR   Isorhamnetin 
ITC   Isothiocyanate 
LC-MS  Liquid chromatography-mass spectrometry 
LDL  Low-density lipoprotein 
LDS   Lithium dodecyl sulfate 
LPH   Lactase-phlorizin hydrolase  
MAPK  Mitogen-activated protein kinase 
M-CSF  Macrophage colony-stimulating factor 
MCT  Monocarboxylate transporters 
MRP2  Multidrug resistance-associated protein 2 
MSFI  Median spot fluorescence intensity 
MT   Multiple testing 
MW   Molecular weight 
MYPT1  Myosin phosphatase target subunit 1 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NaPi  Sodium phosphate 
NO   Nitric oxide 
nopair  "MSFIs representing a phosphorylated (or unphosphorylated) protein 
residue, but lacking a ‗partner‘ antibody corresponding to the alternate unphosphorylated (or 
phosphorylated) protein residue, spotted on the microarray" 
NP-HPLC)  Normal phase HPLC 
OPAC  Oligomeric proanthocyanidin 
OPC  Evesse™ procyanidin-rich apple extract 
PAF   Pomegranate anthocyanin fraction 
PAGE  Polyacrylamide gel electrophoresis 
PBS   Phosphate buffered saline solution 
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PC   Procyanidin 
PEF   Pomegranate ellagitannin fraction 
PEX-100  Phospho Explorer Antibody Microarray 
PGG  1,2,3,4,6-pentagalloyl glucose  
phph  MSFIs representing a phosphorylated protein residue 
PIF   Pomegranate insoluble fraction 
PIP2  Phosphatidylinositol-bisphosphate 
PIP3  Phosphatidylinositol-trisphosphate 
PKA  Protein kinase A 
PKB  Protein kinase B 
PKG  Protein kinase G 
Pnclgn  Punicalagin 
PPF   Pomegranate procyanidin fraction 
p-X (where X is a protein, i.e. p-Akt)  phosphorylated version of X (where is a protein) 
PSF   Pomegranate sugar fraction 
PTEN  Phosphatase and tensin homolog 
PTFE  Polytetrafluoroethylene 
PWSF  Pomegranate water soluble fraction 
PWV  Pulse wave velocity 
RE   Rutin equivalent 
RNA  Ribonucleic acid 
RP-HPLC  Reverse phase HPLC 
RTK  Receptor tyrosine kinase 
SDS   Sodium dodecyl sulfate 
Ser   Serine 
sGC   Soluble guanylyl cyclase 
SGLT1  Sodium-glucose transport protein 1 
SHIP  Src-homology 2-containing inositol 5' phosphatase 
Sin   Sinapoyl 
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Sph   Sophoroside 
TBS   Tris-buffered saline solution 
TBST  Tris-buffered saline solution plus Tween-20 
Thr   Threonine 
TNF-α  Tumor necrosis factor alpha 
TPC   Total phenolic content 
Tris   Tris(hydroxymethyl)aminomethane 
Tyr   Tyrosine 
UDP  Uridine diphosphate 
unph  MFSIs representing an unphosphorylated protein residue 
UPLC  Ultra pressure liquid chromatography 
UV   Ultraviolet 
V-CAM  Vascular cell adhesion molecule 
VEGFR2  Vascular endothelial growth factor receptor 2 
VSMC  Vascular smooth muscle cells 
WST-1  Water soluble Tetrazolium salt 1 
XO   Xanthine oxidase 
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